WO1999055728A2

WO1999055728A2 - Ese genes and proteins

Info

Publication number: WO1999055728A2
Application number: PCT/CA1999/000375
Authority: WO
Inventors: Sean E. Egan; Wei Wang; Ameet Sengar
Original assignee: Hsc Research And Development Limited Partnership
Priority date: 1998-04-27
Filing date: 1999-04-27
Publication date: 1999-11-04
Also published as: WO1999055728A3; AU3695099A

Abstract

The present invention describes the identification, isolation and characterization of novel mammalian proteins encoded by the Ese1 and Ese2 genes which are involved in endocytosis, vesicular trafficking and regulation of the actin cytoskeleton. Transcripts and products of these genes are useful for detecting abnormal cellular endocytosis processes as well as for developing assay systems to find and elucidate further binding partners of the proteins, to develop therapeutics to alter/restore protein function and for the isolation and manufacture of Ese proteins.

Description

ESE GENES AND PROTEINS

Field of the Invention

This invention relates to novel mammalian proteins encoded by the Esel and Ese2 genes which are involved in endocytosis, vesicular trafficking and regulation of the actin cytoskeleton.

Background of the Invention

Endocytosis via clathrin-coated pits is a multipstep process (1, 2). Clathrin heavy and light chains are brought to the plasma membrane through association with a heterotetrameric complex known as clathrin adaptor complex 2, or AP-2. At coated pits, the membrane is bent through the assembly of clathrin triskelion into a caged lattice. The GTPase Dynamin is also recruited to the neck of coated pits where it assembles into a collar for vesicle fission (4, 5). Recruitment of Dynamin to coated pits is believed to require the Amphiphysin I/II heterodimer (6), as these proteins bind Dynamin in vivo and amphiphysin proteins are required for endocytosis in yeast (7). In addition, ectopic expression of either Amphiphysin I or II by themselves (6), or the isolated SH3 domain of Amphiphysin I blocks endocytosis (8, 9). Recent data has revealed that the Rab5 small GTPase is required for sequestration of ligands such as transferrin and Epidermal Growth Factor into coated pits in vitro (10). The mechanism by which these components interact to regulate coated pit assembly, cargo sequestration, followed by vesicle fission is not yet understood.

From biochemical, cell biological and genetic analysis it is clear that additional components such as kinases, phosphatases, ubiquitin conjugating enzymes as well as lipid modifying enzymes are required for clathrin-coat and vesicle formation (1, 11, 12, 13, 14, 15, 16, 17, 18, 19). Indeed there is also strong evidence for a requirement of the actin cytoskeleton in endocytosis and several proteins which may facilitate this connection (1, 7, 20, 21, 22, 23, 24, 25).

The Epsl 5 protein was discovered in a search for substrates of the Epidermal Growth Factor Receptor (26). In 1995, Benmerah et. al. reported that Epsl5 is constitutively associated with α-adaptin of the AP2 complex (27). The Epsl 5 protein has also been localized to the neck of clathrin-coated pits by immunoelectron microscopy (28, 29). Recently, two groups have used dominant inhibitory mutants of Epsl5, or antibodies against Epsl5 (or the related protein Epsl5R), to demonstrate that Epsl5 proteins are required for endocytosis via clathrin-coated pits (30, 31). Epsl 5 contains three large structural domains (26, 32). The N-terminal third contains three copies of an EH domain (for Epsl 5 Homology domain) (32, 33). The central region of Epsl 5 forms an extended coiled-coil, which is followed by a complex C-

SUBSTTTUTE SHEET (RULE 26) terminus containing SH3-binding motifs (34), a large number of DPF repeats (Aspartic acid-Proline-Phenylalanine), and α-adaptin binding sequences (31, 35, 36). The full length Epsl5R protein has a similar overall organization (34). Both Epsl 5 and Epsl5R can be alternatively spliced to produce numerous smaller proteins(37). A protein with similar overall organization has been identified in

Saccharomyces cerevisiae named Panlp. Genetic analysis of PAN 1 has revealed that this gene is required for endocytosis and for organization of the actin cytoskeleton (23, 38). Like Epsl5 and Epsl5R in mammals, the Panlp protein has N-terminal EH domains followed by a central coiled-coil domain and C-terminal proline-rich sequences. A second EH domain containing protein, End3p, has also been described in S. cerevisiae which is required for endocytosis and regulation of the actin cytoskeleton (21, 39). Co-immunoprecipitation studies have shown that Panlp and End3p form a complex in vivo (40) . Indeed, overexpression of End3p can suppress the phenotype of pan 1-4 hypomorphic mutants, and Panlp is mislocalized in end3 mutants indicating that these proteins function together (40). Additional studies have revealed that the EH domains of Panlp bind to yeast homologues of mammalian clathrin-binding proteins, API 80 and CALM (yAP180A and yAP180B), through NPF motifs (Asparagine-Proline-Phenylalanine) in the yAP180 C-termini(25). These data have led to a proposal that the Panlp:End3p complex functions as a multivalent adaptor to coordinate protein-protein interactions during endocytosis (25, 40). At least two additional proteins are predicted to bind to the Panlp:End3p complex in vivo, as strong genetic interactions have been detected between PAN1 and SJL1(25), and between PAN1 and RSP5 (41). SJL1 encodes a phosphatidylinositol polyphosphate-5-phosphatase protein which is related to mammalian synaptojanin (42) and has a C-terminal NPF motif predicted to bind to EH domains in Panlp (or End3p) (25, 43) . RSP5 encodes an E3 ubiquitin-protein ligase which may bind to the C-terminal polyproline sequences in Panlp through one of its three WW domains (25).

Numerous SH3 domain containing proteins have been implicated in the regulation of endocytosis (44). These include Amphiphysin 1(45) and II (6, 46, 47, 48), Rsvl61/Rsvl67(7), Actin Binding Protein- 1(49), Endophilin/SH3P4/8/13 (50, 51) and Grb2 (52). Kay and coworkers have reported the isolation of several novel SH3 encoding cDNAs (53).

The present inventors have identified novel mammalian proteins containing both EH and SH3 domains, which have been named Esel and Ese2. Sequence and functional analysis of the full length proteins have implicated these proteins in receptor mediated endocytosis via clathrin coated pits and therefore the proteins have been named Esel and Ese2 respectively (Ese: for EH-domain and SH3 domain regulator of Endocytosis). Also identified are several mammalian alternative transcript proteins two of which are named EselL and Ese2L.

Summary of the Invention

In accordance with one series of embodiments, this invention provides isolated nucleic acids corresponding to or relating to the nucleic acid sequences disclosed herein which encode the mammalian Esel and Ese2 proteins.

The invention more specifically provides isolated nucleic acids corresponding to or relating to the nucleic acid sequences disclosed herein which encode the mouse Esel and Ese2 proteins.

One of ordinary skill in the art is now able to identify and isolate mammalian Ese protein genes or cDNAs which are allelic variants of the disclosed sequences or are homologues thereof, in other species, including humans, using standard hybridisation screening and PCR techniques. The mammalian polynucleotide may be in the form of DNA, genomic DNA, cDNA, mRNA and various fragments and portions of the gene sequence encoding Ese proteins.

Homologues of the mammalian Ese protein genes are generally those sequences which share at least 80% sequence identity, preferably at least 90% sequence identity to the mammalian Ese gene sequence.

In a further embodiment, the invention provides cDNA sequences encoding murine Esel and Ese2 proteins comprising the nucleotide sequences of Sequence ID NOS: 1, 2, 4 and 5.

In a further embodiment, the invention provides cDNA sequences encoding murine EselL and Ese2L proteins comprising the nucleotides sequences of Sequence ID NOS: 22, 23, 25 and 26.

Also provided are portions of the Ese gene sequences useful as probes or PCR primers or for encoding fragments, functional domains or antigenic determinants of Ese proteins. The probes can be routinely used to screen and identify homologues of the Ese gene or portions thereof while primers are useful in PCR assays for the amplification of desired portions of the selected Ese gene.

The invention also provides portions of the disclosed nucleic acid sequences comprising about 10 consecutive nucleotides to nearly the complete disclosed nucleic acid sequences. The invention provides isolated nucleic acid sequences comprising sequences corresponding to at least 10, preferably 15 and more preferably at least 20 consecutive nucleotides of the Ese genes as disclosed or enabled herein or their complements. In addition, the isolated nucleic acids of the invention include any of the above described nucleotide sequences included in a vector. Expression vectors comprising the nucleotide sequences are provided along with suitable host cells transfected with such expression vectors. In accordance with a further series of embodiments, this invention provides substantially pure mammalian Ese proteins, fragments of these proteins and fusion proteins including these proteins and fragments.

In accordance with a further series of embodiments, this invention provides substantially pure mutant mammalian Ese proteins, fragments of these proteins and fusion proteins including these mutant proteins and fragments.

In a further embodiment, the invention provides amino acid sequences encoding murine Esel and Ese2 proteins comprising the amino acid sequences of Sequence ID NOS: 3 and 6.

In a further embodiment, the invention provides amino acid sequences encoding murine EselL and Ese2L proteins, which are alternative transcripts, comprising the amino acid sequences of Sequence ID NOS: 24 and 27.

The proteins, fragments and fusion proteins have utility, as described herein, for the preparation of polyclonal and monoclonal antibodies to murine and mammalian Ese proteins, for the identification of binding partners of the mammalian Ese proteins and for diagnostic and therapeutic methods, as described herein. For these uses, the present invention provides substantially pure proteins, polypeptides or derivatives of polypeptides which comprise portions of the mammalian Ese amino acid sequences disclosed or enabled herein and which may vary from about 4 to 5 amino acids to the complete amino acid sequence of the proteins. The invention provides substantially pure proteins or polypeptides comprising sequences corresponding to at least 5, preferably at least 10 and more preferably 50 or 100 consecutive amino acids of the mammalian Ese proteins disclosed or enabled herein. Monoclonal antibodies having suitably specific binding affinity for the antigenic regions of a mammalian Ese protein are prepared by the use of corresponding hybridoma cell lines. In addition, polyclonal antibodies may be prepared by inoculation of animals with suitable peptides which add suitable specific binding affinities for antigenic regions of an Ese protein.

In a further embodiment of the invention, a process is provided for producing mammalian Ese proteins comprising culturing one of the above described transfected host cells under suitable conditions, to produce the Ese protein by expressing the DNA sequence. The proteins of the invention may be isolated and purified by any conventional method suitable in relation to the properties revealed by the amino acid sequences of these proteins.

Alternatively, cell lines may be produced which express or over-express the Ese gene products, allowing purification of the proteins for biochemical characterisation, large-scale production, antibody production and patient therapy.

For protein expression, eukaryotic or prokaryotic expression systems may be generated in which an Ese gene sequence is introduced into a plasmid or other vector which is then introduced into living cells. Constructs in which the Ese cDNA sequences containing the entire open reading frame is inserted in the correct orientation into an expression plasmid may be used for protein expression. Alternatively, only portions of the sequence may be inserted. Prokaryotic or eukaryotic expression systems allow various important functional domains of the proteins to be recovered as fusion proteins and used for binding, structural and functional studies and also for the generation of appropriate antibodies.

The present invention includes effective fragments, analogues of the Ese proteins described herein. "Effective" fragments or analogues retain the activity of the described Ese proteins to regulate endocytosis, vesicular trafficking and actin dynamics. The term "analogue" extends to any functional and/or chemical equivalent of a mammalian Ese protein including mimetics and includes proteins having one or more conservative amino acid substitutions, proteins incorporation unnatural amino acids and proteins having modified side chains.

In accordance with a further embodiment of the invention, antibodies are enabled which bind specifically to the Ese proteins disclosed herein. Polyclonal or monoclonal antibodies may be prepared using conventional methods. Antibodies may also be prepared to individual selected domains of the Ese proteins, as described herein.

In a further embodiment, the invention provides pharmaceutical compositions containing an Ese protein, fragment or mimetic thereof or a non- functional mutant Ese protein, fragment or mimetic thereof for the treatment of mammalian disorders which involve abnormal endocytosis, vesicular trafficking and actin dynamics leading to altered cellular functioning. Administration of a therapeutically active amount of a pharmaceutical composition of the present invention means an amount effective, at dosages and for periods of time necessary to achieve the desired result. The composition comprises an Ese protein and a pharmaceutically acceptable carrier.

In accordance with a further embodiment, the invention provides a method for identifying binding partners of the Ese proteins disclosed herein. Such methods in general include various assays including those including radiolabelling of the Ese proteins. Other methods may include but are not restricted to phage display, affinity purification techniques, expression cloning and the yeast 2-hybrid system, as described herein. In accordance with a further embodiment of the present invention, is a method for identifying proteins which phosphorylate Ese proteins. Such method includes known phosphorylation assays.

The identification of proteins or peptides interact with or bind to Ese proteins can provide the basis for the design of peptide antagonists or agonists of Ese protein function or for the design of peptide antagonists or agonists of Ese protein binding partners which affect Ese protein function. Further, the structure of these peptides determined by standard techniques such as protein NMR or x-ray crystallography can provide the structural basis for the design of improved small molecule drugs.

In accordance with a further embodiment, the present invention also provides for the production of mouse models or transgenic non-human animal models for the study of mammalian Ese gene function, for the screening of candidate pharmaceutical compounds, for the creation of in vitro mammalian cell cultures which express the Ese proteins or in which an Ese gene has been inactivated by knock-out deletion, and for the evaluation of potential therapeutic interventions. The invention enables a transgenic animal, including a transgenic insect, wherein the genome of the animal or of an ancestor of the animal has been modified by introduction of a transgene comprising mammalian Ese genes under the transcriptional control of tissue restricted regulatory elements including the mouse mammary-tumour virus long term repeat sequences. Transgenic animals with inappropriate expression of Ese proteins may be examined for phenotypic changes, for example abnormal cellular development or abnormal cellular signalling, vesicular trafficking and actin dynamics and may be used to screen for compounds with potential as pharmaceuticals. Compounds which provide reversal of the phenotypic changes are candidates for development as pharmaceuticals.

Transgenic animals in accordance with the invention can be created by introducing a DNA sequence encoding a selected Ese protein either into embryonic stem (ES) cells of a suitable animal such as a mouse, by transfection or microinjection, or into a germ line or stem cell by a standard technique of oocyte microinjection. Such methods of producing animal models are fully described in the literature. In accordance with another aspect of the present invention is a method for screening a candidate compound for effectiveness as an antagonist of an Ese protein comprising:

(a) providing an assay method for determining the endocytotic regulatory capacity of an Ese protein; and

(b) determining the endocytotic regulatory capacity of the Ese protein in the presence or absence of the candidate compound, wherein a reduced level of endocytosis in the presence of the candidate compound indicates antagonist activity of the compound. In accordance with another aspect of the present invention is a method for treating in a mammal a disorder associated with an undesired level of endocytotic activity of an Ese protein comprising administering to the mammal an effective amount of a substance selected from the group consisting of: (a) an Ese protein antagonist; (b) an antibody which binds specifically to an Ese protein;

(c) an antisense strand comprising a nucleic acid sequence complementary to the sequence or fragment of the sequence and capable of hybridizing to the nucleic acid sequence encoding an Ese protein;

(d) an agent which down regulates the expression of the Ese gene encoding for an Ese protein;

(e) an antagonist of an Ese protein binding partner; and

(f) an Ese agonist.

According to another aspect of the present invention is a method for suppressing in a mammal, the abnormal proliferation of a cell capable of being stimulated to proliferate by a growth factor receptor, the method comprising administering to the mammal an effective amount of a Ese protein antagonist, an Ese agonist or an antibody which binds specifically to an Ese protein.

According to yet another aspect of the present invention is a method for preventing viral infection in a mammal, said method comprising administering to the mammal an effective amount of an Ese protein antagonist, an Ese agonist or an antibody which binds specifically to an Ese protein or an Ese mutant protein not capable of regulating endocytosis.

According to a further aspect of the present invention is a method for promoting endocytosis, vesicular trafficking and/or actin dynamics in selected cells in a mammal in need of such treatment, said method comprising administering to the mammal an effective amount of an Ese protein or an active analogue, mimic or fragment thereof. According to a further aspect of the present invention is a method for blocking clathrin-mediated endocytosis in cultured cells or in selected cells in a mammal in need of such treatment, said method comprising overexpressing Esel protein or an active analogue, mimic or fragment thereof.

According to yet a further aspect of the present invention is a method for regulating endocytosis, vesicular trafficking and/or actin dynamics in cultured cells or in selected cells in a mammal in need of such treatment, said method comprising providing an Esel-Eps 15 complex and further providing a protein binding partner to bind to the complex to regulate components of the endocytic pathway. One such binding partner is dynamin.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the invention are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

Summary of Tables and Drawings

A detailed description of the preferred embodiments are provided herein below with reference to the following tables and drawings in which: Table 1 shows alignment of mouse Esel and Ese2 protein sequences. EH, coiled-coil and SH3 domains are as indicated.

Table 2 shows the alignment of protein sequences of the Ese family in mouse,

Xenopus and Drosophila. EH and SH3 domains are indicated with overlines. Amino acid identities (bolded) and similarily are boxed. Figure 1 shows a Northern blot demonstrating expression of Esel and Ese2 genes in various adult tissues.

Figure 2A shows Western blots demonstrating the association of Ese and

Epsl 5 proteins in vivo. Endogenous Esel proteins were precipitated with Rabbit anti- peptide antisera against the N-terminus of Esel . Imrnunoprecipitates were then analyzed on western blots for the presence of Ese 1/2 with Chicken anti-Ese antisera or for co-precipitation of Epsl 5 with Rabbit antisera raised against the C-terminus of

Epsl5. Figure 2B shows alternative transcripts from the Esel and Ese2 genes which code for EselL and Ese2L proteins respectively, with C-terminal DBL/PH and C2 domains. Esel and Ese2 sequence junctions are indicated in bold red letters. Figure 3 A shows Ese and Epsl 5 associate in vivo. This schematic representation of association of Eps 15/Eps 15R with Ese 1 in the yeast two-hybrid screen. Esel coiled-coil domain fused with the Gal4 DNA binding domain (DBD) interacted with Epsl5/Epsl5R Gal4 activation domain (AD) fusions. The AD- Epsl5 Epsl5R diagram represents the shortest interacting coding region isolated. Figure 3B shows association of Ese and Epsl 5 C-terminal deletion mutants. Cos-1 cells were transfected with pcDNA3Epsl5, pcDNA3Esel or the C-terminal deletion mutants pcDNA3EselδC and pcDNA3Epsl5δC-Flag as indicated. Cell lysates were immunoprecipitated with rabbit anti-Ese 1 or rabbit anti-Epsl5 (left panel); rabbit anti-Ese 1, mouse anti-Flag or rabbit anti-Epsl5 (right panel). Panels represent western blots to detect the presence of Esel in each immunoprecipitation. A 90kDa Esel protein exists in the third and sixth lanes on the left panel which is the C- terminally truncated Esel protein which is co-immunoprecipitated in a complex with Eps 15 in the sixth lane. Also, to be noted is the precipitation of Esel with anti-Flag monoclonal antibody in the sixth lane of the right panel experiment. In this case, Esel has been precipitated in a complex with the C-terminally truncated Epsl5δC protein. Figure 4 shows confocal immunofluorescent micrographs of Cos cells transfected with myc-Esel (A, A'); Epsl5 (B); myc-Esel + Epsl5 (C, C\ C^") or myc-Esel + Epsl5δC (D, D' and D"). Frames C" and D' represents the overlapping images from frames C/C and D/D', respectively. Overlap in frames C" and D" are indicated in yellow. Scale bar is equal to 10 microns. Figure 5 A and 5B show that Esel links to Dynamin and Epsl 5. Figure 5 A is a schematic representation of association between Dynamin and Esel in the yeast two- hybrid screen. Esel SH3 domains fused with the Gal4 DNA binding domain (DBD) interacted with Dynamin Gal4 activation domain (AD) fusions. The AD-Dynamin diagram represents the shortest interacting coding region isolated. Figure 5B shows confocal immunofluorescent microscopy to detect transfected mycEsel (frame a), transfected Eps 15 (frame d) or endogenous Dynamin (frames b and e) in transfected Cos cells. Frame c and f represents the overlapping images from frames a/b and d/e respectively. Scale bar is equal to 10 microns.

Figure 6 shows Esel overexpression blocks endocytosis of Transferrin in Cos- 1 cells. Confocal immunofluorescent microscopy was used to detect transfected mycEsel (frame A), internalized FITC-labeled Transferrin (frame B). Overlapping images are shown in frame C revealing that Esel overexpression blocks clathrin-

SUBSTJΓΓUTΈ SHEET (RULE 26 mediated endocytosis of Transferrin. Mononuclear morphologically normal cells from both transfected and untransfected groups where assessed for internalization of transferrin. Scale bar is equal to 10 microns.

Figure 7 shows a proposed model for Ese regulation of Endocytosis. In the drawings, preferred embodiments of the invention are illustrated by way of example. It is to be expressly understood that the description and drawings are only for the purpose of illustration and as an aid to understanding, and are not intended as a definition of the limits of the invention.

Detailed Description of the Invention

Sequencing of Murine Esel and Ese2 genes

The full length murine Esel cDNA was sequenced (Sequence ID NO:l). It encodes a sequence of 1213 amino acids (Sequence ID NO:3) having a predicted molecular weight of 137 kDa. Murine Ese2 cDNA was also sequenced (Sequence ID NO:4) and encodes a sequence of 1197 amino acids (Sequence ID NO:6) having a predicted molecular weight of 135.7 kDa.

The full length Ese proteins are predicted to encode two N-terminal EH domains followed by a coiled-coil domain and five SH3 domains (Tables 1 and 2). Several Esel isolated clones contain only SH3_A, SH3_B and SH3_E domains. Indeed, the SH3_C domain was not included in the original human SH3P17 partial cDNA. In addition, expressed sequence tags from the Esel gene have been found in the public databases which skip sequences encoding individual EH domains or regions of the coiled-coil domain indicating that this gene is subject to complex alternative splicing and has the potential to encode for many distinct proteins. The predicted Ese2 protein on the other hand encodes a C-terminal extension of 45 amino acids in comparison to the human SH3P18 partial cDNA, suggesting that this gene is also alternatively spliced. The Ese proteins are 53% identical over the full length of Esel (645 of 1213 residues in Esel line up with identical residues in Ese2) and are related to the Ese protein from Xenopus which has recently been submitted to genebank (Accession # AF032118) and Drosophila (59) (Table 2). Xenopus Intersectin is 81% identical to mouse Esel and 54% identical to mouse Ese2 suggesting that Intersectin is an Esel orthologue (980/1213 residues of mouse Esel and 645/1198 residues of mouse Ese2 line up with identical residues in the Xenopus protein). Drosophila Dynamin associated protein. Dapl60-1 is 32% identical to both mouse Ese proteins (393/1213 residues of mouse Esel and 387/1198 residues of mouse Ese2 line up with identical residues in the Drosophila protein). These homologies extend over the entire length

SUBSTΠTJΓΈ HEET of Dap 160-1, except that Dap 160-1 has only four SH3 domains corresponding to the first, second, fourth and fifth SH3 domains of the mouse Ese proteins. Additional sequence analysis reveals the presence of a very large number of potential phosphorylation sites and at least one SH3 -binding consensus (60) in the N-terminus of each Ese protein.

The two EH domains of Esel are highly related to the respective EH domains in Ese2 and these Ese EH domains are most closely related those found in Eps 15 and Epsl5R, two mammalian protein which are required for endocytosis through clathrin- coated pits. EH domains have also been identified in End3 and Panlp which are yeast partners proteins required for endocytosis. The central third of both Ese proteins are predicted to encode an extended coiled-coil which is a domain typically associated with protein-protein association through dimerization or tetramerization as noted for Eps 15 (29, 54). Besides the homology between Esel and Ese2, the Esel SH3 domains are most closely related to SH3 domains from Myosin IB in Acanthamoeba (SH3 _A), Myosin IB in Entamoeba (SH3_B), the YFR024 hypothetic yeast protein

(SH3_C), Myosin IB from Acanthamoeba (SH3_D) and Myosin IC from Acanthamoeba (SH3_E). The same homologies are noted for SH3 domains from Ese2 with the exception of SH3_A which is most similar to the SH3 domain from βPIX, SH3_C which is most similar to an SH3 domain from the mouse Ray protein and SH3_D which is most similar to the SH3 domain from Dictyostelium myosin IB. Additional sequence analysis reveals the presence of a very large number of potential phosphorylation sites in the Ese proteins and a single SH3 binding consensus in the N-termini of each Ese protein.

With the knowledge of the amino acid sequences for Esel and Ese2 proteins and the alternative transcripts EselL and Ese2L, there is provided in accordance with the present invention antibodies which recognize epitopes within these proteins and which can be raised to provide information on the characteristics of the protein as well as for any mutant form of these proteins. The generation of antibodies enables the visualization of the protein in mammalian cells and tissues using Western blotting as described herein. Antibodies to the Esel or Ese2 proteins also allows for the use of immunocytochemistry and immunofluorescence techniques in which the proteins are visualized directly in cells and tissues as described herein. This is most helpful in order to establish the subcellular location of the protein and the tissue specificity of the protein. In general, methods for the preparation of antibodies are well known. In order to prepare polyclonal antibodies, fusion proteins containing defined portions or all of the Esel or Ese2 proteins or any of their alternative transcripts can be synthesized in bacteria by expression of corresponding DNA sequences in a suitable cloning vehicle. The protein can then be purified, coupled to a carrier protein and mixed with Freund's adjuvant (to help stimulate the antigenic response by the rabbits) and injected into rabbits or other laboratory animals. Alternatively, protein can be isolated from cultured cells expressing the protein. Following booster injections at bi-weekly intervals, the rabbits or other laboratory animals are then bled and the sera isolated. The sera can be used directly or purified prior to use, by affinity chromatography. The sera can then be used to probe protein extracts run on a polyacrylamide gel to identify the Esel or Ese2 protein, alternative transcript or any mutant thereof. Alternatively, synthetic peptides can be made to the antigenic portions of these proteins and used to innoculate the animals.

Methods to produce monoclonal antibodies which specifically recognize mammalian Esel or Ese2 proteins or portions thereof, are known in the art. In general, cells actively expressing the protein are cultured or isolated from tissues and the cell extracts isolated. The extracts or recombinant protein extracts, containing the Esel or Ese2 protein, are injected in Freund's adjuvant into mice. After being injected 9 times over a three week period, the mice spleens are removed and resuspended in phosphate buffered saline (PBS). The spleen cells serve as a source of lymphocytes, some of which are producing antibody of the appropriate specificity. These are then fused with a permanently growing myeloma partner cell, and the products of the fusion are plated into a number of tissue culture wells in the presence of a selective agent such as HAT. The wells are then screened to identify those containing cells making useful antibody by ELISA. These are then freshly plated. After a period of growth, these wells are again screened to identify antibody-producing cells. Several cloning procedures are carried out until over 90% of the wells contain single clones which are positive for antibody production. From this procedure a stable lines of clones is established which produce the antibody. The monoclonal antibody can then be purified by affinity chromatography using Protein A or Protein G Sepharose.

The Ese proteins may be isolated and purified by methods selected on the basis of properties revealed by its sequence. Purification can be achieved by protein purification procedures such as chromatography methods (gel-filtration, ion-exchange and immunoaffinity), by high-performance liquid chromatography (HPLC, RP-HPLC, ion-exchange HPLC, size-exclusion HPLC, high-performance chromatofocusing and hydrophobic interaction chomatography) or by precipitation (immunoprecipitation). Polyacrylamide gel electrophoresis can also be used to isolate the Ese proteins based on the molecular weight of the protein, charge properties and hydrophobicity.

Similar procedures to those mentioned can be used to purify the protein from cells transfected with vectors containing an Ese gene (e.g. baculovirus systems, yeast expression systems and eukaryotic expression systems).

The purified proteins can be used in further biochemical analyses to establish secondary and tertiary structure which may aid in the design of pharmaceuticals to interact with the protein, alter the protein charge configuration or charge interaction with other proteins or alter its function. The Ese proteins can also be purified from the creation of fusion proteins which are expressed and recovered from prokaryotic or eukaryotic cells. The fusion proteins can be purified by affinity chromatography based upon the fusion vector sequence. The Ese protein can then be further purified from the fusion protein by enzymatic cleavage of the fusion protein.

Expression of Ese genes

In order to determine where the Ese genes are expressed Northern analysis was performed on mRNA derived from several adult mouse tissues (Figure 1). These genes are both widely expressed and reveal a complex pattern of alternatively spliced transcripts. The highest levels of Esel mRNA were noted in brain, heart and skeletal muscle. Brain and skeletal muscle mRNA also contain an unusually large transcript which may be as much as 15kb in length. Interestingly, these tissues express high levels of many proteins involved in synaptic vesicle recycling and endocytosis.

The Northern blot reveals the presence of many alternative mRNA transcripts for both Esel and Ese2. In addition, numerous Esel expressed sequence tags have been identified which skip sequences encoding individual EH domains or regions of the coiled-coil domain indicating that this gene has the potential to encode for many distinct proteins. Indeed, the SH3_C domain was spliced out of the human SH3P17 partial cDNA described by Sparks 1996 (53). The predicted Ese2 protein on the other hand encodes a C-terminal extension of 45 amino acids in comparison to the human SH3P18 partial cDNA, revealing that this gene is also alternatively spliced. Lung, liver and kidney express high levels of a 2.4kb Ese2 transcript which is significantly smaller than the 3591 bp sequence required to code for our full Ese2 protein as shown in Table 1 or 2, indicating that a major isoform of Ese2 has only a subset of the domains described above. Alternative Splicing of Esel. Ese2 transcripts

Additional transcripts from both Esel and Ese2 genes have also been characterized. One of the Esel clones isolated from a mouse brain cDNA library contained an extended reading frame. PCR was used from mouse brain cDNA libraries to identify the remaining coding sequences from this transcript. The splicing event which produces this extended protein adds an additional 501 amino acids to Esel, and codes for a DBL homology domain, a Pleckstrin homology (PH) domain and a C2 domain (Figure 2B). DBL and PH domains are found together in guanine nucleotide exchange factors for the Rho family of small GTPases. This long form of Esel is therefore expected to function as an activator of Rho-GTPases, which in turn regulate the actin cytoskeleton and numerous signal transduction pathways (61). C2 domains on the other hand are Ca^+" activated membrane binding domains and protein- protein interaction domains (62). A number of expressed sequence tages which code for a novel C2 domain fused to the sequence coding for the last 11 amino acids of Ese2 have been identified. PCR was used to isolate sequences coding for alternatively spliced exon(s) which can be included C-terminal to the SH3 domains but before the stop codon. The alternatively spliced exon(s) of Ese2 also code for a DBL/PH + C2 domain cassette which can be included within the Ese2 transcript (Figure 2B). As the Ese genes are subject to complex alternative splicing to produce proteins with novel predicted functions (eg. regulation of the cytoskeleton and membrane-binding), the alternative proteins are named as modifications of Ese. The Esel and Ese2 long forms described in Figure 2B are called EselL and Ese2L, respectively. In the event that specific domains are spliced out from the transcripts coding for Esel and Ese2 proteins as shown in Table 2, then the name is listed as an Eseδ variant. The protein encoded by the spliced variant in the original SH3P17 clone is designated as EselδS_c to indicate removal of SH3_C.

In an embodiment of the present invention the knowledge of the Esel and Ese2 gene sequences and their expression in heterologous cell systems can be used to demonstrate structure-function relationships as well as provide for cell lines for the purposes of drug screening. Ligating the Esel or Ese2 cDNA sequence into a plasmid expression vector to transfect cells is a useful method to test the proteins influence on various cellular biochemical parameters including the identification of substrates, binding partners as well as activators and inhibitors of the proteins. Plasmid expression vectors containing either the entire, or portions thereof, Esel or Ese2 can be used in in vitro mutagenesis experiments which will identify portions of the protein crucial for regulatory function.

The Esel or Ese2 cDNA sequence (or EselL and Ese2L cDNA sequence) can

SUBSTJTTUTE SHEET (RULE 26 be manipulated in studies to understand the expression of the gene and its product, to achieve production of large quantities of the protein for functional analysis, for antibody production, and for patient therapy. The changes in the sequence may or may not alter the expression pattern in terms of relative quantities, tissue-specificity and functional properties. Partial or full-length cDNA sequences which encode for the Esel or Ese2 protein (or alternative transcripts thereof), modified or unmodified, may be ligated to bacterial expression vectors. E. coli can be used using the T7 RNA polymerase/promoter system using two plasmids or by labeling of plasmid-encoded proteins, or by expression by infection with Ml 3 Phage mGPI-2. E. coli vectors can also be used with Phage lamba regulatory sequences, by fusion protein vectors (eg. lacZ and trpE), by maltose-binding protein fusions, and by glutathione-S-transferase fusion proteins.

Alternatively, the Ese 1 or Ese2 protein or alternative transcripts thereof can be expressed in insect cells using baculoviral vectors, or in mammalian cells using vaccinia virus. For expression in mammalian cells, the cDNA sequence may be ligated to heterologous promoters, such as the simian virus (SV40) promoter in the pSV2 vector and introduced into cells, such as COS cells to achieve transient or long- term expression. The stable integration of the chimeric gene construct may be maintained in mammalian cells by biochemical selection, such as neomycin, G418 and purimycin.

Any of the Esel or Ese2 cDNA sequences can be altered using procedures such as restriction enzyme digestion, fill-in with DNA polymerase, deletion by exonuclease, extension by terminal deoxynucleotide transferase, ligation of synthetic or cloned DNA sequences, site-directed sequence alteration with the use of specific oligonucleotides together with PCR.

The cDNA sequence or portions thereof, or a mini gene consisting of a cDNA with an intron and its own promoter, is introduced into eukaryotic expression vectors by conventional techniques. These vectors permit the transcription of the cDNA in eukaryotic cells by providing regulatory sequences that initiate and enhance the transcription of the cDNA and ensure its proper splicing and polyadenylation. The endogenous Esel or Ese2 gene promoter can also be used. Different promoters within vectors have different activities which alters the level of expression of the cDNA. In addition, certain promoters can also modulate function such as the glucocorticoid- responsive promoter from the mouse mammary tumor virus. Some of the vectors listed contain selectable markers or neo bacterial genes that permit isolation of cells by chemical selection. Stable long-term vectors can be maintained in cells as episomal, freely replicating entities by using regulatory elements of viruses. Cell lines can also be produced which have integrated the vector into the genomic DNA. In this manner, the gene product is produced on a continuous basis.

Vectors are introduced into recipient cells by various methods including calcium phosphate, electroporation, lipofection, DEAE dextran, microinjection, or by protoplast fusion. Alternatively, the cDNA can be introduced by infection using viral vectors.

Eukaryotic expression systems can be used for many studies of the Esel or Ese2 gene and gene product(s) including determination of proper expression and post- translational modifications for full biological activity, identifying regulatory elements located in the 5' region of the Esel or Ese2 gene and their role in tissue regulation of protein expression, production of large amounts of the normal and mutant protein for isolation and purification, to use cells expressing the Esel or Ese2 protein or alternative transcripts thereof as a functional assay system for antibodies generated against the protein or to test effectiveness of pharmacological agents, or as a component of a signal transduction system, to study the function of the normal complete protein, specific portions of the protein, or of naturally occurring and artificially produced mutant proteins.

Using the techniques mentioned, the expression vectors containing the Esel or Ese2 cDNA sequence or portions thereof can be introduced into a variety of mammalian cells from other species or into non-mammalian cells. It is understood that the cDNA sequences for use in the present invention include those sequences disclosed herein encoding Esel, EselL, Ese2 and Ese2L proteins.

The recombinant cloning vector, according to this invention, comprises the selected DNA of the DNA sequences of this invention for expression in a suitable host. The DNA is operatively linked in the vector to an expression control sequence in the recombinant DNA molecule so that Esel or Ese2 proteins or alternative transcripts thereof can be expressed. The expression control sequence may be selected from the group consisting of sequences that control the expression of genes of prokaryotic or eukaryotic cells and their viruses and combinations thereof. The expression control sequence may be selected from the group consisting of the lac system, the tip system, the tac system, the trc system, major operator and promoter regions of phage lambda, the control region of the fd coat protein, early and late promoters of SV40, promoters derived from polyoma, adenovirus, retrovirus, baculovirus, simian virus, 3-phosphoglycerate kinase promoter, yeast acid phosphatase promoters, yeast alpha-mating factors and combinations thereof.

The host cell which may be transfected with the vector of this invention may be selected from the group consisting of E.coli, pseudomonas, bacillus subtillus, bacillus stearothermophilus, or other bacili; other bacteria, yeast, fungi, insect, mouse or other animal, plant hosts, or human tissue cells.

Subcellular localisation of Ese proteins

To determine the subcellular localization of Esel, a myc-epitope tagged version of this protein (mycEsel) was engineered. This tagged protein was expressed in Cos cells and detected by confocal immunofluoresence using the mouse anti-myc monoclonal antibody 9E10 (Figure 4). Interestingly, the transfected Esel protein is highly concentrated into circular domains (Figure 4A and 4A') which are present throughout transfected cells (compare single optical section in Figure 4A with the projection of all sections through the same cell shown in 4A'). In some optical sections rings of fluorescent staining surrounding a non-staining area were observed suggesting that the Esel induced structures are vesicles rather than inclusion bodies (data not shown and Figure 6). Esel overexpressed in 10T1/2, BHK and Hela cells using the vaccinia virus T7 expression system is also localized to large circular domains (data not shown). This concentration of ectopically expressed Esel contrasts with the localization of Eps 15 in transiently transfected cells, Eps 15 being dispersed throughout the cell (Figure 4B). Esel and Eps 15 proteins form a complex in vivo and yet localize to distinct subcellular compartments in transfected Cos cells. We therefore determined the localization of both mycEsel and Eps 15 in Cos cells co- transfected with both genes. In co-transfected cells, mycEsel is still found in circular domains (Figure 4C). Interestingly, the transfected Eps 15 is now also partially co- localized with Esel in the same circular domains (Figure 4C and C"). The C-terminal third of Eps 15 contains several regions which are required for association with α-adaptin of the AP2 clathrin adaptor complex (31). It has been shown that this region of Eps 15 is not required for its association with Esel (Figure 4). In order to test whether Eps 15 function may be required for Ese localization, mycEsel and Epsl5δC have been co-transfected. Interestingly, mycEsel localization is still partially colocalized with Epsl5δC (Figure 4D, D' and D") but is no longer found to be concentrated within circular structures, indicating that Esel requires Epsl 5 function for distinctive subcellular localization in transfected cells. In addition, these data suggest that the Esel :Epsl5 complex may require association with AP2 which binds to the Eps 15 C-terminus in order to form the large circular domains in Esel transfected cells. Identification of binding partners of Ese proteins

In order to identify Ese partners, a systematic analysis was initiated of each domain for binding partners using the yeast two hybrid system. The central coiled-coil domain of Esel from amino acid 330 to 732 was fused to the GAL4 DNA binding domain and transformed into the Yl 90 reporter strain together with plasmid cDNA libraries from several tissue sources. Yeast colonies were selected for growth on Histidine minus plates in the presence of 40mM 3 -amino triazole to select for interaction between library encoded GAL4 activation domain fusions and the GAL4 DNA binding domain Esel coiled-coil bait. Yeast colonies which survived selection for expression of the His3 gene where also tested for induction of the integrated LacZ gene which is GAL4 responsive in Y190. Prey plasmids were recovered from 37 positive yeast colonies which were selected for expression of both His3 and LacZ. Several classes of cDNA were recovered in this screen. One class included Eps 15 which was isolated twice and Epsl5R which was isolated from four yeast colonies. Interestingly these clones were all partial cDNA fusions which minimally included C- terminal sequences from the central coiled-coil domain to the 3"UTR (Figure 3 A). In the case of Eps 15, the positive clones start from amino acid 306 and 376 whereas in Epsl5R the N-terminal boundary of clones were amino acid 4, 10, 222 and 386. These data indicate that minimal sequences required for interaction between the Esel coiled-coil domain and Epsl 5 (R) include either or both of the central coiled-coil and/or the C-terminal third of these proteins.

The Ese proteins were analyzed in vivo to test for their association with Eps 15 or Epsl5R. Polyclonal antisera were raised in chickens against a GST fusion containing the C-terminus of Esel from amino acid 665 to the stop codon. This region of Esel contains all five of the SH3 domains. In addition, polyclonal antisera were generated in rabbits against a peptide representing the first 21 amino acids of Esel. Cell lysates were prepared from A431, PC 12, MDCK and Hela cells which represent cell lines from several distinct tissue types and species. The rabbit anti- peptide antisera were used to precipitate Esel from each lysate and precipitates were analyzed by western blotting using the chicken anti-Ese sera. In each cell line the presence of several specific bands in the range of 150kDa were observed which were precipitated in the absence but not in the presence of the peptide to which the sera was generated (Figure 3A). Thus the Esel protein is expressed in many tissue culture cells and runs in a range consistent with the predicted molecular weight of 137kDa. The same samples were also analyzed for co-immunoprecipitation of Eps 15 proteins. In each case multiple Epsl 5 proteins were detected which co-purify with Esel. The anti- Ese 1 peptide antisera and commercially available anti-Epsl5 antisera which were used were raised against epitopes which are not shared by these proteins indicating that Esel and Eps 15 are constitutively associated partners in vivo. This association is reminiscent of the previously detected complex between two EH domain containing yeast proteins, End3p and Panlp. Esel and Eps 15 proteins both contain central coiled-coil motifs. In addition,

Esel contains multiple C-terminal SH3 domains while Eps 15 contains SH3-binding motifs. In order to map the regions of each protein which are required for their association in vivo, C-terminal truncations of each (Epsl5δC and EselδC) were generated. Full length Eps 15 was co-transfected into Cos-1 cells together with either full length Esel or C-terminally truncated EselδC. Cell lysates were precipitated with either rabbit anti-Epsl5 or with rabbit anti-Ese 1, and precipitates were western blotted with chicken anti Esel antisera. Interestingly, the C-terminally truncated Esel protein was efficiently immunoprecipitated in a complex with Eps 15 using anti-Epsl5 sera. In a reciprocal experiment Cos-1 cells were transfected with Esel alone or together with Eps 15 or C-terminally truncated Epsl 5 which had been Flag-epitope tagged (Epsl5δC-Flag). Cell lysates were prepared and immunoprecipitated with either rabbit anti-Ese 1, mouse anti-Flag, or rabbit anti-Epsl5 antibodies. These immunoprecipitations were also western blotted to analyze for the presence of Esel (Figure 3B). The anti-Flag antibody efficiently precipitated Esel from cells expressing Flag-tagged Eps 15δC indicating that the C-terminally truncated Eps 15 protein can bind to Esel in vivo. The Esel and Eps 15 proteins are therefore associated through interaction of their central coiled-coil regions and do not require the presence of SH3 and SH3-binding motifs in their respective C-termini.

In addition to the identification of Eps 15 and Epsl5R in the yeast two hybrid screen with the coiled-coil domain bait of Esel, the following were also identified as Ese binding proteins: TSG101 (accession #U52945), meningioma expressed antigens 6/11 (accession #U94780 for mea6), β-tropomyosin, rabaptin5 (accession #D86066), Adora2a (accession #Y 13345), LI lipid binding protein (accession #K02109) and numerous cytokeratins and laminins. Novel genes identified in this screen are detailed below.

Also performed was a yeast two hybrid screen using amino acids 665-1213 of Esel as bait. This screen led to the isolation of the following clones which produced GAL4 Activation domain fusions which bound to this SH3 domain bait of Esel . The Ese-binding proteins identified in our SH3 screen were the cbl-b oncoprotein (accession #U26712), Dynamin II (accession #L31398), KIAA0268 (accession #D87742), Jerky (accession #U35730), hnRNP-K (accession #L29769), SAP49

SUBSTTTUTE SHEET (RULE 26 (accession #L35013) and SOS-1 (accession #Z11574). Novel genes identified in this screen are detailed below and several novel clones as outlined below.

These results demonstrate that the novel Ese genes and the proteins that they encode function in a complex with Eps 15 proteins to regulate endocytosis together. In addition, this complex contains binding sites for numerous other proteins.

Furthermore, with the identification of several potential phosphorylation sites on the Ese proteins, these results also suggest that whether or not complexed with Epsl 5, Ese proteins are involved in intracellular signalling processes which are likely to lead to altered cellular activity. Many Ese partners have been identified in these studies. Also revealed is a novel method to identify more Ese partners. Yeast cells have a complex formed by two EH domain proteins (Panlp and End3p) which regulates both endocytosis as well as the actin cytoskeleton. Indeed, the Eps 15 protein has been reported to regulate both endocytosis and the actin cytoskeleton (1). As Eps 15 and Ese function together, and Ese contain many protein-protein interaction surfaces on this complex, strongly suggesting that the Ese proteins and their binding proteins are critical regulators of Epsl5:Ese functions in vivo.

Ese and Dynamin

Yeast two-hybrid screens using baits composed of the GAL4 DNA-binding domain fused to individual SH3 domains of Esel were performed to identify Ese partners which bind the SH3s of this multi-domain protein. Initial screens with SH3B and SH3C domain fusions resulted in the artifactual isolation of many proline-rich fragments which did not represent real Ese partners. Screens were then done with GAL4 fusions containing all five SH3 domains from amino acid 665 to 1213. Forty one His3+/LacZ+ colonies from such screens were selected for further analysis. Six colonies were found to encode fragments of the Dynamin II gene and two encoded fragments of Dynamin I (Figure 5 A). All Dynamin II clones had 5' start sites between amino acid 252 and 278 and terminated within the 3^* UTR. The two Dynamin I clones were identical and contained a small coding rregion from amino acid 673 to the C-terminus. Dynamin sequences contained within each Esel- interacting clone therefore minimally code for the proline-rich motifs (Figure 5A) which are known to bind SH3 domains in vitro (44). This result is consistent with the interaction between Dap 160 and Dynamin that has been recently described in Drosophila (59). To determine the significance of Esel : Dynamin binding, functional interactions between these proteins were tested for. MycEsel was transfected into Cos cells. The subcellular localization of Dynamin in Esel overexpressing cells was analyzed by staining for endogenous Dynamin and the myc tag on Esel . In many Esel transfectants, endogenous Dynamin was recrutied to the Esel staining vesicles and both proteins were co-localized (Figure 5B, panel a, b and c). These results demonstrate that Ese proteins bind Dynamin and can regulate its subcellular localization. Given that Esel functions in a complex with Eps 15 and Ese can regulate the subcellular distribution of Dynamin, it was investigated whether Eps 15 also co-localized with Dynamin. Epsl 5 transfected into Cos cells was diffusely localized (Figure 4). Endogenous Dynamin was not concentrated and was therefore not visable in Eps 15 transfected cells (data not shown). When Esel and Eps 15 were co-transfected however, Eps 15 and endogenous Dynamin are colocalized on the Esel induced circles (Figure 5, panels d, e and f) indicating that all three proteins co- localize at these structures.

Ese and Epsin Family Proteins

In order to identify additional Ese partners, a fusion between GAL4-DBD and the N-terminal EH domain region of Esel (amino acids 1-393) was generated. This fusion protein was also used in yeast two hybrid screens with several GAL4 activation domain cDNA libraries. A total of 11 His3+/LacZ+ colonies were identified as containing library encoded fusion proteins which interact with the Esel EH-domain bait. Two of these clones coded for mouse homologues of the Epsin protein which was recently identified on the basis of its affinity for Epsl 5, and α-adaptin and is required for clathrin-mediated endocytosis (63). The two Epsin clones code for C- terminal fragments from amino acids 403 and 470 respectively. One of the Esel EH- domain interacting clones which was obtained coded for a C-terminal fragment of a novel Epsin-family protein (63, 64). This cDNA has been independently isolated and named Ibp-2 in accession #AF057286. The Ibp2 clone which has been identified includes amino acids 326 to 509 of the partial coding sequence in Genbank. Each Epsin family protein which has been isolated contains a C-terminal region which codes for three copies of an NPF motif. This is also the region of Epsin which binds to Eps 15. It has previously been shown that AP-2 can independently bind both Epsin and Eps 15. It is now demonstrated that the C-terminus of Epsin family proteins can bind not only to the EH domains of Eps 15 but also to the EH domains of Esel. These data suggest that either multiple Epsin proteins exist in the Ese:Epsl5 complex or the interaction between individual proteins in various AP- 2:Epsin:Epsl5:Ese:Dynamin complexes may be subject to dynamic rearrangement during clathrin coated pit formation, invagination and scission. Also identified was a mammalian homologue of drosophila. SINA, seven in absentia. Esel Overexpression Blocks Endocytosis

Overexpression of Panlp in yeast induces phenotypes which are identical to those observed in panl loss-of-fucntion mutants (65) suggesting that by altering the relative ratios of Panlp to its numerous partners, the function of higher order Panlp complexes may be blocked. As the Ese:Epsl5 complex contains many protein-protein interaction domains which bind partners including Dynamin, Epsin and AP-2, it was thought that overexpressed Esel may disrupt the formation of higher order complexes between Ese proteins and partners. It was therefore tested whether clathrin-mediated endocytosis was functional in myc Esel overexpressing cells. Cos-1 cells were transfected with myc -tagged Esel, and 48 hrs post transfection, FITC-labelled

Transferrin was added to cultures for 30 minutes. Cells were then fixed and analyzed for expression of mycEsel and for internalization of Transferrin. As shown in Figure 6, transfected cells do not internalize transferrin in contrast to their untransfected neighbors. Cell counts in a representative experiment indicate that 96% of Esel overexpressing cells do not internalize labeled transferrin (N=46) whereas 100% of untransfected cells were capable of clathrin-mediated endocytosis (N=100). It appears that overexpression of Dynamin II may override the Esel induced endocytic block. These data indicate that overexpression of Esel blocks endocytosis and this may be through sequestration of Dynamin or other Esel partners into non-productive binary complexes during endocytosis or recycling of the tranferrin receptor. Overexpressed Esel would therefore be functioning as a dominant inhibitory protein through recruitment of partners into non-productive complexes which do not contain all of the necessary components for endocytosis to proceed.

Taken together, these studies demonstrate the identification and isolation of novel mammalian Ese proteins encoded by novel Ese genes which are involved in the regulation of endocytosis via clathrin-coated pits, vesicular trafficking and actin dynamics. These studies also demonstrate the identification and isolation of two alternative transcripts of the genes, named EselL and Ese2L. The process of endocytosis including receptor-mediated endocytosis as well as pinocytosis or non- eceptor mediated endocytosis. The novel Ese proteins of the present invention appear to function to regulate endocytosis involving the formation of clathrin-coated pits by the polymerization of clathrin into a lattice along the cytosolic face of a region of membrane causing the region to expand inward. Ultimately, the pit pinches off from the membrane, and the clathrin cage is completed thus producing a coated vesicle. Through the binding of Espl5 to form an Ese-Epsl5 complex via a central binding region, the complex can recruit other proteins such as, Epsin, AP-2 and dynamin and promote coated vesicle formation and perhaps their transport to appropriate locations within the cell and release of internalized proteins and or molecules (Figure 7). The SH3 C-terminal domains of the Ese proteins can bind and interact with several other proteins leading to a host of protein-protein interactions involved in subcellular trafficking and signalling. The Ese proteins may be activated or inactivated via phosphorylation of the proteins at numerous phosphorylation sites by the action of activated receptors on cell surfaces.

Due to the fact that the Ese proteins appear to be a key central player in the complex process of endocytosis involving protein-protein interactions and intracellular signalling, these proteins are most likely involved in a myriad of clinical conditions and processes which are very likely to include but not be limited to regulation of endocytosis (as described above), cell division and cancer (Eps 15 and cbl are oncoproteins), cell migration (regulation of the actin cytoskeleton is required for many forms of cell migration), cell polarity, plane of cell division and cell fate specification (Eps 15 binds to Numb in vivo which is required for these processes (43), RNA localization (several RNA binding proteins have been identified in the present screens) and viral infection and life cycle (Eps 15 binds to RAB a cellular cofactor for HIV Rev (43)). With respect to viral infection Ese proteins may play an important role and thus may be a target for developing therapeutic strategies against viral infection and virally-induced disease states. HIV is known to alter endocytosis of several important cell surface molecules including CD4 and MHC antigens. HIV-NEF has been demonstrated to bind to SH3 domains. NEF induces clathrin coated pit formation. As NEF binds SH3 domains and induces endocytosis, it is possible that Ese proteins may bind to NEF and are involved in NEF function. Therapeutic strategies to provide treatment for viral infection and virally induced disease states may therefore include the inhibition of Ese-NEF interactions, antibodies or other agents directed against Ese complexes to inhibit endocytosis and in this manner inhibit viral infection and virally induced disease states. It is also expected that many types of viruses will interact with the multi-component Epsl5-Ese complex.

Synaptic transmission and abnormal or altered synaptic transmission as seen in various nervous disorders may also be a target for the therapeutic use of Ese proteins and/or antagonists. The Epsl5:Ese complex has been demonstrated to regulate endocytosis, is highly expressed in the brain and Ese binds to Jerky; a protein required to prevent epilepsy in mice (57). Futhermore, Ese proteins are highly expressed not only in the brain but also in the heart and in skeletal muscle which are tissues involving high levels of synaptic transmission. This suggests that Ese protein may be used in the treatment of nervous system disorders involving altered synaptic transmission.

Receptor-mediated cell signaling such as seen with several different types of growth factors also involves endocytosis. Over-expression, mutation or over- stimulation of growth factor receptors has been demonstrated to lead to abnormal cell division and growth as seen in cancer. For example, EGF is a potent mitogen for many epithelial cells and EGF receptor activation is known to stimulate intracellular kinase pathways leading to cell proliferation. Such activity may play a role in cancer progression.By altering the rate of endocytosis by targeting Ese proteins, the cell proliferative effect of growth factor receptor stimulation may be counteracted.

Abnormal cell division and cell migration is seen in several diseases and involves the cell cytoskeleton. The intracellular cytoskeleton is highly organized and consists of microtubules, microfilaments and intermediate filaments acting as an internal reinforcement in the cytoplasm of a cell. Together these structures associate in a regular and defined manner which is regulated by extracellular signals and may transduce plasma membrane signals by association with other proteins or by second messengers. The Ese-Epsl5 complex is very likely to regulate the cytoskeleton by analogy to the role of Panlp:End3p in regulation of yeast cytoskeleton. Furthermore, endocytosis is known to involve a rearrangement of the intracellular cytoskeleton. Cell division and migration require the continual rearrangement of the intracellular cytoskeleton. Therefore, abnormal patterns of cell division and migration may involve altered Ese function and altered endocytosis. The Ese proteins or the genes may therefore be used to alter regulation of endocytosis or the association of the Ese proteins with the cytoskeleton and may restore cell division and migration to normal levels and patterns.

Tissue development also involves the continual remodeling of the cytoskeletal network along with its associated proteins. Developmental diseases can occur as a result of abnormal remodeling of the cytoskeleton leading to altered intracellular signaling. As Ese proteins are likely to be involved with both the cytoskeleton and intracellular signaling they may also be directly involved in the development of certain developmental diseases and therefore may be a target for therapeutic treatment of such diseases. Ese proteins may also be involved in normal development including that of stem cells which are self-renewing cells that divide to produce differentiated daughter cells in various tissues. As Ese proteins are associated with the cytoskeleton they may play a part in the formation of certain types of differentiated cells through the partitioning of RNA and proteins such as nuMb during cell division. Transgenic Animal Models

The creation of transgenic animal models for abnormal endocytotic function characterized by altered Esel or Ese2 activity is important to the understanding of the function of these proteins in intracellular signaling and for the testing of possible therapies for abnormal endocytosis involving protein-protein interactions and intracellular signalling and leading to various clinical conditions. In general, techniques of generating transgenic animals are widely accepted and practiced

There are several ways in which to create an animal model in which the Esel or Ese2 gene expression or function is altered. One could simply generate a specific mutation in the mouse Esel or Ese2 gene as one strategy. Secondly a wild type human Esel or Ese2 gene and/or a humanized murine gene could be inserted into the animals genome by homologous recombination. It is also possible to insert a mutant (single or multiple) human gene as genomic or minigene construct using wild type or mutant or artificial promoter elements. More commonly, and most preferred in the present invention, knock-out of the endogenous murine genes may be accomplished by the insertion of artificially modified fragments of the endogenous gene by homologous recombination. The modifications include insertion of mutant stop codons, the deletion of DNA sequences, or the inclusion of recombination elements (lox p sites) recognized by enzymes such as Cre recombinase. Gene knockout produces homozygous mutant mice, which show symptoms or phenotype similar to those exhibited by a human.

In general, for gene knock-out, embryonic stem cells heterozygous for a knockout mutation in a gene of interest (ie. Esel or Ese2 gene) and homozygous for a marker gene (eg. coat colour) are transplanted into the blastocoel cavity of 4.5 day embryos homozygous for an alternate market. The early embryos then are implanted into a pseudopregnant female. Some of the resulting progeny are chimeras. Chimeric mice then are backcrossed. Intercrossing will eventually produce individuals homozygous for the disrupted allele that is, knockout mice. (Capecchi, MR. 1989. Science. 244:1299-1291).

To inactivate the Esel or Ese2 mouse gene chemical or x-ray mutagenesis of mouse gametes, followed by fertilization, can be applied. Heterozygous offspring can then be identified by Southern blotting to demonstrate loss of one allele by dosage, or failure to inherit one parental allele using RFLP markers. To create a transgenic mouse, a mutant or normal version of the human Esel or Ese2 gene can be inserted into a mouse germ line using standard techniques of oocyte microinjection or transfection or microinjection into stem cells. Alternatively, if it is desired to inactivate or replace the endogenous Esel or Ese2 gene, homologous recombination using embryonic stem cells may be applied.

For oocyte injection, one or more copies of a mutant or normal Esel or Ese2 gene can be inserted into the pronucleus of a just-fertilized mouse oocyte. This oocyte is then reimplanted into a pseudo-pregnant foster mother. The liveborn mice can then be screened for integrants using analysis of tail DNA for the presence of transgenic Esel or Ese2 gene sequences. The transgene can be either a complete genomic sequence injected as a YAC or chromosome fragment, a cDNA with either the natural promoter or a heterologous promoter, or a minigene containing all of the coding region and other elements found to be necessary for optimum expression.

Retro viral infection of early embryos can also be done to insert the human or mouse Esel or Ese2 gene. In this method, the Esel or Ese2 gene is inserted into a retroviral vector which is used to directly infect mouse embryos during the early stages of development to generate a chimera, some of which will lead to germline transmission.

Homologous recombination using stem cells allows for the screening of gene transfer cells to identify the rare homologous recombination events. Once identified, these can be used to generate chimeras by injection of mouse blastocysts, and a proportion of the resulting mice will show germline transmission from the recombinant line. This methodology is especially useful if inactivation of the Esel or Ese2 gene is desired. For example, inactivation of the Esel or Esel gene can be done by designing a DNA fragment which contains sequences from a Esel or Ese2 exon flanking a selectable marker. Homologous recombination leads to the insertion of the marker sequences in the middle of an exon, inactivating the Esel or Ese2 gene. DNA analysis of individual clones can then be used to recognize the homologous recombination events.

This embodiment of the invention has the most significant commercial value as a mouse model for abnormal endocytotic activity and this may include disorders such as those involving abnormal cell division, cancer, abnormal cell migration, viral infection, abnormal tissue development and abnormal synaptic transmission disorders.

Therapy

Gene therapy is another potential therapeutic approach for treating disorders involving abnormal endocytosis, vesicular trafficking and abnormal regulation of the actin cytoskeleton. Such disorders may include for example but not be limited to disorders such as those involving abnormal cell division, cancer, abnormal cell migration, viral infection, abnormal tissue development and abnormal synaptic transmission disorders.

In such therapy, normal copies of a mammalian Ese gene are introduced into patients to code successfully for normal protein in several different affected cell types. The gene must be delivered to those cells in a form in which it can be taken up and code for sufficient protein to provide effective function

Retroviral vectors can be used for somatic cell gene therapy especially because of their high efficiency of infection and stable integration and expression. The targeted cells however must be able to divide and the expression of the levels or normal protein should be high. The full length Ese gene can be cloned into a retroviral vector and driven from its endogenous promoter or from the retroviral long terminal repeat or from a promoter specific for the target cell type of interest.

Other viral vectors which can be used include adeno-associated virus, vaccinia virus, bovine papilloma virus, or a herpevirus such as Epstein-Barr virus.

Gene transfer could also be achieved using non-viral means requiring infection in vitro. This would include calcium phosphate, DEAE dextran, electroporation, and protoplast fusion. Liposomes may also be potentially beneficial for delivery of DNA into a cell. Although these methods are available, many of these are lower efficiency.

Antisense based strategies can employed to explore mammalian Ese gene function and as a basis for therapeutic drug design. The principle is based on the hypothesis that sequence-specific suppression of gene expression can be achieved by intracellular hybridization between mRNA and a complementary antisense species. The formation of a hybrid RNA duplex may then interfere with the processing/transport translation and/or stability of the target Ese mRNA. Hybridization is required for the antisense effect to occur, however the efficiency of intracellular hybridization is low and therefore the consequences of such an event may not be very successful. Antisense strategies may use a variety of approaches including the use of antisense oligonucleotides, injection of antisense RNA and transfection of antisense RNA expression vectors. Antisense effects can be induced by control (sense) sequences, however, the extend of phenotypic changes are highly variable. Phenotypic effects induced by antisense effects are based on changes in criteria such as protein levels. Protein activity measurement, and target mRNA levels. Multidrug resistance is a useful model to study molecular events associated with phenotypic changes due to antisense effects, since the multidrug resistance phenotype can be established by expression of a single gene mdrl (MDR gene) encoding for P- glycoprotein.

Transplantation of normal genes into the affected area of the patient can also be useful therepy for any disease condition which includes abnormal endocytosis, vesicular trafficking and abnormal regulation of the actin cytoskeleton. In this procedure, a normal human Ese gene is transferred into a cultivatable cell type, either exogenously or endogenously to the patient. These cells are then injected serotologically into the disease-affected tissue or tissues. Immunotherapy is also possible for treating disorders which includes abnormal endocytosis, vesicular trafficking and abnormal regulation of the actin cytoskeleton. Antibodies are raised to a mutant Ese protein (or a portion thereof) and are administered to the patient to bind or block the mutant protein and prevent its deleterious effects. Simultaneously, expression of the normal protein product could be encouraged. Alternatively, antibodies are raised to specific complexes between mutant or normal Ese proteins and their binding partners.

A further approach is to stimulate endogenous antibody production to the desired antigen. Administration could be in the form of a one time immunogenic preparation or vaccine immunization. An immunogenic composition may be prepared as injectables, as liquid solutions or emulsions. The Ese protein or other antigen may be mixed with pharmaceutically acceptable excipients compatible with the protein. Such excipients may include water, saline, dextrose, glycerol, ethanol and combinations thereof. The immunogenic composition and vaccine may further contain auxiliary substances such as emulsifying agents or adjuvants to enhance effectivess. Immunogenic compositions and vaccines may be administered parenterally by injection subcutaneously or intramuscularly.

The immunogenic preparations and vaccines are administered in such amount as will be therapeutically effective, protective and immunogenic. Dosage depends on the route of administration and will vary according to the size of the host.

Screening for Disease

In another embodiment of the invention the knowledge of mammalian Esel and Ese2 cDNA sequences provides for screening by conventional methods to obtain the corresponding human sequences and thus screening for various diseases involving abnormal Esel or Ese2 (or alternative transcripts thereof) in which the defect is due to a mutant Esel or Ese2 gene and thus an altered and abnormal endocytosis process involved in various disorders. Mutant forms of the protein may not be able to bind with their normal binding partners and thus endocytosis, vesicular trafficking and/or actin dynamics are negatively affected. Such defects may include, for example, cancer. Other defects may include abnormal cell division, abnormal cell migration, viral infection, abnormal receptor signalling, abnormal tissue development and abnormal synaptic transmission disorders. People at a risk for such an abnormality or, individuals not previously known to be at risk, or people in general may be screened routinely using probes to detect the presence of a mutant Esel or Ese2 gene by a variety of techniques. Genomic DNA used for the diagnosis may be obtained from body cells, such as those present in the blood, tissue biopsy, surgical specimen, or autopsy material. The DNA may be isolated and used directly for detection of a specific sequence or may be PCR amplified prior to analysis. RNA or cDNA may also be used. To detect a specific DNA sequence hybridization using specific oligonucleotides, direct DNA sequencing, restriction enzyme digest, RNase protection, chemical cleavage, and ligase-mediated detection are all methods which can be utilized. Oligonucleotides specific to mutant sequences can be chemically synthesized and labelled radioactively with isotopes, or non-radioactively using biotin tags, and hybridized to individual DNA samples immobilized on membranes or other solid-supports by dot-blot or transfer from gels after electrophoresis. The presence or absence of these mutant sequences are then visualized using methods such as autoradiography, fluorometry, or colorimetric reaction. Suitable PCR primers can be generated which are useful for example in amplifying portions of the subject sequence containing identified mutations.

Direct DNA sequencing reveals sequence differences between normal and mutant Esel or Ese2 DNA. Cloned DNA segments may be used as probes to detect specific DNA segments. PCR can be used to enhance the sensitivity of this method. PCR is an enzymatic amplification directed by sequence-specific primers, and involves repeated cycles of heat denaturation of the DNA, annealing of the complementary primers and extension of the annealed primer with a DNA polymerase. This results in an exponential increase of the target DNA. Other nucleotide sequence amplification techniques may be used, such as ligation-mediated PCR, anchored PCR and enzymatic amplification as would be understood by those skilled in the art.

Sequence alterations may also generate fortuitous restriction enzyme recognition sites which are revealed by the use of appropriate enzyme digestion followed by gel-blot hybridization. DNA fragments carrying the site (normal or mutant) are detected by their increase or reduction in size, or by the increase or decrease of corresponding restriction fragment numbers. Genomic DNA samples may also be amplified by PCR prior to treatment with the appropriate restriction enzyme and the fragments of different sizes are visualized under UV light in the presence of ethidium bromide after gel electrophoresis. Alternatively fluorography may be employed.

Genetic testing based on DNA sequence differences may be achieved by

SUBSTTTUTE SHEET (RULE 26 detection of alteration in electrophoretic mobility of DNA fragments in gels. Small sequence deletions and insertions can be visualized by high resolution gel electrophoresis. Small deletions may also be detected as changes in the migration pattern of DNA heteroduplexes in non-denaturing gel electrophoresis. Alternatively, a single base substitution mutation may be detected based on differential primer length in PCR. The PCR products of the normal and mutant gene could be differentially detected in acrylamide gels.

Nuclease protection assays (SI or ligase-mediated) also reveal sequence changes at specific locations. Alternatively, to confirm or detect a polymorphism restriction mapping changes ligated PCR, ASO, REF-SSCP and SSCP may be used. Both REF-SSCP and SSCP are mobility shift assays which are based upon the change in conformation due to mutations.

DNA fragments may also be visualized by methods in which the individual DNA samples are not immobilized on membranes. The probe and target sequences may be in solution or the probe sequence may be immobilized. Autoradiography, radioactive decay, spectrophotometry, and fluorometry may also be used to identify specific individual genotypes.

According to an embodiment of the invention, the portion of the DNA segment that is informative for a mutation, can be amplified using PCR. The DNA segment immediately surrounding a specific mutation acquired from peripheral blood or other tissue samples from an individual can be screened using constructed oligonucleotide primers. This region would then be amplified by PCR, the products separated by electrophoresis, and transferred to membrane. Labeled probes are then hybridized to the DNA fragments and autoradiography performed. In a further embodiment, the invention provides pharmaceutical compositions comprising Esel or Ese2 proteins or a functional analogue or mimetic of these proteins or their alternative transcripts for the treatment of certain disorders characterized by abnormal endocytosis and thus cell-signalling due to lack or absence of the proteins. Such disorders may include but are not limited to abnormal cell division, cancer, viral infection, abnormal synaptic transmission as seen in central nervous disorders and abnormal cell differentiation. Such compositions as provided herein can be appropriately packaged and targeted to specific cells and/or tissues.

Administration of a therapeutically active amount of a pharmaceutical composition of the present invention means an amount effective, at dosages and for periods of time necessary to achieve the desired result. This may also vary according to factors such as the disease state, age, sex, and weight of the subject, and the ability of the Esel or Ese2 proteins, peptides or alternative transcripts ( for example EselL and Ese2L) to elicit a desired response in the subject. Dosage regima may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. By pharmaceutically acceptable carrier as used herein is meant one or more compatible solid or liquid delivery systems. Some examples of pharmaceutically acceptable carriers are sugars, starches, cellulose and its derivatives, powdered tragacanth, malt, gelatin, collagen, talc, stearic acids, magnesium stearate, calcium sulfate, vegetable oils, polyols, agar, alginic acids, pyrogen-free water, isotonic saline, phosphate buffer, and other suitable non-toxic substances used in pharmaceutical formulations. Other excipients such as wetting agents and lubricants, tableting agents, stabilizers, anti-oxidants and preservatives are also contemplated.

The compositions described herein can be prepared by known methods for the preparation of pharmaceutically acceptable compositions which can be administered to subjects, such that an effective quantity of the active substance is combined in a mixture with a pharmaceutically acceptable carrier. Suitable carriers and formulations adapted for particular modes of administration are described, for example, in Remington's Pharmaceutical Sciences (Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., USA 1985). On this basis the compositions include, albeit not exclusively, solutions of the substance in association with one or more pharmaceutically acceptable vehicles or diluents, and contained in buffered solutions with a suitable pH and iso-osmotic with the physiological fluids.

The pharmaceutical compositions of the invention may be administered therapeutically by various routes such as by injection or by oral, nasal, buccal. rectal, vaginal, transdermal or ocular routes in a variety of formulations, as is known to those skilled in the art.

The present invention also enables the analysis of factors affecting the expression of the Esel or Ese2 gene in humans or in animal models. The invention further provides a system for screening candidate compounds for their ability to turn on or turn off expression of the Esel or Ese2 gene or to screen compounds which are binding partners of these proteins.

For example, a cell culture system can be used to identify compounds which activate production of Esel or Ese2 proteins or, once Esel or Ese2 production has been activated in the cells, they can be used to identify compounds which lead to suppression or switching off of Esel or Ese2 protein production. Compounds thus identified are useful as therapeutics in conditions where Esel or Ese2 production is deficient or excessive.

SUBSTTΓUTE SHEET (RULE 26 Compounds can also be screened in culture for their ability to overcome the effect of Ese protein expression in cell culture, tissue culture or in an animal model.

The present invention enables also a screening method for compounds of therapeutic utility as antagonists of the biological activity, binding activity, of Esel or Ese2 proteins and their binding partners. Those skilled in the art will be able to devise a number of possible screening methods for screening candidate compounds for Esel or Ese2 protein antagonism.

A screening method may also be based on binding to the Esel or Ese2 protein. Such competitive binding assays are well known to those skilled in the art. Once binding has been established for a particular compound, a biological activity assay is employed to determine agonist or antagonist potential.

Cell-free assays can also be readily designed by those skilled in the art to monitor and measure endocytosis, vesicular trafficking and actin dynamics.

To summarize, Ese proteins, Ese complexes including Epsl5, Epsl5R and many of the proteins identified in the screens as well as others identified through similar screens can be targeted for use in therapies to treat diseases including cancer, viral infection based diseases, developmental diseases due to altered cell fate specification and/or division as well as neurological diseases and diseases of altered cell migration and other diseases due to defects in the actin cytoskeleton.

EXAMPLES

The examples are described for the purposes of illustration and are not intended to limit the scope of the invention.

Methods of molecular genetics, protein and peptide biochemistry and immunology referred to but not explicitly described in this disclosure and examples are reported in the scientific literature and are well known to those skilled in the art.

Material and Methods Ese cloning and plasmids High Stringency screening was used to isolate the two mouse Ese cDNAs by previously described methodology (58). Esel was cloned from an adult mouse brain cDNA library using a PCR product from nt 1707-2197 of the coding sequence as probe. Ese2 was cloned from a mixed tissue adult mouse cDNA library using a mixture of three probes EST#583881 (Research Genetics Inc.), EST#652549 (Research Genetics Inc.) and a PCR product from nt 2712 to nt 3456 of the Ese2 coding sequence.

SUBSTTTUTE SHEET (RULE 26 The Esel sequence was obtained from a single clone, whereas the Ese2 reading frame was predicted from the overlap of two cDNA clones. The DBL/PH/C2 region of EselL was obtained using PCR with an upstream primer designed from sequences within the DBL/PH domain region: GAAGGAGAACTCAGACCGGCTGGAGTGGAT (this sequence was obtained from one partial EselL clone which we had isolated from a mouse brain cDNA library). This upstream primer was paired with downstream primers for the vector. The DBL/PH/C2 region of Ese2L was obtained using PCR with upstream and downstream primers flanking the site in Ese2 where sequence divergence had been noted within an EST clone (upstream Ese2 sequence: GACAGAGGAGCGGTACATGGA and downstream Ese2 sequence: AGCTCCCCTGGTTCTGGCTTC). The mouse Eps 15 cDNA was generated through a combination of high stringency library screening with Est sequences from the Eps 15 gene and rt PCT according to established methods.

pcDNA3Esel :

Full length Esel was cloned into the Notl site of pcDNA3 (Invitrogen Inc.). The Esel cDNA includes 53 nucleotides of 5' UTR plus a natural Notl site and 288 nucleotides of 3 'UTR plus a small region of polylinker including a Notl site.

pcDNA3mvcEsel :

The 5' end of pcDNA3Esel from the EcoRI site in the pcDNA3 polylinker to the start codon was replaced with the DNA sequence

GAATTCAGAACCATGGAACAAAAGCTTATTTCTGAAGAAGACTTGGGGCCC ATG: where the first underline corresponds to an EcoRI site which was fused into the pcDNA3 EcoRI site and the extended underlined sequence codes for a myc-epitope tag. This is followed by nine nucleotides which code for glycine, proline and the natural Esel start codon. This sequence was joined to the sequences coding for amino acids 2-1213 (the remainder of Esel). The new start codon in this tagged Esel construct is bolded. The 3' end of Esel in this vector is the same as in pcDNA3Esel above.

pcDNA3EselδC:

The C-terminus of Esel was removed by replacing all sequences from nt 2209 of the coding sequence to the Xhol site in pcDNA3Esel with TGACTCGAG where the stop codon is in bold and the Xhol site is underlined. This construct codes for amino acids 1 -736 of Ese 1.

pCDNA3Eps!5: This plasmid was constructed from four pieces. It contains the full length Epsl 5. The 5 'UTR of this construct has been constructed to be GGATCCACCATG where a BamHI site is underlined and the start codon is bolded. This BamHI site was fused to the BamHI site in pcDNA3. The 3 'UTR in this vector is 204 nt of the mouse natural 3 'UTR fused to a short cloning linker ending in the sequence

AAGCTTGGGCCC where an Apal site is underlined; this Apal site was fused to the Apal site in pcDNA3.

pcDNA3Eps!5δC: This vector is the same as pcDNA3Eps 15 except that sequences downstream from and including mouse Eps 15 coding nucleotide 1500 have been replaced with CCTGGATTACAAGGATGATGATGACAAATGACTCGAG where the first underlined sequence codes for the Flag-epitope, an inframe stop codon is bolded and an Xhol site is underlined. This Xhol site was fused to the polylinker in pcDNA3. The resulting plasmid encodes amino acids 1-501 of mouse Eps 15 fused to a C- terminal Flag epitope. The 5' end of Eps 15 in this construct is as indicated above for pcDNA3Epsl5.

pGBT9Eselcc: The Esel sequence coding for amino acids 330 to 732 were fused directly to

GAATTC (EcoRI site) on the 5' end and to TAGGATCC (stop codon followed by a BamHI site) on the 3' end. This fragment was cloned into EcoRI/BamHI digested pGBT9 in frame with the GAL4 DBD.

pGBT9Ese!A3.3:

This plasmid encodes the bait for our SH3 screen. It encodes all five SH3 domains from amino acid 665-1213 and was subcloned into pGBT9 on an EcoRI fragment which fuses the Esel SH3 region in frame with the DBD of GAL4.

PGBT9EselNterm:

This plasmid codes for the N-terminal 393 amino acids of Esel, including both EH domains. It was subcloned into pGBT9 on an EcoRI/Sall fragment.

Yeast 2-Hybrid Screening pGBT9Eselcc was transformed into S. cerevisiae strain Y190 using 45%

PEG4000, 100 mM LiAc, 10 mM Tris-HCl (pH 7.5) as per standard protocols. Cells were plated onto Sc-Trp drop-out media. Single colonies were isolated and expression of bait was analyzed by Western Blot using antibodies against the GAL4 DBD. A clone expressing the bait fusion was used to inoculate a 100 mL Sc-Trp liquid culture grown overnight at 30°C. Cells were then re-inoculated into YPD at a density of 5x10^ cells/mL and grown at 30°C until the titer reached 2x10? cells/mL. Cells were pelleted, resuspended in 50 mL 100 mM LiAc and incubated for 10 min at 30°C. Once again the cells were pelleted, resuspended in 20 mL PLA [35% PEG, 100 mM LiAc, 2 mg/mL salmon sperm DNA] containing 30 μg plasmid library (cloned in pAD-GAL4) incubated at 30°C for 30 min.; then heat shocked at 42°C for 40 min., pelleted, resuspended in water and plated onto [Sc-Trp-Leu-His+40 mM 3 -AT]. Plates were incubated at 30°C until colonies were formed. Colonies were picked, patched and grown at 30°C overnight on Whatman filter paper laid on top of Sc-Trp-Leu-His plates. Filters were submerged in liquid nitrogen for 15 seconds then placed on top of blotting paper soaked in Z-buffer + X-gal. β-galactosidase activity was measured by the appearance of blue colour. Plasmids from β-galactosidase positive colonies were shuttled to bacteria by electroporation and isolated for sequencing.

Northern Blot analysis

A multiple tissue northern blot (Clontech) was prehybridized in 5 mL of

ExpressHyb Solution (Clontech) at 68°C for 30 min. Probe was added at lxl 0⁶ cpm/mL for 1 hr. The Blot was washed twice (2X SSC, 0.05% SDS) at room temperature, twice (0.1X SSC, 0.1% SDS) at 50°C and then exposed to film overnight.

Antibodies and Western Blot analysis Western blot analysis was performed according to standard protocols. Briefly, cultured cell lines or 48 hours post tranfection Cos-1 cells where washed with PBS and lysed in one ml of cold lysis buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 10%) glycerol, 1% Triton X100, 1 mM EGTA, 1.5 mM MgCl₂, 10 mM NaF, 10 mg mH aprotinin, 1 mM PMSF, 10 mg ml^{- 1} leupeptin, 1 mM Na3V04). Supernatants were clarified by centrifugation and immunoprecipitated with specific antiserum as indicated. Antigen-Antibody complexes where purified on anti-rabbit agarose or anti- mouse agarose (Sigma Chemical Co.) Samples were run on 7.5% PAGE gels and transferred to nitrocellulose membranes. Filters were blocked in 5% dry milk powder/0.05% Tween 20/PBS, washed in 1% dry milk powder/0.05% Tween 20/PBS, and probed with the appropriate antisera at lmg/ml in wash buffer (In the case of chicken anti-Ese 1 we used lOμg/ml to probe western blots). Probed filters were further washed, probed again with 1/5000 dilution of horseradish peroxidase conjugated anti-rabbit IgG, anti-mouse IgG antibodies (Amersham), or anti-chicken- IgY (Zymed); washed and signal detected using the Enhanced Chemiluminescence detection system as per manufacturers instructions (Amersham). Rabbit anti-Ese 1 antisera was raised against a peptide of the following sequence: MAQFPTPFGGSLDVWAITVEE. The antisera was affinity purified over the same peptide (Research Genetics). This peptide was also used at 5μg to compete for the 5μg of antibody per immunoprecipitation reaction. Chicken anti-Ese 1 antisera was raised against a fusion protein between GST and amino acids 665-1213 of mouse Ese 1. This sera was cleared of antibodies reacting against GST by incubation with glutathione s-transferase on glutathione agarose beads.

Rabbit antibodies have also been raised against a peptide encoding the first twenty one amino acids of mouse Ese2. These antibodies were affinity purified and used to immunoprecipitate endogenous Esel containing protein complexes from cultured PC 12 cells. A protein of approximately 130 kDa was co-immunoprecipitated in complex with Ese2. This protein was isolated from a silver stained gel slice, digested with trypsin and the resulting peptide fragments were analyzed using both MALDI-TOF and Q-TOF Mass Spectrometers. Taken together, these mass spec analyses revealed that the Ese-2 binding protein in question is a Rho-Family exchange protein variably known as KIAA0362, Dbs and Ost. The gene encoding KIAA0362, Dbs and Ost proteins is subject to complex alternative splicing but each protein is predicted to contain the DBL/PH exchange domain. Thus Ese proteins are found in complex with exchange proteins for the Rho-family of small GTP-binding proteins.

Monoclonal antibodies against Ese proteins were produced by immunizing mice with a GST fusion protein encoding the Esel C-terminus (from amino acid 665 to the stop codon) according to standard protocols. After multiple injections, the mouse spleens were removed and resuspended in phosphate buffered saline (PBS). The spleen cells served as a source of lymphocytes. These lymphocytes were fused with a permanently growing myeloma partner cell, and the products of the fusion were plated into 96well plates in the presence of selective media. The culture supernatents were then screened by ELISA to identify those containing cells which were secreting anti-Ese antibodies. A histidine tagged version of the Esel C-terminus was used in these ELISA screens to ensure that anti-Ese antibodies were detected rather than antibodies directed against the GST portion of our original immunogen. From this procedure we isolated several independent stable hybridoma cloned lines which secrete anti-Ese antibodies. The monoclonal antibodies have then been purified on protein A/G columns as per standard protocols and demonstrated to bind Ese protein.

Immunofluorescence

For Immunofluorescent staining, Cos-1 cells were typically plated at a density of 2x10³ per 22x50mm coverglass and transfected with 2.5μg of plasmid using Superfect (Qiagen Inc.). After 2 hours, the cells were washed with 10%>FBS in Iscove's Media and fed with fresh 10%FBS in Iscove's Media. Two days later, these cultures where fixed with cold methanol for 30 minutes at room temperature. Cultures were washed three times 10 minutes with Phosphate buffered saline (PBS), blocked for one hour at room temperature with 1%BSA in PBS and then incubated with primary antibody in blocking solution for one hour, also at room temperature. Slides were then washed three times 10 minutes with PBS, incubated with secondary antibody/ 1% BS A/PBS in the dark for one hour at room temperature. Finally, slides were washed three times 10 minutes in the dark at room temperature and mounted using Dabco anti-fade solution (Sigma Chemical Co.). Slides were analyzed on the confocal microscope using the 63x objective and optical filters to separate signals on each channel.

For primary antibodies Mouse anti-myc monoclonal 9E10 (lOμg/ml: Santa Cruz Biotech.), Rabbit anti-myc (5μg/ml: Upstate Biotechnology Inc.), Rabbit anti- Epsl5 antisera #C20 (lμg/ml: Santa Cruz Biotech), Rabbit anti-Flag epitope antisera (5μg/ml: Zymed) and mouse anti-Dynamin I #D25520, which recognizes Dynamin in Cos-1 cells by both immunoprecipitation and western blotting (data not shown) (20μg/ml: Transduction labs, Inc.) were used. As secondary antibodies we used FITC-labelled goat anti-mouse (1 :80 dilution) and Texas Red-labelled goat anti-rabbit antibodies (1 :100 dilution) (Jackson Immuno Research Laboratories Inc.). Endogenous Eps 15 staining above background in non-transfected cells was undetected. Prominent cytoplasmic Eps 15 staining in transfected cells obscured the detection of clathrin-coated pit associated Eps 15 at the membrane (Figure 4B). In Figure 5B panel a and b, Dynamin staining with both primary and secondary antibodies was performed first. MycEsel was then stained for using biotinylated 9E10 followed by streptavidin conjugated to Texas Red. Following application of the secondary antibody to stain for Dynamin, all further incubations and washes were performed under dark condition. Endocytosis assays were performed as previously described (6, 9).

Mouse Esel cDNA - Sequence ID NO:l CGGCACGAGGAGGAGTGGAGCGGCGCGGGAGGGCGCGCAGCTTGGTTGC TCCGTAGTACGGCGGCTCGCAAGGGAGCATCCCGAGCGGGCTCCGGGACG GCCGGGAGGCAGGCAGGCGGGCGGGCGGGGATGGTGTGCGCGGCTGCGG ACTCGGCGTTCCTCGCGCGGCGTGCGGGCTGCACTGATTTGTGTGAGGGG CGGCCGCGCGCACCCGCCCGGAGATGAGGCGTCGATCAGCAAGGTGAAC GTAATAGAACCATGGCTC AGTTTCCCACACCTTTCGGTGGTAGCCTGGATG TCTGGGCCATAACTGTGGAGGAAAGGGCCAAGCATGACCAGCAGTTCCTT AGCCTGAAGCCGATAGCGGGATTTATTACTGGTGATCAAGCGAGGAACTT TTTTTTCCAATCTGGGTTACCTCAGCCTGTCTTAGCACAAATATGGGCGCT AGCGGACATGAATAACGATGGAAGGATGGATCAAGTGGAATTTTCCATAG CCATGAAGCTTATC AAACTGAAGCTAC AAGGATATC AGCTCCCCTCCAC A CTTCCCCCTGTCATGAAACAGCAACCAGTGGCTATTTCCAGTGCACCAGCA TTTGGTATAGGAGGGATTGCTAGCATGCCACCACTCACAGCTGTTGCTCCT GTGCCAATGGGCTCCATTCCAGTTGTTGGAATGTCTCCACCCTTAGTATCT TCTGTCCCTCCAGCAGCAGTGCCTCCCCTGGCTAACGGGGCTCCTCCCGTC ATACAGCCTCTGCCTGCGTTTGCGCATCCTGCAGCCACATGGCCAAAGAG TTCTTCCTTCAGCAGATCTGGTCCAGGGTCACAATTAAACACTAAGTTACA GAAGGCACAATCATTCGATGTCGCCAGCGCCCCTCCAGCAGCAGAATGGG CTGTGCCTCAGTCATCAAGGCTGAAATACAGGCAGTTATTCAACAGCCAC GACAAAACTATGAGTGGACACTTAACAGGTCCCCAGGCAAGAACTATTCT CATGCAATCAAGTTTACCCCAGGCTCAGCTGGCTTCAATATGGAATCTTTC TGACATTGATCAAGATGGAAAACTCACTGCAGAAGAATTTATCCTAGCTA TGCACCTAATTGATGTTGCCATGTCTGGTCAGCCACTGCCGCCCGTCCTGC CTCCAGAATACATCCCTCCTTCCTTCAGAAGAGTTCGCTCCGGCAGTGGGA TGTCCGTCATAAGCTCTTCTTCTGTGGATCAGAGGCTGCCTGAGGAGCCGT CGTCAGAGGATGAGCAGCAGCCAGAGAAGAAACTGCCTGTGACATTTGAA GATAAGAAGCGGGAGAACTTCGAGCGAGGCAGTGTGGAGCTGGAGAAGC GCCGCCAAGCGCTCTTGGAGCAGCAGCGCAAAGAGCAGGAGCGGTTGGC TCAGCTGGAGCGCGCCGAGCAGGAGAGGAAAGAGCGGGAGCGCCAGGAG CAGGAGGCCAAGCGGCAGCTGGAGCTGGAGAAGCAGCTGGAGAAGCAGC GGGAGCTGGAGCGGC AGCGAGAGGAGGAGAGGAGGAAGGAGATCGAGA GGCGCGAGGCCGCAAAACGGGAACTGGAAAGGCAGCGACAACTTGAATG GGAACGGAACCGGAGACAGGAACTCCTGAATCAGAGGAACAAGGAGCAG

SUBSTTTUTE SHEET (RULE 26 GAGGGCACCGTGGTCCTGAAGGCAAGGAGGAAGACTCTGGAGTTTGAGTT AGAAGCTCTGAATGACAAAAAGCATCAGCTAGAAGGAAAACTTCAGGAT ATCAGGTGTCGACTGGCAACCCAGAGGCAAGAAATTGAGAGCACGAACA AGTCTAGAGAGCTAAGAATTGCTGAAATCACCCACTTACAGCAGCAGTTG CAGGAATCTCAGCAAATGCTTGGAAGACTTATTCCAGAGAAACAGATACT CAGTGACCAGTTAAAACAAGTCCAGCAGAACAGTTTGCATAGAGACTCGC TTCTTACCCTCAAAAGAGCCTTGGAAGCAAAGGAGCTGGCCCGGCAGCAG CTCCGGGAGCAGCTGGACGAGGTGGAGAGAGAGACCAGGTCAAAGCTGC AGGAGATTGATGTTTTCAACAACCAGCTGAAGGAACTGAGAGAGATACAT AGC AAACAGCAACTCC AGAAGCAGAGGTCCCTGGAGGC AGCGCGACTGA AGCAGAAAGAGCAGGAGAGGAAGAGCCTGGAGTTAGAGAAGCAAAAGG AAGACGCTCAGAGACGAGTTCAGGAAAGGGACAAGCAATGGCTGGAGCA TGTGCAGCAGGAGGAGCAGCCACGCCCCCGGAAACCCCACGAGGAGGAC AGACTGAAGAGGGAAGACAGTGTCAGGAAGAAGGAGGCGGAAGAGAGA GCCAAGCCGGAAATGCAAGACAAGCAGAGTCGGCTTTTCCATCCGCATCA GGAGCCAGCTAAGCTGGCCACCCAGGCACCCTGGTCTACCACAGAGAAAG GCCCGCTTACCATTTCTGCACAGGAGAGTGTAAAAGTGGTATATTACCGA GCGCTGTACCCCTTTGAATCCAGAAGTCACGATGAGATCACCATCCAGCC AGGAGATATAGTCATGGTGGATGAAAGCCAGACTGGAGAGCCAGGATGG CTTGGAGGAGAGCTGAAAGGGAAGACGGGATGGTTCCCTGCAAACTATGC AGAAAAGATTCCAGAAAATGAGGTTCCCACTCCAGCCAAACCAGTGACCG ATCTGACATCTGCCCCTGCCCCCAAACTGGCTCTGCGTGAGACCCCTGCTC CTTTGCCAGTGACCTCTTCTGAGCCCTCCACAACCCCCAACAACTGGGCAG ACTTCAGTTCCACGTGGCCCAGCAGCTCAAACGAGAAGCCAGAAACGGAC AACTGGGATACGTGGGCGGCTCAGCCTTCTCTGACCGTACCTAGTGCTGG CCAGTTACGGCAGAGATCAGCCTTTACCCCAGCCACAGCCACTGGCTCCT CCCCATCTCCCGTCCTGGGCCAGGGTGAAAAGGTGGAAGGGCTACAAGCG CAAGCCCTGTATCCCTGGAGAGCCAAAAAAGACAACCACTTAAATTTTAA CAAAAGTGACGTCATCACCGTTCTGGAACAGCAAGACATGTGGTGGTTTG GAGAAGTTCAAGGTCAGAAGGGTTGGTTCCCCAAGTCTTACGTGAAACTC ATTTCAGGGCCCGTAAGGAAATCCACAAGCATCGATACTGGCCCTACTGA AAGTCCTGCTAGTCTAAAGAGAGTGGCTTCCCCGGCCGCCAAGCCAGCCA TTCCCGGAGAAGAGTTTATTGCCATGTACACATACGAGAGTTCTGAGCAA GGAGATTTAACCTTTCAGCAAGGGGATGTGATTGTGGTTACCAAGAAAGA TGGTGACTGGTGGACGGGAACGGTGGGCGACAAGTCCGGAGTCTTCCCTT CTAACTATGTGAGGCTTAAAGATTCAGAGGGCTCTGGAACTGCTGGGAAA ACAGGGAGTTTAGGAAAAAAACCTGAAATTGCCCAGGTTATTGCTTCCTA CGCTGCTACTGGTCCCGAACAACTCACCCTGGCTCCTGGGCAGCTGATTCT GATCCGGAAAAAGAACCCAGGTGGATGGTGGGAAGGAGAACTGCAAGCT CGAGGGAAAAAGCGCCAGATAGGGTGGTTTCCAGCAAATTATGTCAAACT TCTAAGCCCCGGAACAAGCAAAATCACCCCAACTGAGCTACCCAAGACCG CAGTGCAGCCAGCAGTGTGCCAGGTGATCGGGATGTACGATTACACCGCC CAGAACGATGACGAACTAGCCTTCAGCAAAGGCCAGATCATCAACGTCCT CAACAAGGAGGACCCGGACTGGTGGAAAGGAGAAGTCAGTGGGCAAGTT GGGCTCTTCCCATCCAATTATGTAAAGCTGACCACAGACATGGACCCCAG CCAGCAATGAATCATATGTTGTCCATCCCCCCCTCAGGCTTGAAAGTCCTC AAAGAGACCCACTATCCCATATCACTGCCCAGAGGGATGATGGGAGATGC AGCCTTGATCATGTGACTTGCAGCATGATCACCTACTGCCTTCTGAGTAGA AGAACTCACTGCAGAGCAGTTTACCTCATTTGACCTTAGTTGCATGTGATC GAAATGTCTGAGTCACTGCGTGCAGAGGCAGAAGCAAATTGCAGAACTGC ACAGGGTGGTGGGTCCTTTTGGGGCTTTCCTAGTCACTCAGACTGACCGGC CCCGCCTTCACACGGGCGCTTTCAATAGTTTTAAGATTATTTTTAAATGTG TATTTTAGCCTTTTAATAAAAATCTCAATCAATTACTTCTTTGCCTATTTTG GTTTTACAAAAACACCCACTATCAAGGAGTGCCTGTCTGCGGACGATTAA AATGCTGTTCCGGGCGTACCGTAAACTGAGAGCTTGCTGTACCTTTGCCGT TTGTCCAGTGTTCCCAACCACATTGTGTAGTTTGGGGCTGTTCCCTGCCGT AGAGCACAGAGGAGATGGGTGTACCTGTTTTGAAAATGTGTATGTAGACT GAGCCTGACTATGGAAGGGGTTATGCTTGTCTGTGACCATCACGTGTACCT GTCGCGCATGTACCATCTGTACCGAAGAAGTAGCTCTTCCTCCATGGCTAA ACCCACCACCGTGTACAGTGCTCTCATCTACTGCATTCATTTTACTTTGCA CAGTGACCTTGTAGCCACCTGAGGAAGCACCCATGTTTCCGTTTGGTCTCA GATGTACCTAGTTGTGCCCGTGTTTTGTTTTTATTTTTCAATCTGGCATGTC TTCACACCATAAACTAGTAAGACGCCAACTGCCCAGGCGGTTACGATCAT CAGTACCCACCGTCTTAGTCTCTGTTACGTGAAGTTTATTCCAGTTGCTTTT TATGGAATATCTTGAACAAGTAATCTTCTTGACAAGAAAGAATGTATAGA AGTCTCCCTGCAATTAATTTCCCAGTGTTTACATTTTTTAACTAGACTGTGG GGGTTGCTACAGATTAATATGAAATGGCGCTCCTGGTCCGTGTGTGTGTTA ACTTGTGCTGTAGCTGAAGCCGTGTGTCCTTAGATATTAGTTGGAAGTCGG GAAGAGAATTCGATATCAAGCTT

Mouse Esel coding sequence - Sequence ID NO:2 ATGGCTCAGTTTCCCACACCTTTCGGTGGTAGCCTGGATGTCTGGGCCATA ACTGTGGAGGAAAGGGCCAAGCATGACCAGCAGTTCCTTAGCCTGAAGCC GATAGCGGGATTTATTACTGGTGATCAAGCGAGGAACTTTTTTTTCCAATC TGGGTTACCTCAGCCTGTCTTAGCACAAATATGGGCGCTAGCGGACATGA ATAACGATGGAAGGATGGATCAAGTGGAATTTTCCATAGCCATGAAGCTT ATCAAACTGAAGCTACAAGGATATCAGCTCCCCTCCACACTTCCCCCTGTC ATGAAACAGCAACCAGTGGCTATTTCCAGTGCACCAGCATTTGGTATAGG AGGGATTGCTAGCATGCCACCACTCACAGCTGTTGCTCCTGTGCCAATGG GCTCCATTCCAGTTGTTGGAATGTCTCCACCCTTAGTATCTTCTGTCCCTCC AGCAGCAGTGCCTCCCCTGGCTAACGGGGCTCCTCCCGTCATACAGCCTCT GCCTGCGTTTGCGCATCCTGCAGCCACATGGCCAAAGAGTTCTTCCTTCAG CAGATCTGGTCCAGGGTCACAATTAAACACTAAGTTACAGAAGGCACAAT CATTCGATGTCGCCAGCGCCCCTCCAGC AGC AGAATGGGCTGTGCCTCAG TCATCAAGGCTGAAATACAGGCAGTTATTCAACAGCCACGACAAAACTAT GAGTGGACACTTAACAGGTCCCCAGGCAAGAACTATTCTCATGCAATCAA GTTTACCCCAGGCTCAGCTGGCTTCAATATGGAATCTTTCTGACATTGATC AAGATGGAAAACTCACTGCAGAAGAATTTATCCTAGCTATGCACCTAATT GATGTTGCCATGTCTGGTCAGCCACTGCCGCCCGTCCTGCCTCCAGAATAC ATCCCTCCTTCCTTCAGAAGAGTTCGCTCCGGCAGTGGGATGTCCGTCATA AGCTCTTCTTCTGTGGATCAGAGGCTGCCTGAGGAGCCGTCGTCAGAGGA TGAGCAGCAGCCAGAGAAGAAACTGCCTGTGACATTTGAAGATAAGAAG CGGGAGAACTTCGAGCGAGGCAGTGTGGAGCTGGAGAAGCGCCGCCAAG CGCTCTTGGAGCAGCAGCGCAAAGAGCAGGAGCGGTTGGCTCAGCTGGA GCGCGCCGAGCAGGAGAGGAAAGAGCGGGAGCGCCAGGAGCAGGAGGC CAAGCGGCAGCTGGAGCTGGAGAAGCAGCTGGAGAAGCAGCGGGAGCTG GAGCGGCAGCGAGAGGAGGAGAGGAGGAAGGAGATCGAGAGGCGCGAG GCCGCAAAACGGGAACTGGAAAGGCAGCGACAACTTGAATGGGAACGGA ACCGGAGACAGGAACTCCTGAATCAGAGGAACAAGGAGCAGGAGGGCAC CGTGGTCCTGAAGGCAAGGAGGAAGACTCTGGAGTTTGAGTTAGAAGCTC TGAATGACAAAAAGCATCAGCTAGAAGGAAAACTTCAGGATATCAGGTGT CGACTGGCAACCCAGAGGCAAGAAATTGAGAGCACGAACAAGTCTAGAG AGCTAAGAATTGCTGAAATCACCCACTTACAGCAGCAGTTGCAGGAATCT CAGCAAATGCTTGGAAGACTTATTCCAGAGAAACAGATACTCAGTGACCA GTTAAAACAAGTCCAGCAGAACAGTTTGCATAGAGACTCGCTTCTTACCC TCAAAAGAGCCTTGGAAGCAAAGGAGCTGGCCCGGCAGCAGCTCCGGGA GCAGCTGGACGAGGTGGAGAGAGAGACCAGGTCAAAGCTGCAGGAGATT GATGTTTTCAACAACCAGCTGAAGGAACTGAGAGAGATACATAGCAAACA GCAACTCCAGAAGCAGAGGTCCCTGGAGGCAGCGCGACTGAAGCAGAAA GAGCAGGAGAGGAAGAGCCTGGAGTTAGAGAAGCAAAAGGAAGACGCTC AGAGACGAGTTCAGGAAAGGGACAAGCAATGGCTGGAGCATGTGCAGCA GGAGGAGCAGCCACGCCCCCGGAAACCCCACGAGGAGGACAGACTGAAG AGGGAAGACAGTGTCAGGAAGAAGGAGGCGGAAGAGAGAGCCAAGCCG GAAATGCAAGACAAGCAGAGTCGGCTTTTCCATCCGCATCAGGAGCCAGC TAAGCTGGCCACCCAGGCACCCTGGTCTACCACAGAGAAAGGCCCGCTTA CCATTTCTGCACAGGAGAGTGTAAAAGTGGTATATTACCGAGCGCTGTAC CCCTTTGAATCCAGAAGTCACGATGAGATCACCATCCAGCCAGGAGATAT AGTCATGGTGGATGAAAGCCAGACTGGAGAGCCAGGATGGCTTGGAGGA GAGCTGAAAGGGAAGACGGGATGGTTCCCTGCAAACTATGCAGAAAAGA TTCCAGAAAATGAGGTTCCCACTCCAGCCAAACCAGTGACCGATCTGACA TCTGCCCCTGCCCCCAAACTGGCTCTGCGTGAGACCCCTGCTCCTTTGCCA GTGACCTCTTCTGAGCCCTCCACAACCCCCAACAACTGGGCAGACTTCAGT TCCACGTGGCCCAGCAGCTCAAACGAGAAGCCAGAAACGGACAACTGGG ATACGTGGGCGGCTCAGCCTTCTCTGACCGTACCTAGTGCTGGCCAGTTAC GGCAGAGATCAGCCTTTACCCCAGCCACAGCCACTGGCTCCTCCCCATCTC CCGTCCTGGGCCAGGGTGAAAAGGTGGAAGGGCTAC AAGCGC AAGCCCT GTATCCCTGGAGAGCCAAAAAAGACAACCACTTAAATTTTAACAAAAGTG ACGTCATCACCGTTCTGGAACAGCAAGACATGTGGTGGTTTGGAGAAGTT CAAGGTCAGAAGGGTTGGTTCCCCAAGTCTTACGTGAAACTCATTTCAGG GCCCGTAAGGAAATCCACAAGCATCGATACTGGCCCTACTGAAAGTCCTG CTAGTCTAAAGAGAGTGGCTTCCCCGGCCGCCAAGCCAGCCATTCCCGGA GAAGAGTTTATTGCCATGTACACATACGAGAGTTCTGAGCAAGGAGATTT AACCTTTCAGCAAGGGGATGTGATTGTGGTTACCAAGAAAGATGGTGACT GGTGGACGGGAACGGTGGGCGACAAGTCCGGAGTCTTCCCTTCTAACTAT GTGAGGCTTAAAGATTCAGAGGGCTCTGGAACTGCTGGGAAAACAGGGA GTTTAGGAAAAAAACCTGAAATTGCCCAGGTTATTGCTTCCTACGCTGCTA CTGGTCCCGAACAACTCACCCTGGCTCCTGGGCAGCTGATTCTGATCCGGA AAAAGAACCCAGGTGGATGGTGGGAAGGAGAACTGCAAGCTCGAGGGAA AAAGCGCCAGATAGGGTGGTTTCCAGCAAATTATGTCAAACTTCTAAGCC CCGGAACAAGCAAAATCACCCCAACTGAGCTACCCAAGACCGCAGTGCA GCCAGCAGTGTGCCAGGTGATCGGGATGTACGATTACACCGCCCAGAACG ATGACGAACTAGCCTTCAGCAAAGGCCAGATCATCAACGTCCTCAACAAG GAGGACCCGGACTGGTGGAAAGGAGAAGTCAGTGGGCAAGTTGGGCTCTT CCCATCCAATTATGTAAAGCTGACCACAGACATGGACCCCAGCCAGCAAT GAATCATATGTTGTCCATCCCCCCCTCAGGCTTGAAAGTCCTCAAAGAGAC CC ACTATCCC ATATC ACTGCCC AGAGGG ATGA

Mouse Esel protein - Sequence ID NO:3 MAQFPTPFGGSLDVWAITVEERAKHDQQFLSLKPIAGFITGDQARNFFFQSGL PQPVLAQIWALADMNNDGRMDQVEFSIAMKLIKLKLQGYQLPSTLPPVMKQ QPVAISSAPAFGIGGIASMPPLTAVAPVPMGSIPVVGMSPPLVSSVPPAAVPPL ANGAPPVIQPLPAFAHPAATWPKSSSFSRSGPGSQLNTKLQKAQSFDVASAPP AAEWAVPQSSRLKYRQLFNSHDKTMSGHLTGPQARTILMQSSLPQAQLASIW NLSDIDQDGKLTAEEFILAMHLIDVAMSGQPLPPVLPPEYIPPSFRRVRSGSGM SVISSSSVDQRLPEEPSSEDEQQPEKKLPVTFEDKKRENFERGSVELEKRRQAL LEQQRKEQERLAQLERAEQERKERERQEQEAKRQLELEKQLEKQRELERQRE EERRKEIERREAAKRELERQRQLE WERNRRQELLNQRNKEQEGTVVLKARR KTLEFELEALNDKKHQLEGKLQDIRCRLATQRQEIESTNKSRELRIAEITHLQQ QLQESQQMLGRLIPEKQILSDQLKQVQQNSLHRDSLLTLKRALEAKELARQQ LREQLDEVERETRSKLQEIDVFNNQLKELREIHSKQQLQKQRSLEAARLKQKE QERKSLELEKQKEDAQRRVQERDKQWLEHVQQEEQPRPRKPHEEDRLKRED SVRKKEAEERAKPEMQDKQSRLFHPHQEPAKLATQAPWSTTEKGPLTISAQE SVKVVYYRALYPFESRSHDEITIQPGDIVMVDESQTGEPGWLGGELKGKTGW FPANYAEKIPENEVPTPAKPVTDLTSAPAPKLALRETPAPLPVTSSEPSTTPNN WADFSSTWPSSSNEKPETDNWDTWAAQPSLTVPSAGQLRQRSAFTPATATGS SPSPVLGQGEKVEGLQAQALYPWRAKKDNHLNFNKSDVITVLEQQDMWWF GEVQGQKGWFPKSYVKLISGPVRKSTSIDTGPTESPASLKRVASPAAKPAIPGE EFIAMYTYESSEQGDLTFQQGDVIVVTKKDGDWWTGTVGDKSGVFPSNYVR LKDSEGSGTAGKTGSLGKKPEIAQVIASYAATGPEQLTLAPGQLILIRKKNPGG WWEGELQARGKKRQIGWFPANYVKLLSPGTSKITPTELPKTAVQPAVCQVIG MYDYTAQNDDELAFSKGQILNVLNKEDPDWWKGEVSGQVGLFPSNYVKLTT DMDPSQQ

Mouse Ese2 cDNA - Sequence ID NO:4

CCCTTCCTTTCCTTTTTTTGTGTTCGCCTTCGGCCGTGCCGGCTGAGAGCCC

AGCAGCCGTGACAGGCTGCGCAACAGGTTCGCTGCGGCCGGCCTGACGAC TGACCCGGCGGCGGCGGCCGCGGCACGGCAGGGTCTTCCCGGAGCTTGGC CGCGCCCACGCGCCGGTGTCGAGGAGCGCGCGGGGTCGCGCCGGGACGT GCGCGAGGCGCCAGATGGCTGAGAGCTGCAAGAAGAAGTCAGGATCATG ATGGCTCAGTTTCCCACAGCGATGAATGGAGGGCCAAATATGTGGGCTAT TACATCTGAAGAACGTACTAAGCATGATAAACAGTTTGATAACCTCAAAC CTTC AGGAGGTTACATAAC AGGTGATCAAGCCCGTACTTTTTTCCTACAGT CAGGTCTGCCGGCCCCGGTTTTAGCTGAAATATGGGCCTTATCAGATCTGA ACAAGGATGGGAAGATGGACCAGCAAGAGTTCTCTATAGCTATGAAACTC ATCAAGTTAAAGTTGCAGGGCCAACAGCTGCCTGTAGTCCTCCCTCCTATC ATGAAACAACCCCCTATGTTCTCTCCACTAATCTCTGCTCGTTTTGGGATG GGAAGCATGCCCAATCTGTCCATTCATCAGCCATTGCCTCCAGTTGCACCT ATAGCAACACCCTTGTCTTCTGCTACGTCAGGGACCAGTATTCCTCCCCTA ATGATGCCTGCTCCCCTAGTGCCTTCTGTTAGTACATCCTCATTACCAAAT GGAACTGCCAGTCTCATTCAGCCTTTATCCATTCCTTATTCTTCTTCAACAT TGCCTCATGCATCATCTTACAGCCTGATGATGGGAGGATTTGGTGGTGCTA GTATCCAGAAGGCCCAGTCTCTGATTGATTTAGGATCTAGTAGCTCAACTT CCTCAACTGCTTCCCTCTCAGGGAACTCACCTAAGACAGGGACCTCAGAG TGGGCAGTTCCTC AGCCTTC AAGATTAAAGTATCGGCAAAAATTTAATAGT CTAGACAAAGGCATGAGCGGATACCTCTCAGGTTTTCAAGCTAGAAATGC CCTTCTTCAGTCAAATCTCTCTCAAACTCAGCTAGCTACTATTTGGACTCT GGCTGACATCGATGGTGACGGACAGTTGAAAGCTGAAGAATTTATTCTGG CGATGCACCTCACTGACATGGCCAAAGCTGGACAGCCACTACCACTGACG TTGCCTCCCGAGCTTGTCCCTCCATCTTTCAGAGGGGGAAAGCAAGTTGAT TCTGTTAATGGAACTCTGCCTTCATATCAGAAAACACAAGAAGAAGAGCC TCAGAAGAAACTGCCAGTTACTTTTGAGGACAAACGGAAAGCCAACTATG AACGAGGAAACATGGAGCTGGAGAAGCGACGCCAAGTGTTGATGGAGCA GCAGCAGAGGGAGGCTGAACGCAAAGCCCAGAAAGAGAAGGAAGAGTG GGAGCGGAAACAGAGAGAACTGCAAGAGCAAGAATGGAAGAAGCAGCTG GAGTTGGAGAAACGCTTGGAGAAACAGAGAGAGCTGGAGAGACAGCGGG AGGAAGAGAGGAGAAAGGAGATAGAAAGACGAGAGGCAGCAAAACAGG AGCTTGAGAGACAACGCCGTTTAGAATGGGAAAGACTCCGTCGGCAGGAG CTGCTCAGTCAGAAGACCAGGGAACAAGAAGACATTGTCAGGCTGAGCTC CAGAAAGAAAAGTCTCCACCTGGAACTGGAAGCAGTGAATGGAAAACAT CAGCAGATCTCAGGCAGACTACAAGATGTCCAAATCAGAAAGCAAACAC AAAAGACTGAGCTAGAAGTTTTGGATAAACAGTGTGACCTGGAAATTATG GAAATCAAACAACTTCAACAAGAGCTTAAGGAATATCAAAATAAGCTTAT CTATCTGGTCCCTGAGAAGCAGCTATTAAACGAAAGAATTAAAAACATGC AGCTCAGTAACACACCTGATTCAGGGATCAGTTTACTTCATAAAAAGTCA TCAGAAAAGGAAGAATTATGCCAAAGACTTAAAGAACAATTAGATGCTCT TGAAAAAGAAACTGCATCTAAGCTCTCAGAAATGGATTCATTTAACAATC AGCTGAAGGAACTCAGAGAAAGCTATAATACACAGCAGTTAGCCCTTGAA CAACTTCATAAAATCAAACGTGACAAATTGAAGGAAATCGAAAGAAAAA GATTAG AGC AAATTC AAAAAAAGAAACT AGAAGATGAGGCTGC AAGG AA AGCAAAGCAAGGAAAAGAAAACTTGTGGAGAGAAAGTATTAGAAAGGAA GAAGAGGAAAAGCAAAAACGACTCCAGGAAGAAAAGTCACAGGACAAA ACTCAAGAAGAGGAACGAAAAGCTGAGGCAAAACAAAGTGAGACAGCCA GTGCTTTGGTGAATTACAGAGCACTGTACCCTTTTGAAGCAAGAAACCAT GATGAGATGAGTTTTAGTTCTGGGGATATAATTCAGGTTGATGAAAAAAC TGTAGGAGAGCCTGGTTGGCTTTATGGTAGTTTTCAGGGAAAGTTTGGCTG GTTCCCCTGCAACTATGTAGAAAAAGTGCTGTCAAGTGAAAAAGCTCTGT CTCCTAAGAAGGCCTTACTTCCTCCTACAGTGTCTCTCTCTGCTACCTCAA CTTCTTCCCAGCCACCAGCATCAGTGACTGATTATCACAATGTATCCTTCT CAAACCTTACTGTTAATACAACATGGCAGCAGAAGTCAGCTTTTACCCGC ACTGTGTCCCCTGGATCTGTGTCCCCCATTCACGGACAGGGGCAGGCTGTA GAAAACCTGAAAGCCCAGGCCCTTTGTTCCTGGACGGCAAAGAAGGAGA ACCACCTGAACTTCTCAAAGCACGACGTCATCACTGTCCTGGAGCAGCAG GAAAACTGGTGGTTTGGGGAGGTGCACGGAGGAAGAGGATGGTTCCCCA AGTCTTATGTCAAGCTCATTCCTGGGAATGAAGTACAGCGAGGAGAGCCA GAAGCTTTGTATGCAGCTGTGACTAAGAAACCTACCTCCACAGCCTATCC AGTTACCTCCACAGCCTATCCAGTTGGAGAAGACTACATTGCACTTTATTC ATACTCAAGTGTAGAGCCCGGGGATTTGACTTTCACTGAAGGTGAAGAAA TTCTAGTGACCCAGAAAGATGGAGAGTGGTGGACAGGAAGTATTGGAGA GAGAACTGGAATCTTCCCGTCCAACTACGTCAGACCAAAGGATCAAGAGA ATTTTGGGAATGCTAGCAAATCTGGAGCATCAAACAAAAAACCCGAGATC GCTCAAGTAACTTCAGCATATGCTGCTTCAGGGACTGAGCAGCTCAGCCTT GCGCCAGGACAGTTAATATTAATCTTAAAGAAAAACACAAGCGGGTGGTG GCAAGGAGAGCTACAGGCCAGAGGGAAGAAACGACAGAAGGGATGGTTT CCTGCCAGCCATGTAAAGCTGCTAGGTCCAAGCAGTGAAAGAACCATGCC TACTTTTCACGCTGTATGTCAAGTGATTGCTATGTATGACTACATGGCGAA TAACGAAGATGAGCTCAATTTCTCCAAAGGACAGCTGATTAATGTTATGA ACAAAGATGACCCTGACTGGTGGCAAGGAGAAACCAATGGTCTGACTGGT CTCTTTCCTTCAAACTATGTTAAGATGACAACAGACTCAGATCCAAGTCAA CAGTGGTGTGCTGACCTCCAAGCCCTGGACACAATGCAGCCTACGGAGAG GAAGCGACAGGGCTACATTCACGAGCTCATTCAGACAGAGGAGCGGTAC ATGGACGACCTGCAACTTTTTGAACAAAAAACTCTCCTTTGAGGGCCTGG GGAAGCCAGAACCAGGGGAGCTGCCCACAAGGCTGGGTCTAAAGACAGA TTTTGCTCTCCCAGGACAGAGGAGCATCACATCGGCTTCATCCATCCAAAC AAGCCACACTCGCTGGGCCTGGTATTTTATTGCACCACTAAAATTGCTAGC AATCTATGCAAACATGATCTTTTTAAACAAACGCCACAGCACAGTGCCTT GTACTAGTGTTAACCTGTTC AGCTGTGTTAGATGCC AGGGTTTCC ATTTTC AGGGCTATAAAAGTATTATGTGGGAAATGAGACATCAGACCACCGGACGT TACCACTTGGCAAATCTGTCCACTGTGGAGTTGGTGATGTTGGAACCATTC CACACTATGTGACCTCTGCTGGGTCACACACTCAGGAGGTGAAGGGCTGA GATGAAATGCTGCAGCCTTGGGGCTTGTGCAGCCTGATACTGAAATAGCA TCCACTTGTGCACTGAATAAATAGAAACTTGATCGTTTTATTCTGACTAGA TATTATCATTCTCTGCTAAGACAATATAGTTTGAAATATTATAGTTTGAAT ATAAGGAGGAAAGCTTGATGTACTTTAAATATACTGTGAACTCTAATAAT GTGGGGATATTTTTCAACTTTAATTTTCTTAAGTATAAATTATTTATGTAAA TTCTTTGTTTTGCATATTTCATAGAACATGCATCTTTAAGCTTTATCATTGC CAACAATGTACAGAAAGAGAATAAAAGTATAAGTTTATGAATGTAAAAA AAAAAAAAAAAAAAA

Mouse Ese2 coding sequence - Sequence ID NO: 5

ATGGCTCAGTTTCCCACAGCGATGAATGGAGGGCCAAATATGTGGGCTAT TACATCTGAAGAACGTACTAAGCATGATAAACAGTTTGATAACCTCAAAC CTTCAGGAGGTTACATAACAGGTGATCAAGCCCGTACTTTTTTCCTACAGT CAGGTCTGCCGGCCCCGGTTTTAGCTGAAATATGGGCCTTATCAGATCTGA ACAAGGATGGGAAGATGGACCAGCAAGAGTTCTCTATAGCTATGAAACTC ATCAAGTTAAAGTTGCAGGGCCAACAGCTGCCTGTAGTCCTCCCTCCTATC ATGAAACAACCCCCTATGTTCTCTCCACTAATCTCTGCTCGTTTTGGGATG GGAAGCATGCCCAATCTGTCCATTCATCAGCCATTGCCTCCAGTTGCACCT ATAGCAACACCCTTGTCTTCTGCTACGTCAGGGACCAGTATTCCTCCCCTA ATGATGCCTGCTCCCCTAGTGCCTTCTGTTAGTACATCCTCATTACCAAAT GGAACTGCCAGTCTCATTCAGCCTTTATCCATTCCTTATTCTTCTTCAACAT TGCCTCATGCATCATCTTACAGCCTGATGATGGGAGGATTTGGTGGTGCTA GTATCCAGAAGGCCCAGTCTCTGATTGATTTAGGATCTAGTAGCTCAACTT CCTCAACTGCTTCCCTCTCAGGGAACTCACCTAAGACAGGGACCTCAGAG TGGGCAGTTCCTCAGCCTTCAAGATTAAAGTATCGGCAAAAATTTAATAGT CTAGACAAAGGCATGAGCGGATACCTCTCAGGTTTTCAAGCTAGAAATGC CCTTCTTCAGTCAAATCTCTCTCAAACTCAGCTAGCTACTATTTGGACTCT GGCTGACATCGATGGTGACGGACAGTTGAAAGCTGAAGAATTTATTCTGG CGATGCACCTCACTGACATGGCCAAAGCTGGACAGCCACTACCACTGACG TTGCCTCCCGAGCTTGTCCCTCCATCTTTCAGAGGGGGAAAGCAAGTTGAT TCTGTTAATGGAACTCTGCCTTCATATCAGAAAACACAAGAAGAAGAGCC TCAGAAGAAACTGCCAGTTACTTTTGAGGACAAACGGAAAGCCAACTATG AACGAGGAAACATGGAGCTGGAGAAGCGACGCCAAGTGTTGATGGAGCA GCAGC AGAGGGAGGCTGAACGCAAAGCCC AGAAAGAGAAGGAAGAGTG GGAGCGGAAACAGAGAGAACTGCAAGAGCAAGAATGGAAGAAGCAGCTG GAGTTGGAGAAACGCTTGGAGAAACAGAGAGAGCTGGAGAGACAGCGGG AGGAAGAGAGGAGAAAGGAGATAGAAAGACGAGAGGCAGCAAAACAGG AGCTTGAGAGACAACGCCGTTTAGAATGGGAAAGACTCCGTCGGCAGGAG CTGCTCAGTCAGAAGACCAGGGAACAAGAAGACATTGTCAGGCTGAGCTC CAGAAAGAAAAGTCTCCACCTGGAACTGGAAGCAGTGAATGGAAAACAT CAGCAGATCTCAGGCAGACTACAAGATGTCCAAATCAGAAAGCAAACAC AAAAGACTGAGCTAGAAGTTTTGGATAAACAGTGTGACCTGGAAATTATG GAAATCAAACAACTTCAACAAGAGCTTAAGGAATATCAAAATAAGCTTAT CTATCTGGTCCCTGAGAAGCAGCTATTAAACGAAAGAATTAAAAACATGC AGCTCAGTAACACACCTGATTCAGGGATCAGTTTACTTCATAAAAAGTCA TCAGAAAAGGAAGAATTATGCCAAAGACTTAAAGAACAATTAGATGCTCT TGAAAAAGAAACTGCATCTAAGCTCTCAGAAATGGATTCATTTAACAATC AGCTGAAGGAACTCAGAGAAAGCTATAATACACAGCAGTTAGCCCTTGAA CAACTTCATAAAATCAAACGTGACAAATTGAAGGAAATCGAAAGAAAAA GATTAGAGCAAATTCAAAAAAAGAAACTAGAAGATGAGGCTGCAAGGAA AGC AAAGCAAGGAAAAGAAAACTTGTGGAGAGAAAGTATTAGAAAGGAA GAAGAGGAAAAGCAAAAACGACTCCAGGAAGAAAAGTCACAGGACAAA ACTCAAGAAGAGGAACGAAAAGCTGAGGCAAAACAAAGTGAGACAGCCA GTGCTTTGGTGAATTACAGAGCACTGTACCCTTTTGAAGCAAGAAACCAT GATGAGATGAGTTTTAGTTCTGGGGATATAATTCAGGTTGATGAAAAAAC TGTAGGAGAGCCTGGTTGGCTTTATGGTAGTTTTCAGGGAAAGTTTGGCTG GTTCCCCTGCAACTATGTAGAAAAAGTGCTGTCAAGTGAAAAAGCTCTGT CTCCTAAGAAGGCCTTACTTCCTCCTACAGTGTCTCTCTCTGCTACCTCAA CTTCTTCCCAGCCACCAGCATCAGTGACTGATTATCACAATGTATCCTTCT CAAACCTTACTGTTAATACAACATGGCAGCAGAAGTCAGCTTTTACCCGC ACTGTGTCCCCTGGATCTGTGTCCCCCATTCACGGACAGGGGCAGGCTGTA GAAAACCTGAAAGCCCAGGCCCTTTGTTCCTGGACGGCAAAGAAGGAGA ACCACCTGAACTTCTCAAAGCACGACGTCATCACTGTCCTGGAGCAGCAG GAAAACTGGTGGTTTGGGGAGGTGCACGGAGGAAGAGGATGGTTCCCCA AGTCTTATGTCAAGCTCATTCCTGGGAATGAAGTACAGCGAGGAGAGCCA GAAGCTTTGTATGCAGCTGTGACTAAGAAACCTACCTCCACAGCCTATCC AGTTACCTCCACAGCCTATCCAGTTGGAGAAGACTACATTGCACTTTATTC ATACTCAAGTGTAGAGCCCGGGGATTTGACTTTCACTGAAGGTGAAGAAA TTCTAGTGACCCAGAAAGATGGAGAGTGGTGGACAGGAAGTATTGGAGA GAGAACTGGAATCTTCCCGTCCAACTACGTCAGACCAAAGGATCAAGAGA ATTTTGGGAATGCTAGCAAATCTGGAGCATCAAACAAAAAACCCGAGATC GCTCAAGTAACTTCAGCATATGCTGCTTCAGGGACTGAGCAGCTCAGCCTT GCGCCAGGACAGTTAATATTAATCTTAAAGAAAAACACAAGCGGGTGGTG GCAAGGAGAGCTACAGGCCAGAGGGAAGAAACGACAGAAGGGATGGTTT CCTGCCAGCCATGTAAAGCTGCTAGGTCCAAGCAGTGAAAGAACCATGCC TACTTTTCACGCTGTATGTCAAGTGATTGCTATGTATGACTACATGGCGAA TAACGAAGATGAGCTCAATTTCTCCAAAGGACAGCTGATTAATGTTATGA ACAAAGATGACCCTGACTGGTGGCAAGGAGAAACCAATGGTCTGACTGGT CTCTTTCCTTCAAACTATGTTAAGATGACAACAGACTCAGATCCAAGTCAA CAGTGGTGTGCTGACCTCCAAGCCCTGGACACAATGCAGCCTACGGAGAG GAAGCGACAGGGCTACATTCACGAGCTCATTCAGACAGAGGAGCGGTAC ATGGACGACCTGCAACTTTTTGAACAAAAAACTCTCCTTTGA

mouse Ese2 - Sequence ID NO:6

MAQFPTAMNGGPNMWAITSEERTKHDKQFDNLKPSGGYITGDQARTFFLQS GLPAPVLAEIWALSDLNKDGKMDQQEFSIAMKLIKLKLQGQQLPVVLPPIMK QPPMFSPLISARFGMGSMPNLSIHQPLPPVAPIATPLSSATSGTSIPPLMMPAPL VPSVSTSSLPNGTASLIQPLSIPYSSSTLPHASSYSLMMGGFGGASIQKAQSLID LGSSSSTSSTASLSGNSPKTGTSEWAVPQPSRLKYRQKFNSLDKGMSGYLSGF QARNALLQSNLSQTQLATIWTLADIDGDGQLKAEEFILAMHLTDMAKAGQPL PLTLPPELVPPSFRGGKQVDSVNGTLPSYQKTQEEEPQKKLPVTFEDKRKANY ERGNMELEKRRQVLMEQQQREAERKAQKEKEEWERKQRELQEQEWKKQLE LEKRLEKQRELERQREEERRKEIERREAAKQELERQRRLEWERLRRQELLSQK TREQEDIVRLSSRKKSLHLELEAVNGKHQQISGRLQDVQIRKQTQKTELEVLD KQCDLEIMEIKQLQQELKEYQNKLIYLVPEKQLLNERIKNMQLSNTPDSGISLL HKKSSEKEELCQRLKEQLDALEKETASKLSEMDSFNNQLKELRESYNTQQLA LEQLHKIKRDKLKEIERKRLEQIQKKKLEDEAARKAKQGKENLWRESIRKEEE EKQKRLQEEKSQDKTQEEERKAEAKQSETASALVNYRALYPFEARNHDEMS FSSGDIIQVDEKTVGEPGWLYGSFQGKFGWFPCNYVEKVLSSEKALSPKKALL PPTVSLSATSTSSQPPASVTDYHNVSFSNLTVNTTWQQKSAFTRTVSPGSVSPI HGQGQAVENLKAQALCSWTAKKENHLNFSKHDVITVLEQQENWWFGEVHG GRGWFPKSYVKLIPGNEVQRGEPEALYAAVTKKPTSTAYPVTSTAYPVGEDY IALYSYSSVEPGDLTFTEGEEILVTQKDGEWWTGSIGERTGIFPSNYVRPKDQE NFGNASKSGASNKKPEIAQVTSAYAASGTEQLSLAPGQLILILKKNTSGWWQ GELQARGKKRQKGWFPASHVKLLGPSSERTMPTFHAVCQVIAMYDYMANN EDELNFSKGQLINVMNKDDPDWWQGETNGLTGLFPSNYVKMTTDSDPSQQ WCADLQALDTMQPTERKRQGYIHELIQTEERYMDDLQLFEQKTLL

Mouse Ese2 alternative transcript partial cDNA sequence - Sequence ID NO: 7 CCGTCTTCCACATTTCCCACATTGATCGTGTGTACACACTCCGAACAGACA ACATCAACGAGAGGACGGCCTGGGTCCAGAAGATCAAGGGTGCCTCAGA GCAGTACATCGACACTGAGAAGAAGAAACGGGAAAAGGCTTACCAAGCC CGTTCTCAAAAGACTTCAGGTATTGGGCGTCTGATGGTGCATGTCATTGAA GCTACAGAATTAAAAGCCTGCAAACCAAACGGGAAAAGTAATCCATACTG TGAAGTCAGCATGGGCTCCCAAAGCTATACCACCAGGACCCTGCAGGACA CACTAAACCCCAAGTGGAACTTCAACTGCCAGTTCTTCATCAAGGATCTTT ACCAGGACGTTCTGTGTCTCACTATGTTTGACAGAGACCAGTTTTCTCCAG ATGACTTCTTGGGTCGTACTGAAGTTCCAGTGGCAAAAATCCGAACAGAA CAGGAAAGCAAAGGCCCCACCACCCGCCGACTACTACTGCACGAAGTCCC CACTGGAGAAGTCTGGGTCCGCTTTGACCTGCAACTTTTTGAACAAAAAA CTCTCCTTTGAGGGCCTGGGGAAGCCAGAACCAGGGGAGCTGCCCACAAG GCTGGGTCTAAAGACAGATTTTGCTCTCCCAGGACAGAGGAGCATCACAT GGCTTCATCCATCAAACAGCCACACTCGCTGGGCCTGTATTTTATTGCACA CTAAATTGCTAGCAATCTATGCAAACATGATCTTT

Mouse Ese2 alternative partial protein containing C2 membrane-binding domains - Sequence ID NO: 8

VFHISHIDRVYTLRTDNINERTAWVQKIKGASEQYIDTEKKKREKAYQARSQK TSGIGRLMVHVIEATELKACKPNGKSNPYCEVSMGSQSYTTRTLQDTLNPKW NFNCQFFIKDLYQDVLCLTMFDRDQFSPDDFLGRTEVPVAKIRTEQESKGPTT RRLLLHEVPTGEVWVRFDLQLFEQKTLL

Novel Ese-coiled-coil interacting clones: Mouse homologue of C07E3.1 protein (clone 65): - Sequence ID NO:9

GAATTCGGCACGAGGGCTGAGAGAAGCGGACTCCGAGGACTCTGATGCTG AAGAGAAGCCTGTTAAGCAGGAGGACTTCCCGAAGATTTAGGACCAAAG AAGTTAAAGACGGGTGGCAATTTTAAGCCCAGCCAGAAAGGCTTTTCAGG AGGAACCAAGTCCTTCATGGACTTTGGCAGCTGGGAGAGACACACGAAAG GGATCGGGCAGAAGCTGCTGCAGAAGATGGGCTACGTCCCTGGGCGTGGC CTGGGGAAGAACGCACAGGGGATCATCAACCCCATCGAAGCCAAACAGA GAAAAGGCAAGGGAGCCGTGGGGGCCTATGGCTCGGAGAGGACCACTCA GTCTCTGCAGGACTTCCCCGTGGCCGACTCGGAAGAGGAGGCAGAAGAGG AGTTTCAGAAGGAGCTGAGCCAATGGAGGAAAGACCCCAGCGGGAGCAA GAAGAAGCCAAAGTACTCTTACAAGACTGTGGAGGAGCTGAAGGCCAAG GGCAGGGTCAGCAAGAAGCTCACAGCACCTCAGAAGGAACTGTCTCAGGT CAAGGTGATCGACATGACAGGCCGGGAGCAGAAGGTGTACTACAGCTAC 55728

-50-

AGCCAAATCAGCCACAAGCACAGCGTGCCCGATGAAGGGGTGCCATTGCT GGCGCAGCTGCCCCCCACAGCCGGCAAGGAAGCCAGGATGCCGGGCTTTG CACTGCCTGAGCTGGAGCACAACCTGCAGCTGCTCATTGAGCGCACGGAG CAGGAGATCATCCAGAGCGACCGGCAGCTCCAGTATGAGCGGGACATGGT GGTCAGCCTGTCGCATGAGCTGGAGAAGACGGCCGAGGTTCTTGCACATG AGGAGCGTGTCATCTCTAACCTCAGCAAGGTGCTGGCCCTGGTGGAGGAA TGTGAGCGCCGCATGCAGCCCCATGGCACCGACCCCCTCACTCTGGATGA GTGTGCCCGCATCTTTGAGACACTACAGGACAAGTATTATGAGGAGTACC GCCTGGCGGACCGCGCAGACCTCGCTGTGGCCATTGTCTACCCGCTCGTG AAGGACTACTTTAAGGATTGGCACCCCTCGAGGG

Mouse partial C07E3.1 protein (clone 65): - Sequence ID NO: 10 GTKSFMDFGSWERHTKGIGQKLLQKMGYVPGRGLGKNAQGIINPIEAKQRKG KGAVGAYGSERTTQSLQDFPVADSEEEAEEEFQKELSQWRKDPSGSKKKPKY SYKTVEELKAKGRVSKKLTAPQKELSQVKVIDMTGREQKVYYS YSQISHKHS VPDEGVPLLAQLPPTAGKEARMPGFALPELEHNLQLLIERTEQEIIQSDRQLQY ERDMVVSLSHELEKTAEVLAHEERVISNLSKVLALVEECERRMQPHGTDPLT LDECARIFETLQDKYYEEYRLADRADLAVAIVYPLVKDYFKDWHPSR

Mouse Novel cDNA clone 42/ Est accession #W29719 and #AA915044: - Sequence ID NO: 11

CATGGCGGCGGCTGCGGAGGGCGTCCCGGCGACGCGACGGAGGACGAGC CACCTCGAGATGATGCTGCGGTGGAGACAGCCGAGGAAGCAAAGGAGC

Mouse Novel cDNA clone 70: - Sequence ID NO: 12

CTTGAGTCTACTGAAAATACCCTGCAGGAAGCTACATCATCCATGTCTTTG ATGACCCAATTTGAACAGGAAGTATCTGGCCTCCAAAGACCATACGTGAT ATTGAGACTAGCGAAGAGATGC

Mouse Novel cDNA clone 83/Est accession #AA589041 and W98708: - Sequence ID NO: 13

GAATTCGGCACGAGGGAGTCTGGTTCTGGAAAGCCGACAGAAGCTGAGCT TGTCAACTTAGATTTCTTGGGAGATTTGGATGTTCCGGTATCTGCCCCACC CCTGTGTGTCTGAGCTCGAGTCTCTCTGCTGGACTATGG

Novel Ese-SH3 interacting clones:

Mouse YNK1 partial cDNA: - Sequence ID NO: 14 CTTTACGAGCAGAGGGAGCCAAATTCAGAGCCGTTTTAGATAAAGCTGTG CAAGCGGATGGACAGGTGAAGGAGCGCTACCAGTCCCATCGAGACACCA TCGCACTTCTGTGTAAGCCGGAGCCAGAGCTGAATGCTGCCATCCCCTCTG CTAACCCAGCAAAGACCATGCAGGGCAGCGAGGTTGTAAGTGTCTTAAAG TCCTTATTATCAAATCTTGATGAAATCAAGAAGGAAAGAGAGAGTCTTGA GAATGACCTGAAGTCAGTGAATTTTGACATGACAAGCAAGTTTTTGACAG CTCTGGCCCAAGATGGCGTGATAAATGAGGAGGCTCTCTCTGTCACTGAG CTGGATCGGATCTATGGCGGTCTAACAAGTAAAGTTCAAGAGTCTCTGAA GAAACAAGAGGGACTTCTAAAAAATATACAGGTCTCACACCAAGAATTCT CCAAAATGAAGC AATCTAAC AACGAGGCTAACTTGAGAGAAGAAGTTCTG AAGAACCTAGCAACTGCGTATGACAACTTTGTTGAGCTTGTAGCTAACTTG AAGGAGGGCACAAAGTTTTACAATGAGCTGACTGAGATCCTGGTCAGGTT CCAGAACAAATGCAGTGACATAGTGTTTGCACGGAAGACAGAAAGAGAC GAGCTCTTGAAGGATCTGCAGCAGAGCATTGCCAGAGAGCCCAGCGCTCC TTCAATCCCTCCTCCAGCCTATCAGTCCTCCCCAGCAGCGGGGCATGCAGC AGCGCCTCCAACTCCAGCCCCAAGAACCATGCCGCCTGCTAAGCCCCAGC CTCCAGCCCGGCCTCCACCTCCTGTGCTTCCTGCAAACCGAGTTCCTCCTG CTTCTGCTGCTGCTGCCCCTGCAGGCGTGGGGACGGCTTCAGCAGCGCCG CCACAGACCCCTGGCTCTGCTCCCCCGCCACAGGCTCAGGGACCACCATA CCCTACCTATCCAGGATATCCCGGGTATTGCCAAATGCCCATGCCCATGGG CTACAACCCCTACGCATATGGCCAGTACAATATGCCGTACCCACCGGTGT ATCACCAGAGCCCCGGACAGGCTCCATACCCAGGACCCCAGCAGCCTACC TACCCCTTCCCTCAGCCCCCGCAGCAGTCCTACTATCCACAGCAGTAACGC TGCCACGTGCTGCTGGTTCAGATCAGAGCGACAGGACAGCAGCTGCCACC AGCTCTAAGCCACGCTCTGGCCACTCGAGAGTATCTTGCTCTATTGATTGC TGTGGATGATTTCTGTCTGTGGCTAAAGCCGAAGGCTGGGCCCCACCTCCA CATTTGATCGCACTCGTGAGATTCTGCTGCTGTTGCAGTATAAACGCTAGC TATAATAGCATTTGAAAAAAATTACAGTTCCATAAAATGCTGAAAATGAG AAATTAAACCTGCAAGTGAAACATTTGAAATTAGCATACTTTATAAGATG C AGTTGGGAC AAAGATGGCTTAAGTACTGATATTTAAGGAAAAAGTTTTC TTTCTCTTTTGGTTTATTGATTTAGTTTAATTTCTATTATGATATTTTGCATA ATCAAGGCATTGTAAATCTTATAATTTAAAAATAAATTACTTACGAACAGT TGTCATTGTTATGTTTTGTCATTGATTCTCATTGCTGTCTAGTTCCTTTCTG GTATTAGCCTCTCCTTCTGTATGTTCACAGGCTCCATTACTGTGTTGAATTG CGTGACGTCAGGTGAGCAGTCAGGGAGGGCTGCTCTGCGGACGCCAAGCG CACACCAGCTTGTCTCAGGCTCAGCAGTCAGCTCATCTGGACATTTCTATT TAAAAGTCCTTTAATGTGGAAGATACACACAATTGTTACCAAAGGTTCTTC CAATTAATTTTACAATTTAAAAAGTATGTATTAATGTTTTATTGTTAGATTT TCCAAAAAAATGATGCAAATTCTGGTAATATTCATTTCCCTCACCCATAAT TTGGTTAAAATGAGTAGTTTTAGCCATACAGTCTCATCTGCTGTGGAGGAA CCTGGAGAAAGTCCCCTGTGCCTTTCTAGCCCTTGGGTTCTATTCTTATCCT GCAATGTCTACTGCACAGTGTGTTTGAGCAGATCCTAACCCTCCTTTTACA GTTTCTTCTTCTTACTTCTTTATTCTTTTTGTGGCTCCTGAAATCTGAGGTTA TTTTGTAATTCAGGAGCATGCAGGACAATTGTTGGGACATGTGCCTAGTCC GGAATACAGCCCAGGACAGCAAGGAGATGCGTCCTGCACCAGGAAGCCG TGCAGGCAGGAGCTGTCCAAGGTCCCGGCGGCTCTGCCTGTGTGAGGCAG GAGAATGAGC AGATTCCCTAATCTATGTTCTCGAAGTTTAATGCTGATGTT GTCTTGCCTTATCCTCATTTAACTGATACTGTCACCCAGTCCACCTTTGCTC TCATTGCAAAGTGATAGTGTAATTTCAAATGTAAGACTGAAGATACGATT GTAAAAGGGAGTAAACTGGTTTAAACGTGTTATTCTAAAGCACCTTACTTT GTTGTTGTATGCAGAAAACACAGATGCGCTAATTCAGTATAAATGACTGA TTGCCTGGAATTTGGACGTTGGCTTAAAGTCCGATAGCTAAACCTTGGCAA AACATAACAAACATTTCATTGCTCAGCCTCAGTGCTCTGGAGTATTCAGTG TATGAGACAGGTTTATTTGAGTCCTCTGTAAATGGCATTTGAATTTTATAT TCTCCCCTCCCGAGTATCTTATAAGACATCCCCTGAGTTAGGGAGTTCCCA GACTGCTACTCTATTCCTTATGAATGCAAAACAACCACCAATAGAACAAA AAAAAAAAAAAAAACTCGAG

Mouse YNK1 partial coding cDNA - Sequence ID NO: 15

CTTTACGAGCAGAGGGAGCCAAATTCAGAGCCGTTTTAGATAAAGCTGTG

CAAGCGGATGGACAGGTGAAGGAGCGCTACCAGTCCCATCGAGACACCA TCGCACTTCTGTGTAAGCCGGAGCCAGAGCTGAATGCTGCCATCCCCTCTG CTAACCCAGCAAAGACCATGCAGGGCAGCGAGGTTGTAAGTGTCTTAAAG TCCTTATTATCAAATCTTGATGAAATCAAGAAGGAAAGAGAGAGTCTTGA GAATGACCTGAAGTCAGTGAATTTTGACATGACAAGCAAGTTTTTGACAG CTCTGGCCCAAGATGGCGTGATAAATGAGGAGGCTCTCTCTGTCACTGAG CTGGATCGGATCTATGGCGGTCTAACAAGTAAAGTTCAAGAGTCTCTGAA GAAACAAGAGGGACTTCTAAAAAATATACAGGTCTCACACCAAGAATTCT CCAAAATGAAGCAATCTAACAACGAGGCTAACTTGAGAGAAGAAGTTCTG AAGAACCTAGCAACTGCGTATGACAACTTTGTTGAGCTTGTAGCTAACTTG AAGGAGGGCACAAAGTTTTACAATGAGCTGACTGAGATCCTGGTCAGGTT CCAGAACAAATGCAGTGACATAGTGTTTGCACGGAAGACAGAAAGAGAC GAGCTCTTGAAGGATCTGCAGCAGAGCATTGCCAGAGAGCCCAGCGCTCC TTCAATCCCTCCTCCAGCCTATCAGTCCTCCCCAGCAGCGGGGCATGCAGC AGCGCCTCCAACTCCAGCCCCAAGAACCATGCCGCCTGCTAAGCCCCAGC CTCCAGCCCGGCCTCCACCTCCTGTGCTTCCTGCAAACCGAGTTCCTCCTG CTTCTGCTGCTGCTGCCCCTGCAGGCGTGGGGACGGCTTCAGCAGCGCCG CCACAGACCCCTGGCTCTGCTCCCCCGCCACAGGCTCAGGGACCACCATA CCCTACCTATCCAGGATATCCCGGGTATTGCCAAATGCCCATGCCCATGGG CTACAACCCCTACGCATATGGCCAGTACAATATGCCGTACCCACCGGTGT ATCACCAGAGCCCCGGACAGGCTCCATACCCAGGACCCCAGCAGCCTACC TACCCCTTCCCTCAGCCCCCGCAGCAGTCCTACTATCCACAGCAGTAA

Mouse YNK1 partial protein - Sequence ID NO: 16

LRAEGAKFRAVLDKAVQADGQVKERYQSHRDTIALLCKPEPELNAAIPSANP AKTMQGSEVVSVLKSLLSNLDEIKKERESLENDLKSVNFDMTSKFLTALAQD GVINEEALSVTELDRIYGGLTSKVQESLKKQEGLLKNIQVSHQEFSKMKQSNN EANLREEVLKNLATAYDNFVELVANLKEGTKFYNELTEILVRFQNKCSDIVFA RKTERDELLKDLQQSIAREPS APSIPPP A YQSSPAAGHAAAPPTPAPRTMPPAK PQPPARPPPPVLPANRVPPASAAAAPAGVGTASAAPPQTPGSAPPPQAQGPPY PTYPGYPGYCQMPMPMGYNPYAYGQYNMPYPPVYHQSPGQAPYPGPQQPT YPFPQPPQQSYYPQQ

Mouse novel cDNA clone 4: - Sequence ID NO: 17

GGTCTTGGCTAGAATTTTAAATTTCTTCTCATTTGAGTAAAATGTTGCATTC TGAAGTCCCATGCTACCTGAAGTTGCATTTGGAGTCCCAAGCTACTGGAAT GTTTATATGTGACCGTTTCCCAGGAGGCTTACACTGCAGAAGGAAGAATG AATCTAGGTGAGGTGGGCAGCTGCTTGGCAGTCCTCTCTTGTGCCCCAACT GTAAACCAGATAGAAATGTTCAGGGGAGGATACTTTCATTATTGTGGTTTG TAGTGTTAAGATGATTGCTTCTGCCTTGGAAATACCTCAAGCTGTTCTTAT TTAACAGGTAAGTGACTGAGTATAATATTCCAGAAAAATTTGAAATCCTA ATTTCTTCCATATTTCATTAAATTTTTTGCATACAGGTCTAACAAATATGGA TATGTATACACATCCTCTTTAATGAAGGTATTATTTTGGTTACTTTTCCTAA GATATACCTTAAAAGATGTTCTATACATTTCCTACTTAAATTCTGGGGGAT TTGGAGTATGTACATGATAAAAAAGATTATAATATATCGATTGAAGTTACT TTATTTTCTAATTAGAATTATTTTAATAGTCCTTTATTGAATAAGTGCTGTA ATTTGTTTGCTATGAGACTTATTCCTGATGTGAATGTAAATTATTTTTCCAC ATGCATGAAAAAATGTATGTACTAATCAGAGTTGTCTCCATTGCATTGAAA TTACTTGTTTTGAACTAAAGTAACTCATATTTATGTAGTAGAATGCTTATG TTTTCAGACTTTGTAATGATTTCCTTTGGATGTATTTTAAATCAATCGGTCT GGGTAACATATCAGTTTAGATTAATATGTGCTTAAAAGAAGAAAAAAATT CAATGGTTCATAGTAGAAATGTGCCACACTTAAATAAGCTCTGTATGACAT GAAATTCTGTTAAAACATTGTAATTCATGGTGACTTTTAACTTATAAAAAT ACTACTTGCACGGGTTACTTGATTTATGGATATATGAAAACTTCTCAGGAC GAAAGTTCTTCTTTCTCTAGAACTATTCTTCTGTCGGTCATGCAGAATGCT GTTATTCTGAAAAGTGTCCCTGTTGCATATGATGGTCACTTTATTTGGGGG GATTCTTCATAAGATGTGAGATGTTGATGCCAGTCTTTCCCAAGTAAGTGC TCGTAAAAAAGGACTACTAACTAGCCTGCATCTGTCTCTAACTGGGACCA AGGGGTCTGCTGAAGGAAACTGAAGAGCTCTAACATTTTCACAGCTTGGA GAAGATAGAATCTTTAAAAGTACAACTGAAGCTTGATCTATTTTACAAGT GCATTGATGGCCCCTGTCCTTCTCTGGTTCCTGTCATTTGAAACCAACTCCT GTTGTAAATAGGAAGAATATGGGACATTCATATTTAAGAAAATTTGATGT CATTAGGTGACTAAGTAGAAGGCTTAGAAAAATGTATTCATTTGCAAGTA TTTTGGCACAAGAAATTTTCCAACTGAATAGTAAGCAAAAGCTAAGTTGTT TCATTGAAATCATAAGGCAGTTTAAGATAAACTGGAGAAGATAACTGTTC TAATAGAGGATAATCGAATTGATTGTCAAGTGGATGTTATTTATTGGATAG TGACAGAGTTTATTTGTAACCTTAATTATATTAAAAGTTATTCTGTTAGGA TGTTTTGTATTAATAAACGTGAACAAAATTAAAAAAAAAAAAAAAAAAAC TCGAGGG

Mouse Novel cDNA clone 8/47/52: - Sequence ID NO: 18

GAGAAGGCGGCCTGCCGCAGCGGGACAACCTAGAGCGCGACGTGGAGGC GCGTAGCGGAGCTGGAGCAACTGCGCACCGAGGTGGATGTGCGCATTAGC GCNNTGGACACCTGCGTCAAGGCCAAGTCGCTGCCAGCCGTCCCGCCGAG AGTCTCAGGCCCACCCCCGAACCCTCCACCCATTGATCCAGCTAGCCTGG AGGAATTCAAGAAAAGGATCCTGGAGTCTCAGCGGCTCCCTGTAGTCAAC CCTGCWGCCCAACCCAGCGGTTGAGRACCCAGCTGCCGCAGGACGCTGG GTGCCAGAATCGCCCACCTGTGGATGGGGGCAGCCAGGTGCCCACAGTGC TGGACACCCGCCGTGCCTGCCGGCAGCCTCCACCCCCAGCGCCTTCTCTGG CACCCCTTCACTGTCCCSTGCATCCCCRCCATTCSSCASWSASKGGATTTAA GGCACACACAGCTGTGAGATGACTTCACATCGACCCCTTGTGCAGTGACC CGGATGGTGCCCCACCCACACATGAAGCACCCACAGCTCAGCTGCCACCC TAGGCAACTCCTCCGGTTTCCTATCACTCTGCTCCTGACCCGGGAGGTGAG AACAGGAAGCCCAGCCTTCAGCTCCCTTGGGAGTTTCCAGCCTCCCTCTTA AAGGCCACTAGGGTTTCCAGATCCTATTTGAGAGTCTCCAGGCCTCCCCTG AAGGGTTCTAGCC ACC ACGCCCAC AGGAT CCC ATTAGGTTTTAAAGTCTT TTCCAGAGTCCGCTGGTTCCCCTCCTCCTCACAAGGAAGGGCCTCAATTGT AGATGAGCGTTCCGGGTGGATCTTAGAGCCCTAGAGGGAGGCTTTTGCTT -:»

GTARCCCCCTAAAGATATTACTGGCACATAATAAATATGAAAGTCCTTTG AAA

GTTGGACACTGCGCAAATGGGGCTCTCCATGGACCGCAGCCCATACGCCC GCACGGGGGACCAGCAGCGCGGCTCTGGTTCTACCTGCGCTATTTCTTCCT CTTCGTGTCGCTCATTCAGTTCCTCATCATCCTGGGCCTGGTCCTCTTCATG ATCTATGGCAATGTGCACGCCACCACTGAGTCCAGCCTGCGCGCCACGGA GATCCGCGCCGACAGCCTGTACAGCCAGGTGGTTGGACTATCGGCCTCAC AGGCTAACCTGAGCAAACAGCTGAACATCAGCTTGCTTGTCAAGGAAACA GTCATGCAGCAACTGTTGACTACGCGACGTGAGATGGAGCGCATCAACGC C AGCTTCCGCC AGTGCC AAGGCGACCTGATCACCTACATAAACTATAATC GCTTCATCGCCGCTATCATCCTGAGCGAGAAGCAGTGCCAGGAACAGCTG AAGGAGGTCAACAAGACCTGCGAACTTTACTCTTCAAGCTGGGAGAAAAA GTTAAGACACTGGAGATGGAGGTGGCCAAGGAGAAGGCAGTGTGCTCCA AGGACAAGGAGAGCCTGCTGGCAGGAAAGCGGCAGACGGAAGAGCAGCT GGAGGCCTGTG

Mouse Novel cDNA clone 18/25: - Sequence ID NO: 19

5'end of partial clone

TGTGCGCCGCCTCTAGAACTAGTGGATCCCCCGGGCCTGCAGGAATTCCG GCACGACGGCCGAGCGCCGCGGACCACCCGCGGCTGCCCGCCGAGCCGTC GACATGTGGGGGGACTGGGGTGGGAGCGGCCGGAGCAGCGCCAGGTACC CGGGCGCGCAGAACCATGGCTCTCGCTCGCCTGTCCTGACCTGGCTTGCTC GCCCCACCGAAGAATGTCAGCCAAGTCCAAGGGGAACCCTCCTCGTCCTC CGCAGCCGAGGGACCGCCGGCAGCCTCCAAAACCAAGGTGAAGGAGCAG ATCAAGATCATAGTGGAGGATCTGGAATTAGTCCTGGGCGACCTGAAGGA CGTGGCCAAAGAACTTAAGGAGGTGGTTGACCAGATTGACACCCTGACCT CTGATCTACAGCTGGAAGATGAGATGACCGACAGCTCCAAAACAGACACT CTGAACAGCAGCTCCAGTGGGACAACAGCCTCCAGCATAGAGAAGATCA AAGAACAGGCCAATGCTCCCCTCATTAAACCTCCAGCACACCCGTCTGCT ATCCTGACTGTCCTGAGAAAGCCAAACCCTCCACCGCCTCCTCCAAGGTTG ACACCCGTGAGGTGTGAAGAGCCTCAGAGAGTGGTGCCGACTGCCAACCC TGTAAAGACCAATGGCACTCTTCTGCGGAATGGAGGCTTAGCGGGGAGGC CCAACAAAATTCCAAATGGAG

3' end - Sequence ID NO:20

CTCGAGTTTTTTTTTTTTTTTTTTTTTTTTTTTCATTATTTACTATTATTTATT GACATATTTCCAAAGCTCAAAATATTTTATTATACATATAGTTGAACATAT GTTTCAAATTGTATAGTATAGAAAATAAACTTTTTTGTAGTGTCCTCAGCA TTTCATGATGCAAAACTATTGACAAACATCTTTAGAAAAATAATAAAATA GTCCTTCGGTATTAAAATTCTTATTAAAAAGCATTAGATCAAAGGGAGAA CTATGACATCATCAATGCATAGATGAGATAGGCATGAATGGAATGAGTTG CCCTGGCTTTATCAACAAATCAAAATATCTGACATCCCAGCTCTTATAATA GACCAAAATACTTGGAATCAGAAGGTCACAGTTTGTTTTAGGTCAATCAC AAAAAAATAAAATTCATTCATACTTTCTCAATTTTCCGCAGTTTCTGATGA TGGAACATAGAAAACAATGTACGTCCAGGACAGAGGCGCTACTCTGCATA CTTACCACGTGATTTTTTATGCCACTTTGTTGAATGCAGATTAATATATTTG GGCTTTTTATTGCTTGAGTAGAAAGTGCTCATTACTTATTATTTTACGTTTA TCATATAGAAAATTAAAAACAAACAGAACGTTTTCTTAAATGGCAGATAT CACACTGTGGTAGTGGTGGATTTCCTCAGGATGGTCTTCTGTGGTTTTGGT GCAGCGGGAGGAGGCACGGTTGCAGGTGTGGGAGGGGGGAAACTGTTAC TGTGGCTTATTCCCAGTCCCCCATTTTCTAATGGGAAAT

Mouse Novel cDNA clone 95/ EST accession #AA1 19951 : - Sequence ID NO:21 GCACAGCCCCCCTCCATCCTGAAGAAAACCTCAGCGTATGGGCCTCCAGC TTCGGGCCGTGTCTATCCTTCCTCTCCTGGGACATGGTGTTCCCCGCTTGCC CCCCTGGCAGAAAACCG

Mouse EselL cDNA: Sequence ID NO:22

CGGCACGAGGAGGAGTGGAGCGGCGCGGGGAGGGCGCGCAGCTTGGTTG CTCCGTAGTACGGCGGCTCGCAAGGGAGCATCCCGAGCGGGCTCCGGGAC GGCCGGGAGGCAGGCAGGCGGGCGGGCGGGGATGGTGTGCGCGGCTGCG GACTCGGCGTTCCTCGCGCGGCGTGCGGGCTGCACTGATTTGTGTGAGGG GCGGCCGCGCGCACCCGCCCGGAGATGAGGCGTCGATCAGCAAGGTGAA CGTAATAGAACCATGGCTCAGTTTCCCACACCTTTCGGTGGTAGCCTGGAT GTCTGGGCCATAACTGTGGAGGAAAGGGCCAAGCATGACCAGCAGTTCCT TAGCCTGAAGCCGATAGCGGGATTTATTACTGGTGATCAAGCGAGGAACT TTTTTTTCCAATCTGGGTTACCTCAGCCTGTCTTAGCACAAATATGGGCGC TAGCGGACATGAATAACGATGGAAGGATGGATCAAGTGGAATTTTCCATA GCCATGAAGCTTATCAAACTGAAGCTACAAGGATATCAGCTCCCCTCCAC ACTTCCCCCTGTCATGAAACAGCAACCAGTGGCTATTTCCAGTGCACCAGC ATTTGGTATAGGAGGGATTGCTAGCATGCCACCACTCACAGCTGTTGCTCC TGTGCCAATGGGCTCCATTCCAGTTGTTGGAATGTCTCCACCCTTAGTATC TTCTGTCCCTCCAGCAGCAGTGCCTCCCCTGGCTAACGGGGCTCCTCCCGT CATACAGCCTCTGCCTGCGTTTGCGCATCCTGCAGCCACATGGCCAAAGA GTTCTTCCTTCAGCAGATCTGGTCCAGGGTCACAATTAAACACTAAGTTAC AGAAGGCACAATCATTCGATGTCGCCAGCGCCCCTCCAGCAGCAGAATGG GCTGTGCCTCAGTCATCAAGGCTGAAATACAGGCAGTTATTCAACAGCCA CGACAAAACTATGAGTGGACACTTAACAGGTCCCCAGGCAAGAACTATTC TCATGCAATCAAGTTTACCCCAGGCTCAGCTGGCTTCAATATGGAATCTTT CTGACATTGATCAAGATGGAAAACTCACTGCAGAAGAATTTATCCTAGCT ATGCACCTAATTGATGTTGCCATGTCTGGTCAGCCACTGCCGCCCGTCCTG CCTCCAGAATACATCCCTCCTTCCTTCAGAAGAGTTCGCTCCGGCAGTGGG ATGTCCGTCATAAGCTCTTCTTCTGTGGATCAGAGGCTGCCTGAGGAGCCG TCGTCAGAGGATGAGCAGCAGCCAGAGAAGAAACTGCCTGTGACATTTGA AGATAAGAAGCGGGAGAACTTCGAGCGAGGCAGTGTGGAGCTGGAGAAG CGCCGGCAAGCGCTCTTGGAGCAGCAGCGCAAAGAGCAGGAGCGGTTGG CTCAGCTGGAGCGCGCCGAGCAGGAGAGGAAAGAGCGGGAGCGCCAGGA GCAGGAGGCC AAGCGGCAGCTGGAGCTGGAGAAGCAGCTGGAGAAGCAG CGGGAGCTGGAGCGGCAGCGAGAGGAGGAGAGGAGGAAGGAGATCGAG AGGCGCGAGGCCGCAAAACGGGAACTGGAAAGGCAGCGACAACTTGAAT GGGAACGGAACCGGAGACAGGAACTCCTGAATCAGAGGAACAAGGAGCA GGAGGGCACCGTGGTCCTGAAGGCAAGGAGGAAGACTCTGGAGTTTGAGT TAGAAGCTCTGAATGACAAAAAGCATCAGCTAGAAGGAAAACTTCAGGAT ATCAGGTGTCGACTGGCAACCCAGAGGCAAGAAATTGAGAGCACGAACA AGTCTAGAGAGCTAAGAATTGCTGAAATCACCCACTTACAGCAGCAGTTG CAGGAATCTCAGCAAATGCTTGGAAGACTTATTCCAGAGAAACAGATACT CAGTGACCAGTTAAAACAAGTCCAGCAGAACAGTTTGCATAGAGACTCGC TTCTTACCCTCAAAAGAGCCTTGGAAGCAAAGGAGCTGGCCCGGCAGCAG CTCCGGGAGCAGCTGGACGAGGTGGAGAGAGAGACCAGGTCAAAGCTGC AGGAGATTGATGTTTTCAACAACCAGCTGAAGGAACTGAGAGAGATACAT AGCAAACAGCAACTCCAGAAGCAGAGGTCCCTGGAGGCAGCGCGACTGA AGCAGAAAGAGCAGGAGAGGAAGAGCCTGGAGTTAGAGAAGCAAAAGG AAGACGCTCAGAGACGAGTTC AGGAAAGGG AC AAGC AATGGCTGGAGC A TGTGCAGCAGGAGGAGCAGCCACGCCCCCGGAAACCCCACGAGGAGGAC AGACTGAAGAGGGAAGACAGTGTCAGGAAGAAGGAGGCGGAAGAGAGA GCCAAGCCGGAAATGCAAGACAAGCAGAGTCGGCTTTTCCATCCGCATCA GGAGCCAGCTAAGCTGGCCACCCAGGCACCCTGGTCTACCACAGAGAAAG GCCCGCTTACCATTTCTGCACAGGAGAGTGTAAAAGTGGTATATTACCGA GCGCTGTACCCCTTTGAATCCAGAAGTCACGATGAGATCACCATCCAGCC AGGAGATATAGTCATGGTGGATGAAAGCCAGACTGGAGAGCCAGGATGG CTTGGAGGAGAGCTGAAAGGGAAGACGGGATGGTTCCCTGCAAACTATGC

AGAAAAGATTCCAGAAAATGAGGTTCCCACTCCAGCCAAACCAGTGACCG ATCTGACATCTGCCCCTGCCCCCAAACTGGCTCTGCGTGAGACCCCTGCTC CTTTGCCAGTGACCTCTTCTGAGCCCTCCACAACCCCCAACAACTGGGCAG ACTTCAGTTCCACGTGGCCCAGCAGCTCAAACGAGAAGCCAGAAACGGAC AACTGGGATACGTGGGCGGCTCAGCCTTCTCTGACCGTACCTAGTGCTGG CCAGTTACGGCAGAGATCAGCCTTTACCCCAGCCACAGCCACTGGCTCCT CCCCATCTCCCGTCCTGGGCCAGGGTGAAAAGGTGGAAGGGCTACAAGCG CAAGCCCTGTATCCCTGGAGAGCCAAAAAAGACAACCACTTAAATTTTAA CAAAAGTGACGTCATCACCGTTCTGGAACAGCAAGACATGTGGTGGTTTG GAGAAGTTCAAGGTCAGAAGGGTTGGTTCCCCAAGTCTTACGTGAAACTC ATTTCAGGGCCCGTAAGGAAATCCACAAGCATCGATACTGGCCCTACTGA AAGTCCTGCTAGTCTAAAGAGAGTGGCTTCCCCGGCCGCCAAGCCAGCCA TTCCCGGAGAAGAGTTTATTGCCATGTACACATACGAGAGTTCTGAGCAA GGAGATTTAACCTTTCAGC AAGGGGATGTGATTGTGGTTACCAAGAAAGA TGGTGACTGGTGGACGGGAACGGTGGGCGACAAGTCCGGAGTCTTCCCTT CTAACTATGTGAGGCTTAAAGATTCAGAGGGCTCTGGAACTGCTGGGAAA ACAGGGAGTTTAGGAAAAAAACCTGAAATTGCCCAGGTTATTGCTTCCTA CGCTGCTACTGGTCCCGAACAACTCACCCTGGCTCCTGGGCAGCTGATTCT GATCCGGAAAAAGAACCCAGGTGGATGGTGGGAAGGAGAACTGCAAGCT CGAGGGAAAAAGCGCCAGATAGGGTGGTTTCCAGCAAATTATGTCAAACT TCTAAGCCCCGGAACAAGCAAAATCACCCCAACTGAGCTACCCAAGACCG CAGTGCAGCCAGCAGTGTGCCAGGTGATCGGGATGTACGATTACACCGCC CAGAACGATGACGAACTAGCCTTCAGCAAAGGCCAGATCATCAACGTCCT CAACAAGGAGGACCCGGACTGGTGGAAAGGAGAAGTCAGTGGGCAAGTT GGGCTCTTCCCATCCAATTATGTAAAGCTGACCACAGACATGGACCCCAG CCAGCAATGGTGCTCAGACCTGCATCTCTTAGATATGCTGACCCCGACTGA GAGGAAGCGGCAAGGCTACATCCATGAACTCATTGTCACGGAGGAGAACT ACGTGAACGACTTGCAGCTGGTCACAGAGATCTTTCAGAAACCCCTGACG GAGTCTG AGCTGCTG AC AGAAAAAG AGGTTGCT ATG ATTTTTGTTAACTG GAAGGAGCTGATCATGTGTAATATCAAACTGCTGAAAGCGCTGAGAGTCC GCAAGAAGATGTCTGGGGAGAAGATGCCGGTGAAGATGATTGGCGACAT CCTGAGCGCCCAGCTGCCGCACATGCAGCCTTACATCCGCTTCTGCAGCTG CCAGCTCAATGGGGCTGCCCTCATCCAGCAGAAGACGGACGAGGCTCCAG ACTTCAAGGAGTTCGTCAAAAGACTGGCAATGGACCCTCGGTGCAAAGGA ATGCCTCTGTCCAGCTTTATACTGAAGCCTATGCAGCGTGTCACAAGATAC CCGCTGATCATTAAAAACATCCTGGAAAACACTCCTGAGAACCATCCAGA CCACAGCCACCTGAAGCATGCCCTGGAAAAGGCGGAGGAGCTGTGCTCCC AGGTGAACGAGGGAGTTCGAGAGAAGGAGAACTCAGACCGGCTGGAGTG GATCCAAGCCCACGTGCAGTGTGAAGGCCTTTCTGAGCAACTGGTGTTCA ATTCAGTGACCAACTGCTTGGGACCACGCAAGTTTCTGCACAGCGGGAAG CTCTACAAGGCCAAGAGCAATAAAGAACTGTATGGCTTCCTCTTCAACGA CTTCCTCCTGCTGACCCAAATCACAAAGCCCTTAGGCTCTTCCGGCACCGA CAAAGTCTTCAGCCCCAAATCTAACCTTCAGTATAAAATGTACAAAACGC CCATTTTCTTAAATGAGGTTCTAGTAAAATTGCCCACGGACCCTTCTGGAG ATGAGCCTATCTTCCACATTTCCCACATCGACCGGGTCTACACCCTCCGAG C AGAGAGC ATAAATGAGAGGACTGCCTGGGTGC AGAAAATC AAGGCGGC GTCTGAGCTCTACATAGAGACGGAGAAAAAGAAGCGAGAGAAGGCGTAC CTGGTCCGTTCCCAGCGGGCGACCGGTATTGGAAGGTTGATGGTGAACGT GGTAGAAGGCATTGAGCTGAAGCCCTGTCGGTCACATGGAAAGAGCAACC CGTACTGTGAGGTGACCATGGGCTCTCAGTGCCACATCACCAAGACAATC CAGGACACGCTAAACCCCAAGTGGAATTCTAACTGCCAGTTCTTCATCAG AGACCTGGAGCAGGAGGTTCTCTGCATCACAGTGTTTGAGAGGGACCAGT TCTCGCCTGATGATTTTTTGGGTCGGACAGAGATCCGAGTGGCCGACATCA AGAAAGACCAGGGCTCCAAGGGGCCGGTTACGAAGTGTCTCCTGCTGCAT GAGGTCCCCACGGGAGAGATTGTGGTCCGCCTTGACCTGCAGTTGTTTGAT GAGCCGTAGCAGCCCTGCGATGATCGTAGATGACTTCCTCCTCAAGGCCC CGTGCGGGCGTGCTGTCTGGTGGTCAGCCTCAGAGCAACGGGGATGAAGC AAAGACGAAGCCCCTCGAGGCTGCTAGGAGTCGTTCTCGACAATCCTGCC CTTCAAACCATGTCTCATTTTATGAATCCAAATTCTCTTTTCCTTTGCTCTC CCTATGGTCTCATCATGGCTTCTAGAGTCTCTGAAATCTGTGACCTTTAAC TAGGTTCCATTGGGAGCCTGGCTCCTTCCCTGGGCTGGAGGTGTGGGTCTG GTTTCTATAAAATAGATTATAAACTCGAGAATCACTAGT

Mouse EselL coding:Sequence ID NO:23 ATGGCTCAGTTTCCCACACCTTTCGGTGGTAGCCTGGATGTCTGGGCCATA ACTGTGGAGGAAAGGGCCAAGCATGACCAGCAGTTCCTTAGCCTGAAGCC GATAGCGGGATTTATTACTGGTGATCAAGCGAGGAACTTTTTTTTCCAATC TGGGTTACCTCAGCCTGTCTTAGCACAAATATGGGCGCTAGCGGACATGA ATAACGATGGAAGGATGGATCAAGTGGAATTTTCCATAGCCATGAAGCTT ATCAAACTGAAGCTACAAGGATATCAGCTCCCCTCCACACTTCCCCCTGTC ATG AAAC AGC AACC AGTGGCTATTTCC AGTGC ACC AGC ATTTGGTATAGG AGGGATTGCTAGCATGCCACCACTCACAGCTGTTGCTCCTGTGCCAATGG GCTCCATTCCAGTTGTTGGAATGTCTCCACCCTTAGTATCTTCTGTCCCTCC AGCAGCAGTGCCTCCCCTGGCTAACGGGGCTCCTCCCGTCATACAGCCTCT GCCTGCGTTTGCGCATCCTGCAGCCACATGGCCAAAGAGTTCTTCCTTCAG CAGATCTGGTCCAGGGTCACAATTAAACACTAAGTTACAGAAGGCACAAT CATTCGATGTCGCCAGCGCCCCTCCAGCAGCAGAATGGGCTGTGCCTCAG TCATCAAGGCTGAAATACAGGCAGTTATTCAACAGCCACGACAAAACTAT GAGTGGACACTTAACAGGTCCCCAGGCAAGAACTATTCTCATGCAATCAA GTTTACCCCAGGCTCAGCTGGCTTCAATATGGAATCTTTCTGACATTGATC AAGATGGAAAACTCACTGCAGAAGAATTTATCCTAGCTATGCACCTAATT GATGTTGCCATGTCTGGTCAGCCACTGCCGCCCGTCCTGCCTCCAGAATAC ATCCCTCCTTCCTTC AGAAGAGTTCGCTCCGGCAGTGGGATGTCCGTCATA AGCTCTTCTTCTGTGGATCAGAGGCTGCCTGAGGAGCCGTCGTCAGAGGA TGAGCAGCAGCCAGAGAAGAAACTGCCTGTGACATTTGAAGATAAGAAG CGGGAGAACTTCGAGCGAGGCAGTGTGGAGCTGGAGAAGCGCCGGCAAG CGCTCTTGGAGCAGCAGCGCAAAGAGCAGGAGCGGTTGGCTCAGCTGGA GCGCGCCGAGCAGGAGAGGAAAGAGCGGGAGCGCCAGGAGCAGGAGGC CAAGCGGCAGCTGGAGCTGGAGAAGCAGCTGGAGAAGCAGCGGGAGCTG GAGCGGCAGCGAGAGGAGGAGAGGAGGAAGGAGATCGAGAGGCGCGAG GCCGCAAAACGGGAACTGGAAAGGCAGCGACAACTTGAATGGGAACGGA ACCGGAGACAGGAACTCCTGAATCAGAGGAACAAGGAGCAGGAGGGCAC CGTGGTCCTGAAGGCAAGGAGGAAGACTCTGGAGTTTGAGTTAGAAGCTC TGAΛTGACAAAAAGCATCAGCTAGAAGGAAAACTTCAGGATATCAGGTGT CGACTGGCAACCCAGAGGCAAGAAATTGAGAGCACGAACAAGTCTAGAG AGCTAAGAATTGCTGAAATCACCCACTTACAGCAGCAGTTGCAGGAATCT CAGCAAATGCTTGGAAGACTTATTCCAGAGAAACAGATACTCAGTGACCA GTTAAAACAAGTCCAGCAGAACAGTTTGCATAGAGACTCGCTTCTTACCC TCAAAAGAGCCTTGGAAGCAAAGGAGCTGGCCCGGCAGCAGCTCCGGGA GCAGCTGGACGAGGTGGAGAGAGAGACCAGGTCAAAGCTGCAGGAGATT GATGTTTTCAACAACCAGCTGAAGGAACTGAGAGAGATACATAGCAAACA GCAACTCCAGAAGCAGAGGTCCCTGGAGGCAGCGCGACTGAAGCAGAAA GAGCAGGAGAGGAAGAGCCTGGAGTTAGAGAAGCAAAAGGAAGACGCTC AGAGACGAGTTCAGGAAAGGGACAAGCAATGGCTGGAGCATGTGCAGCA GGAGGAGCAGCCACGCCCCCGGAAACCCCACGAGGAGGACAGACTGAAG AGGGAAGACAGTGTCAGGAAGAAGGAGGCGGAAGAGAGAGCCAAGCCG GAAATGCAAGACAAGCAGAGTCGGCTTTTCCATCCGCATCAGGAGCCAGC TAAGCTGGCCACCCAGGCACCCTGGTCTACCACAGAGAAAGGCCCGCTTA CCATTTCTGCACAGGAGAGTGTAAAAGTGGTATATTACCGAGCGCTGTAC CCCTTTGAATCCAGAAGTCACGATGAGATCACCATCCAGCCAGGAGATAT AGTCATGGTGGATGAAAGCCAGACTGGAGAGCCAGGATGGCTTGGAGGA GAGCTGAAAGGGAAGACGGGATGGTTCCCTGCAAACTATGCAGAAAAGA TTCCAGAAAATGAGGTTCCCACTCCAGCCAAACCAGTGACCGATCTGACA TCTGCCCCTGCCCCCAAACTGGCTCTGCGTGAGACCCCTGCTCCTTTGCCA GTGACCTCTTCTGAGCCCTCCACAACCCCCAACAACTGGGCAGACTTCAGT TCCACGTGGCCCAGCAGCTCAAACGAGAAGCCAGAAACGGACAACTGGG ATACGTGGGCGGCTCAGCCTTCTCTGACCGTACCTAGTGCTGGCCAGTTAC GGCAGAGATCAGCCTTTACCCCAGCCACAGCCACTGGCTCCTCCCCATCTC CCGTCCTGGGCCAGGGTGAAAAGGTGGAAGGGCTACAAGCGCAAGCCCT GTATCCCTGGAGAGCCAAAAAAGACAACCACTTAAATTTTAACAAAAGTG ACGTCATCACCGTTCTGGAACAGCAAGACATGTGGTGGTTTGGAGAAGTT CAAGGTCAGAAGGGTTGGTTCCCCAAGTCTTACGTGAAACTCATTTCAGG GCCCGTAAGGAAATCCACAAGCATCGATACTGGCCCTACTGAAAGTCCTG CTAGTCTAAAGAGAGTGGCTTCCCCGGCCGCCAAGCCAGCCATTCCCGGA GAAGAGTTTATTGCCATGTACACATACGAGAGTTCTGAGCAAGGAGATTT AACCTTTCAGCAAGGGGATGTGATTGTGGTTACCAAGAAAGATGGTGACT GGTGGACGGGAACGGTGGGCGACAAGTCCGGAGTCTTCCCTTCTAACTAT GTGAGGCTTAAAGATTCAGAGGGCTCTGGAACTGCTGGGAAAACAGGGA GTTTAGGAAAAAAACCTGAAATTGCCCAGGTTATTGCTTCCTACGCTGCTA CTGGTCCCGAACAACTCACCCTGGCTCCTGGGCAGCTGATTCTGATCCGGA AAAAGAACCCAGGTGGATGGTGGGAAGGAGAACTGCAAGCTCGAGGGAA AAAGCGCCAGATAGGGTGGTTTCCAGCAAATTATGTCAAACTTCTAAGCC CCGGAACAAGCAAAATCACCCCAACTGAGCTACCCAAGACCGCAGTGCA GCCAGCAGTGTGCCAGGTGATCGGGATGTACGATTACACCGCCCAGAACG ATGACGAACTAGCCTTCAGCAAAGGCCAGATCATCAACGTCCTCAACAAG GAGGACCCGGACTGGTGGAAAGGAGAAGTCAGTGGGCAAGTTGGGCTCTT CCCATCCAATTATGTAAAGCTGACCACAGACATGGACCCCAGCCAGCAAT GGTGCTCAGACCTGCATCTCTTAGATATGCTGACCCCGACTGAGAGGAAG CGGCAAGGCTACATCCATGAACTCATTGTCACGGAGGAGAACTACGTGAA CGACTTGCAGCTGGTCACAGAGATCTTTCAGAAACCCCTGACGGAGTCTG AGCTGCTGACAGAAAAAGAGGTTGCTATGATTTTTGTTAACTGGAAGGAG CTGATCATGTGTAATATCAAACTGCTGAAAGCGCTGAGAGTCCGCAAGAA GATGTCTGGGGAGAAGATGCCGGTGAAGATGATTGGCGACATCCTGAGCG CCCAGCTGCCGCACATGCAGCCTTACATCCGCTTCTGCAGCTGCCAGCTCA ATGGGGCTGCCCTCATCCAGCAGAAGACGGACGAGGCTCCAGACTTCAAG GAGTTCGTCAAAAGACTGGCAATGGACCCTCGGTGCAAAGGAATGCCTCT GTCCAGCTTTATACTGAAGCCTATGCAGCGTGTCACAAGATACCCGCTGAT CATTAAAAACATCCTGGAAAACACTCCTGAGAACCATCCAGACCACAGCC ACCTGAAGCATGCCCTGGAAAAGGCGGAGGAGCTGTGCTCCCAGGTGAAC GAGGGAGTTCGAGAGAAGGAGAACTCAGACCGGCTGGAGTGGATCCAAG CCCACGTGCAGTGTGAAGGCCTTTCTGAGCAACTGGTGTTCAATTCAGTGA CCAACTGCTTGGGACCACGCAAGTTTCTGCACAGCGGGAAGCTCTACAAG GCCAAGAGCAATAAAGAACTGTATGGCTTCCTCTTCAACGACTTCCTCCTG CTGACCCAAATCACAAAGCCCTTAGGCTCTTCCGGCACCGACAAAGTCTT CAGCCCCAAATCTAACCTTCAGTATAAAATGTACAAAACGCCCATTTTCTT AAATGAGGTTCTAGTAAAATTGCCCACGGACCCTTCTGGAGATGAGCCTA TCTTCCACATTTCCCACATCGACCGGGTCTACACCCTCCGAGCAGAGAGCA TAAATGAGAGGACTGCCTGGGTGCAGAAAATCAAGGCGGCGTCTGAGCTC TACATAGAGACGGAGAAAAAGAAGCGAGAGAAGGCGTACCTGGTCCGTT CCCAGCGGGCGACCGGTATTGGAAGGTTGATGGTGAACGTGGTAGAGGCA TTGAGCTGAAGCCCTGTCGGTCACATGGAAAGAGCAACCCGTACTGTGAG GTGACCATGGGCTCTCAGTGCCACATCACCAAGACAATCCAGGACACGCT AAACCCCAAGTGGAATTCTAACTGCCAGTTCTTCATCAGAGACCTGGAGC AGGAGGTTCTCTGCATCACAGTGTTTGAGAGGGACCAGTTCTCGCCTGAT GATTTTTTGGGTCGGACAGAGATCCGAGTGGCCGACATCAAGAAAGACCA GGGCTCCAAGGGGCCGGTTACGAAGTGTCTCCTGCTGCATGAGGTCCCCA CGGGAGAGATTGTGGTCCGCCTTGACCTGCAGTTGTTTGATGAGCCGTAG

Murine EselL protein: Sequence ID NO: 24

MAQFPTPFGGSLDVWAITVEERAKHDQQFLSLKPIAGFITGDQARNFFFQSGL

PQPVLAQIWALADMNNDGRMDQVEFSIAMKLIKLKLQGYQLPSTLPPVMKQ QPVAISSAPAFGIGGIASMPPLTAVAPVPMGSIPVVGMSPPLVSSVPPAAVPPL ANGAPPVIQPLPAFAHPAATWPKSSSFSRSGPGSQLNTKLQKAQSFDVASAPP AAEWAVPQSSRLKYRQLFNSHDKTMSGHLTGPQARTILMQSSLPQAQLASIW NLSDIDQDGKLTAEEFILAMHLIDVAMSGQPLPPVLPPEYIPPSFRRVRSGSGM SVISSSSVDQRLPEEPSSEDEQQPEKKLPVTFEDKKRENFERGSVELEKRRQAL LEQQRKEQERLAQLERAEQERKERERQEQEAKRQLELEKQLEKQRELERQRE EERRKEIERREAAKRELERQRQLEWERNRRQELLNQRNKEQEGTVVLKARR KTLEFELEALNDKKHQLEGKLQDIRCRLATQRQEIESTNKSRELRIAEITHLQQ QLQESQQMLGRLIPEKQILSDQLKQVQQNSLHRDSLLTLKRALEAKELARQQ LREQLDEVERETRSKLQEIDVFNNQLKELREIHSKQQLQKQRSLEAARLKQKE QERKSLELEKQKEDAQRRVQERDKQWLEHVQQEEQPRPRKPHEEDRLKRED SVRKKEAEERAKPEMQDKQSRLFHPHQEPAKLATQAPWSTTEKGPLTISAQE SVKVVYYRALYPFESRSHDEITIQPGDIVMVDESQTGEPGWLGGELKGKTGW FPANYAEKIPENEVPTPAKPVTDLTSAPAPKLALRETPAPLPVTSSEPSTTPNN WADFSSTWPSSSNEKPETDNWDTWAAQPSLTVPSAGQLRQRSAFTPATATGS SPSPVLGQGEKVEGLQAQALYPWRAKKDNHLNFNKSDVITVLEQQDMWWF GEVQGQKGWFPKSYVKLISGPVRKSTSIDTGPTESPASLKRVASPAAKPAIPGE EFIAMYTYESSEQGDLTFQQGDVIVVTKKDGDWWTGTVGDKSGVFPSNYVR LKDSEGSGTAGKTGSLGKKPEIAQVIASYAATGPEQLTLAPGQLILIRKKNPGG WWEGELQARGKKRQIGWFPANYVKLLSPGTSKITPTELPKTAVQPAVCQVIG MYDYTAQNDDELAFSKGQIINVLNKEDPDWWKGEVSGQVGLFPSNYVKLTT DMDPSQQWCSDLHLLDMLTPTERKRQGYIHELIVTEENYV DLQLVTEIFQK PLTESELLTEKEVAMIFVNWKELIMCNIKLLKALRVRKKMSGEKMPVKMIGD ILSAQLPHMQPYIRFCSCQLNGAALIQQKTDEAPDFKEFVKRLAMDPRCKGM PLSSFILKPMQRVTRYPLIIKNILENTPENHPDHSHLKHALEKAEELCSQVNEG VREKENSDRLEWIQAHVQCEGLSEQLVFNSVTNCLGPRKFLHSGKLYKAKSN KELYGFLFNDFLLLTQITKPLGSSGTDKVFSPKSNLQYKMYKTPIFLNEVLVKL PTDPSGDEPIFHISHIDRVYTLRAESINERTAWVQKIKAASEL YIETEKKKREKA YLVRSQRATGIGRLMVNVVEGIELKPCRSHGKSNPYCEVTMGSQCHITKTIQD TLNPKWNSNCQFFIRDLEQEVLCITVFERDQFSPDDFLGRTEIRVADIKKDQGS KGPVTKCLLLHEVPTGEIVVRLDLQLFDEP

Mouse Ese2L cDNA: Sequence ID NO:25

CCCTTCCTTTCCTTTTTTTGTGTTCGCCTTCGGCCGTGCCGGCTGAGAGCCC AGCAGCCGTGACAGGCTGCGCAACAGGTTCGCTGCGGCCGGCCTGACGAC TGACCCGGCGGCGGCGGCCGCGGCACGGCAGGGTCTTCCCGGAGCTTGGC CGCGCCCACGCGCCGGTGTCGAGGAGCGCGCGGGGTCGCGCCGGGACGT GCGCGAGGCGCCAGATGGCTGAGAGCTGCAAGAAGAAGTCAGGATCATG ATGGCTCAGTTTCCCACAGCGATGAATGGAGGGCCAAATATGTGGGCTAT TACATCTGAAGAACGTACTAAGCATGATAAACAGTTTGATAACCTCAAAC CTTCAGGAGGTTACATAACAGGTGATCAAGCCCGTACTTTTTTCCTACAGT CAGGTCTGCCGGCCCCGGTTTTAGCTGAAATATGGGCCTTATCAGATCTGA ACAAGGATGGGAAGATGGACCAGCAAGAGTTCTCTATAGCTATGAAACTC ATCAAGTTAAAGTTGCAGGGCCAACAGCTGCCTGTAGTCCTCCCTCCTATC ATGAAACAACCCCCTATGTTCTCTCCACTAATCTCTGCTCGTTTTGGGATG GGAAGCATGCCCAATCTGTCCATTCATCAGCCATTGCCTCCAGTTGCACCT ATAGCAACACCCTTGTCTTCTGCTACGTCAGGGACCAGTATTCCTCCCCTA ATGATGCCTGCTCCCCTAGTGCCTTCTGTTAGTACATCCTCATTACCAAAT GGAACTGCCAGTCTCATTCAGCCTTTATCCATTCCTTATTCTTCTTCAACAT TGCCTCATGCATCATCTTACAGCCTGATGATGGGAGGATTTGGTGGTGCTA GTATCCAGAAGGCCCAGTCTCTGATTGATTTAGGATCTAGTAGCTCAACTT CCTCAACTGCTTCCCTCTCAGGGAACTCACCTAAGACAGGGACCTCAGAG TGGGCAGTTCCTCAGCCTTCAAGATTAAAGTATCGGCAAAAATTTAATAGT CTAGACAAAGGCATGAGCGGATACCTCTCAGGTTTTCAAGCTAGAAATGC CCTTCTTCAGTCAAATCTCTCTCAAACTCAGCTAGCTACTATTTGGACTCT GGCTGACATCGATGGTGACGGACAGTTGAAAGCTGAAGAATTTATTCTGG CGATGCACCTCACTGACATGGCCAAAGCTGGACAGCCACTACCACTGACG TTGCCTCCCGAGCTTGTCCCTCCATCTTTCAGAGGGGGAAAGCAAGTTGAT TCTGTTAATGGAACTCTGCCTTCATATCAGAAAACACAAGAAGAAGAGCC TCAGAAGAAACTGCCAGTTACTTTTGAGGACAAACGGAAAGCCAACTATG AACGAGGAAACATGGAGCTGGAGAAGCGACGCCAAGTGTTGATGGAGCA GCAGCAGAGGGAGGCTGAACGCAAAGCCCAGAAAGAGAAGGAAGAGTG GGAGCGGAAACAGAGAGAACTGCAAGAGCAAGAATGGAAGAAGCAGCTG GAGTTGGAGAAACGCTTGGAGAAACAGAGAGAGCTGGAGAGACAGCGGG AGGAAGAGAGGAGAAAGGAGATAGAAAGACGAGAGGCAGCAAAACAGG AGCTTGAGAGACAACGCCGTTTAGAATGGGAAAGACTCCGTCGGCAGGAG CTGCTCAGTCAGAAGACCAGGGAACAAGAAGACATTGTCAGGCTGAGCTC CAGAAAGAAAAGTCTCCACCTGGAACTGGAAGCAGTGAATGGAAAACAT CAGCAGATCTCAGGCAGACTACAAGATGTCCAAATCAGAAAGCAAACAC AAAAGACTGAGCTAGAAGTTTTGGATAAACAGTGTGACCTGGAAATTATG GAAATCAAACAACTTCAACAAGAGCTTAAGGAATATCAAAATAAGCTTAT CTATCTGGTCCCTGAGAAGCAGCTATTAAACGAAAGAATTAAAAACATGC AGCTCAGTAACACACCTGATTCAGGGATCAGTTTACTTCATAAAAAGTCA TCAGAAAAGGAAGAATTATGCCAAAGACTTAAAGAACAATTAGATGCTCT TGAAAAAGAAACTGCATCTAAGCTCTCAGAAATGGATTCATTTAACAATC AGCTGAAGGAACTCAGAGAAAGCTATAATACACAGCAGTTAGCCCTTGAA CAACTTCATAAAATCAAACGTGACAAATTGAAGGAAATCGAAAGAAAAA GATTAGAGCAAATTCAAAAAAAGAAACTAGAAGATGAGGCTGCAAGGAA AGCAAAGCAAGGAAAAGAAAACTTGTGGAGAGAAAGTATTAGAAAGGAA GAAGAGGAAAAGCAAAAACGACTCCAGGAAGAAAAGTCACAGGACAAA ACTCAAGAAGAGGAACGAAAAGCTGAGGCAAAACAAAGTGAGACAGCCA GTGCTTTGGTGAATTACAGAGCACTGTACCCTTTTGAAGCAAGAAACCAT GATGAGATGAGTTTTAGTTCTGGGGATATAATTCAGGTTGATGAAAAAAC TGTAGGAGAGCCTGGTTGGCTTTATGGTAGTTTTCAGGGAAAGTTTGGCTG GTTCCCCTGC AACTATGTAGAAAAAGTGCTGTC AAGTGAAAAAGCTCTGT CTCCTAAGAAGGCCTTACTTCCTCCTACAGTGTCTCTCTCTGCTACCTCAA CTTCTTCCCAGCCACCAGCATCAGTGACTGATTATCACAATGTATCCTTCT CAAACCTTACTGTTAATACAACATGGCAGCAGAAGTCAGCTTTTACCCGC ACTGTGTCCCCTGGATCTGTGTCCCCCATTCACGGACAGGGGCAGGCTGTA GAAAACCTGAAAGCCCAGGCCCTTTGTTCCTGGACGGCAAAGAAGGAGA ACCACCTGAACTTCTCAAAGCACGACGTCATCACTGTCCTGGAGCAGCAG GAAAACTGGTGGTTTGGGGAGGTGCACGGAGGAAGAGGATGGTTCCCCA AGTCTTATGTCAAGCTCATTCCTGGGAATGAAGTACAGCGAGGAGAGCCA GAAGCTTTGTATGCAGCTGTGACTAAGAAACCTACCTCCACAGCCTATCC AGTTACCTCCACAGCCTATCCAGTTGGAGAAGACTACATTGCACTTTATTC ATACTCAAGTGTAGAGCCCGGGGATTTGACTTTCACTGAAGGTGAAGAAA TTCTAGTGACCCAGAAAGATGGAGAGTGGTGGACAGGAAGTATTGGAGA GAGAACTGGAATCTTCCCGTCCAACTACGTCAGACCAAAGGATCAAGAGA ATTTTGGGAATGCTAGCAAATCTGGAGCATCAAACAAAAAACCCGAGATC GCTCAAGTAACTTCAGCATATGCTGCTTCAGGGACTGAGCAGCTCAGCCTT GCGCCAGGACAGTTAATATTAATCTTAAAGAAAAACACAAGCGGGTGGTG GCAAGGAGAGCTAC AGGCC AGAGGGAAGAAACGACAGAAGGGATGGTTT CCTGCCAGCCATGTAAAGCTGCTAGGTCCAAGCAGTGAAAGAACCATGCC TACTTTTCACGCTGTATGTCAAGTGATTGCTATGTATGACTACATGGCGAA TAACGAAGATGAGCTCAATTTCTCCAAAGGACAGCTGATTAATGTTATGA ACAAAGATGACCCTGACTGGTGGCAAGGAGAAACCAATGGTCTGACTGGT CTCTTTCCTTCAAACTATGTTAAGATGACAACAGACTCAGATCCAAGTCAA CAGTGGTGTGCTGACCTCCAAGCCCTGGACACAATGCAGCCTACGGAGAG GAAGCGACAGGGCTACATTCACGAGCTCATTCAGACAGAGGAGCGGTAC ATGGACGACGACCTGCAGCTGGTCATCGAGGTCTTCCAGAAACGGATGGC TGAGGAAGGCTTCCTCACTGAAGCAGACATGGCTCTGATCTTTGTGAACT GGAAAGAGCTCATCATGTCCAACACGAAGCTGCTGAGGGCCTTGCGGGTG AGGAAGAAGACTGGGGGTGAGAAGATGCCAGTTCAGATGATTGGAGACA TCCTGGCGGCAGAGCTGTCCCACATGCAGGCCTACATCCGCTTCTGCAGCT GTCAGCTTAATGGGGCAACCCTGTTACAGCAGAAGACAGACGAGGACAC GGACTTCAAGGAATTTCTAAAGAAGTTGGCATCAGACCCACGATGCAAAG GGATGCCCCTCTCCAGCTTCCTGCTGAAGCCCATGCAGAGGATCACTCGCT ACCCGCTGCTCATCCGAAGTATCCTGGAGAACACTCCACAGAGTCATGTT GACCACTCCTCCCTGAAGCTGGCCCTAGAACGTGCTGAGGAGCTGTGCTC TCAGGTGAACGAGGGAGTCCGGGAGAAGGAAAATTCAGACCGGCTGGAG TGGATCCAGGCACACGTGCAGTGCGAAGGCTTGGCAGAGCAACTTATTTT CAACTCCCTCACCAACTGCCTGGGCCCCCGGAAGCTTCTGCACAGCGGGA AGCTGTACAAGACCAAGAGCAATAAGGAGCTGCACGCCTTCCTCTTCAAC GACTTCCTGCTGCTCACCTACCTGGTCAGGCAGTTTGCCGCCGCCTCTGGC CACGAGAAGCTCTTCAACTCCAAGTCCAGTGCTCAGTTCCGGATGTACAA AACGCCCATTTTCCTGAATGAAGTGTTGGTGAAACTTCCCACAGACCCTTC CGGCGATGAGCCCGTCTTCCACATTTCCCACATTGATCGTGTGTACACACT CCGAACAGACAACATCAACGAGAGGACGGCCTGGGTCCAGAAGATCAAG GGTGCCTCAGAGCAGTACATCGACACTGAGAAGAAGAAACGGGAAAAGG CTTACCAAGCCCGTTCTCAAAAGACTTCAGGTATTGGGCGTCTGATGGTGC ATGTCATTGAAGCTACAGAATTAAAAGCCTGCAAACCAAACGGGAAAAGT AATCCATACTGTGAAGTCAGCATGGGCTCCCAAAGCTATACCACCAGGAC CCTGCAGGACACACTAAACCCCAAGTGGAACTTCAACTGCCAGTTCTTCA TCAAGGATCTTTACCAGGACGTTCTGTGTCTCACTATGTTTGACAGAGACC AGTTTTCTCCAGATGACTTCTTGGGTCGTACTGAAGTTCCAGTGGCAAAAA TCCGAACAGAACAGGAAAGCAAAGGCCCCACCACCCGCCGACTACTACTG CACGAAGTCCCCACTGGAGAAGTCTGGGTCCGCTTTGACCTGCAACTTTTT GAACAAAAAACTCTCCTTTGAGGGCCTGGGGAAGCCAGAACCAGGGGAG CTGCCC ACAAGGCTGGGTCTAAAGACAGATTTTGCTCTCCCAGGACAGAG GAGCATCACATGGCTTCATCCATCAAACAGCCACACTCGCTGGGCCTGTA TTTTATTGCACACTAAATTGCTAGCAATCTATGCAAACATGATCTTTTAAA CAAACGCCACAGCACAGTGCCTTGTACTAGTGTTAACCTGTTCAGCTGTGT TAGATGCCAGGGTTTCCATTTTCAGGGCTATAAAAGTATTATGTGGAAATG AGGCATCAGACCACCGGACGTTACCACTTGGCAAATCTGTCCACTGTGGA GTTGGTGATGTTGGAACCATTCCACACTATGTGACCTCTGCTGGGTCACAC ACTCAGGAGGTGAAGGGCTGAGATGAAATGCTGCAGCCTTGGGGCTTGTG CAGCCTGATACTGAAATAGCATCCACTTGTGCACTGAATAAATAGAAACT TGATCGTTTTATTCTGACTAGATATTATCATTCTCTGCTAAGACAATATAGT TTGAAATATTATAGTTTGAATATAAGGAGGAAAGCTTGATGTACTTTAAAT ATACTGTGAACTCTAATAATGTGGGGATATTTTTCAACTTTAATTTTCTTAA GTATAAATTATTTATGTAAATTCTTTGTTTTGCATATTTCATAGAACATGCA TCTTTAAGCTTTATCATTGCCAACAATGTACAGAAAGAGAATAAAAGTAT AAGTTTATGA TGTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

Murine Ese2L coding: Sequence ID NO: 26

ATGGCTCAGTTTCCCACAGCGATGAATGGAGGGCCAAATATGTGGGCTAT TACATCTGAAGAACGTACTAAGCATGATAAACAGTTTGATAACCTCAAAC CTTCAGGAGGTTACATAACAGGTGATCAAGCCCGTACTTTTTTCCTACAGT CAGGTCTGCCGGCCCCGGTTTTAGCTGAAATATGGGCCTTATCAGATCTGA ACAAGGATGGGAAGATGGACCAGCAAGAGTTCTCTATAGCTATGAAACTC ATCAAGTTAAAGTTGCAGGGCCAACAGCTGCCTGTAGTCCTCCCTCCTATC ATGAAACAACCCCCTATGTTCTCTCCACTAATCTCTGCTCGTTTTGGGATG GGAAGCATGCCCAATCTGTCCATTCATCAGCCATTGCCTCCAGTTGCACCT ATAGCAACACCCTTGTCTTCTGCTACGTCAGGGACCAGTATTCCTCCCCTA ATGATGCCTGCTCCCCTAGTGCCTTCTGTTAGTACATCCTCATTACCAAAT GGAACTGCCAGTCTCATTCAGCCTTTATCCATTCCTTATTCTTCTTCAACAT TGCCTCATGCATCATCTTACAGCCTGATGATGGGAGGATTTGGTGGTGCTA GTATCCAGAAGGCCCAGTCTCTGATTGATTTAGGATCTAGTAGCTCAACTT CCTCAACTGCTTCCCTCTCAGGGAACTCACCTAAGACAGGGACCTCAGAG TGGGCAGTTCCTCAGCCTTCAAGATTAAAGTATCGGCAAAAATTTAATAGT CTAGAC AAAGGC ATGAGCGGATACCTCTCAGGTTTTCAAGCTAGAAATGC CCTTCTTCAGTCAAATCTCTCTCAAACTCAGCTAGCTACTATTTGGACTCT GGCTGACATCGATGGTGACGGACAGTTGAAAGCTGAAGAATTTATTCTGG CGATGCACCTCACTGACATGGCCAAAGCTGGACAGCCACTACCACTG ACGTTGCCTCCCGAGCTTGTCCCTCCATCTTTCAGAGGGGGAAAGCAAGTT G ATTCTGTTAATGGAACTCTGCCTTCATATCAGAAAAC ACAAGAAGAAGA GCCTCAGAAGAAACTGCCAGTTACTTTTGAGGACAAACGGAAAGCCAACT ATGAACGAGGAAACATGGAGCTGGAGAAGCGACGCCAAGTGTTGATGGA GCAGCAGCAGAGGGAGGCTGAACGCAAAGCCCAGAAAGAGAAGGAAGA GTGGGAGCGGAAACAGAGAGAACTGCAAGAGCAAGAATGGAAGAAGCA GCTGGAGTTGGAGAAACGCTTGGAGAAACAGAGAGAGCTGGAGAGACAG CGGGAGGAAGAGAGGAGAAAGGAGATAGAAAGACGAGAGGCAGCAAAA CAGGAGCTTGAGAGACAACGCCGTTTAGAATGGGAAAGACTCCGTCGGCA GGAGCTGCTCAGTCAGAAGACCAGGGAACAAGAAGACATTGTCAGGCTG AGCTCCAGAAAGAAAAGTCTCCACCTGGAACTGGAAGCAGTGAATGGAA AACATCAGCAGATCTCAGGCAGACTACAAGATGTCCAAATCAGAAAGCA AACACAAAAGACTGAGCTAGAAGTTTTGGATAAACAGTGTGACCTGGAAA TTATGGAAATCAAACAACTTCAACAAGAGCTTAAGGAATATCAAAATAAG CTTATCTATCTGGTCCCTGAGAAGCAGCTATTAAACGAAAGAATTAAAAA CATGCAGCTCAGTAACACACCTGATTCAGGGATCAGTTTACTTCATAAAA AGTCATCAGAAAAGGAAGAATTATGCCAAAGACTTAAAGAACAATTAGAT GCTCTTGAAAAAGAAACTGCATCTAAGCTCTCAGAAATGGATTCATTTAA CAATCAGCTGAAGGAACTCAGAGAAAGCTATAATACACAGCAGTTAGCCC TTGAACAACTTCATAAAATCAAACGTGACAAATTGAAGGAAATCGAAAGA AAAAGATTAGAGCAAATTCAAAAAAAGAAACTAGAAGATGAGGCTGCAA GG AAAG C AAAGC AAGG AAAAG AAAACTTGTGG AG AGAAAGTATTAGAAA GGAAGAAGAGGAAAAGCAAAAACGACTCCAGGAAGAAAAGTCACAGGA CAAAACTCAAGAAGAGGAACGAAAAGCTGAGGCAAAACAAAGTGAGACA GCCAGTGCTTTGGTG

AATTACAGAGCACTGTACCCTTTTGAAGCAAGAAACCATGATGAGATGAG TTTTAGTTCTGGGGATATAATTCAGGTTGATGAAAAAACTGTAGGAGAGC CTGGTTGGCTTTATGGTAGTTTTCAGGGAAAGTTTGGCTGGTTCCCCTGCA ACTATGTAGAAAAAGTGCTGTCAAGTGAAAAAGCTCTGTCTCCTAAGAAG GCCTTACTTCCTCCTACAGTGTCTCTCTCTGCTACCTCAACTTCTTCCCAGC CACCAGCATCAGTGACTGATTATCACAATGTATCCTTCTCAAACCTTACTG TTAATACAACATGGCA GCAGAAGTCAGCTTTTACCCGCACTGTGTCCCCTGGATCTGTGTCCCCCAT TCACGGACAGGGGCAGGCTGTAGAAAACCTGAAAGCCCAGGCCCTTTGTT CCTGGACGGCAAAGAAGGAGAACCACCTGAACTTCTCAAAGCACGACGTC ATCACTGTCCTGGAGCAGCAGGAAAACTGGTGGTTTGGGGAGGTGCACGG AGGAAGAGGATGGTTCCCCAAGTCTTATGTCAAGCTCATTCCTGGGAATG AAGTAC AGCGAGGAGAGCCAGAAGCTTTGTATGCAGCTGTGACTAAGAAA CCTACCTCCACAGCCTATCCAGTTACCTCCACAGCCTATCCAGTTGGAGAA GACTACATTGCACTTTATTCATACTCAAGTGTAGAGCCCGGGGATTTGACT TTCACTGAAGGTGAAGAAATTCTAGTGACCCAGAAAGATGGAGAGTGGTG GACAGGAAGTATTGGAGAGAGAACTGGAATCTTCCCGTCCAACTACGTCA GACCAAAGGATCAAGAGAATTTTGGGAATGCTAGCAAATCTGGAGCATCA AACAAAAAACCCGAGATCGCTCAAGTAACTTCAGCATATGCTGCTTCAGG GACTGAGCAGCTCAGCCTTGCGCCAGGACAGTTAATATTAATCTTAAAGA AAAACACAAGCGGGTGGTGGCAAGGAGAGCTACAGGCCAGAGGGAAGAA ACGACAGAAGGGATGGTTTCCTGCCAGCCATGTAAAGCTGCTAGGTCCAA GCAGTGAAAGAACCATGCCTACTTTTCACGCTGTATGTCAAGTGATTGCTA TGTATGACTACATGGCGAATAACGAAGATGAGCTCAATTTCTCCAAAGGA CAGCTGATTAATGTTATGAACAAAGATGACCCTGACTGGTGGCAAGGAGA AACCAATGGTCTGACTGGTCTCTTTCCTTCAAACTATGTTAAGATGACAAC AGACTCAGATCCAAGTCAACAGTGGTGTGCTGACCTCCAAGCCCTGGACA CAATGCAGCCTACGGAGAGGAAGCGACAGGGCTACATTCACGAGCTCATT CAGACAGAGGAGCGGTACATGGACGACGACCTGCAGCTGGTCATCGAGG TCTTCCAGAAACGGATGGCTGAGGAAGGCTTCCTCACTGAAGCAGACATG GCTCTGATCTTTGTGAACTGGAAAGAGCTCATCATGTCCAACACGAAGCT GCTGAGGGCCTTGCGGGTGAGGAAGAAGACTGGGGGTGAGAAGATGCCA GTTCAGATGATTGGAGACATCCTGGCGGCAGAGCTGTCCCACATGCAGGC CTACATCCGCTTCTGCAGCTGTCAGCTTAATGGGGCAACCCTGTTACAGCA GAAGACAGACGAGGACACGGACTTCAAGGAATTTCTAAAGAAGTTGGCAT

SUBSTTIUTE SHEET RULE 26 CAGACCCACGATGCAAAGGGATGCCCCTCTCCAGCTTCCTGCTGAAGCCC ATGCAGAGGATCACTCGCTACCCGCTGCTCATCCGAAGTATCCTGGAGAA CACTCCACAGAGTCATGTTGACCACTCCTCCCTGAAGCTGGCCCTAGAAC GTGCTGAGGAGCTGTGCTCTCAGGTGAACGAGGGAGTCCGGGAGAAGGA AAATTCAGACCGGCTGGAGTGGATCCAGGCACACGTGCAGTGCGAAGGCT TGGCAGAGCAACTTATTTTCAACTCCCTCACCAACTGCCTGGGCCCCCGGA AGCTTCTGCACAGCGGGAAGCTGTACAAGACCAAGAGCAATAAGGAGCT GCACGCCTTCCTCTTCAACGACTTCCTGCTGCTCACCTACCTGGTCAGGCA GTTTGCCGCCGCCTCTGGCCACGAGAAGCTCTTCAACTCCAAGTCCAGTGC TCAGTTCCGGATGTACAAAACGCCCATTTTCCTGAATGAAGTGTTGGTGAA ACTTCCCACAGACCCTTCCGGCGATGAGCCCGTCTTCCACATTTCCCACAT TGATCGTGTGTACACACTCCGAACAGACAACATCAACGAGAGGACGGCCT GGGTCCAGAAGATCAAGGGTGCCTCAGAGCAGTACATCGACACTGAGAA GAAGAAACGGGAAAAGGCTTACCAAGCCCGTTCTCAAAAGACTTCAGGTA TTGGGCGTCTGATGGTGCATGTCATTGAAGCTACAGAATTAAAAGCCTGC AAACCAAACGGGAAAAGTAATCCATACTGTGAAGTCAGCATGGGCTCCCA AAGCTATACCACCAGGACCCTGCAGGACACACTAAACCCCAAGTGGAACT TCAACTGCCAGTTCTTCATCAAGGATCTTTACCAGGACGTTCTGTGTCTCA CTATGTTTGACAGAGACCAGTTTTCTCCAGATGACTTCTTGGGTCGTACTG AAGTTCCAGTGGCAAAATCCGAACAGAACAGGAAAGCAAAGGCCCCACC ACCCGCCGACTACTACTGCACGAAGTCCCCACTGGAGAAGTCTGGGTCCG CTTTGACCTGCAACTTTTTGAACAAAAAACTCTCCTTTGA

Mouse Ese2L protein: Sequence ID NO:27 MAQFPTAMNGGPNMWAITSEERTKHDKQFDNLKPSGGYITGDQARTFFLQS GLPAPVLAEIWALSDLNKDGKMDQQEFSIAMKLIKLKLQGQQLPVVLPPIMK QPPMFSPLISARFGMGSMPNLSIHQPLPPVAPIATPLSSATSGTSIPPLMMPAPL VPSVSTSSLPNGTASLIQPLSIPYSSSTLPHASSYSLMMGGFGGASIQKAQSLID LGSSSSTSSTASLSGNSPKTGTSEWAVPQPSRLKYRQKFNSLDKGMSGYLSGF QARNALLQSNLSQTQLATIWTLADIDGDGQLKAEEFILAMHLTDMAKAGQPL PLTLPPELVPPSFRGGKQVDSVNGTLPSYQKTQEEEPQKKLPVTFEDKRKANY ERGNMELEKRRQVLMEQQQREAERKAQKEKEEWERKQRELQEQEWKKQLE LEKRLEKQRELERQREEERRKEIERREAAKQELERQRRLEWERLRRQELLSQK TREQEDIVRLSSRKKSLHLELEAVNGKHQQISGRLQDVQIRKQTQKTELEVLD KQCDLEIMEIKQLQQELKEYQNKLIYLVPEKQLLNERIKNMQLSNTPDSGISLL HKKSSEKEELCQRLKEQLDALEKETASKLSEMDSFNNQLKELRESYNTQQLA LEQLHKIKRDKLKEIERKRLEQIQKKKLEDEAARKAKQGKENLWRESIRKEEE EKQKRLQEEKSQDKTQEEERKAEAKQSETASALVNYRALYPFEARNHDEMS FSSGDIIQVDEKTVGEPGWLYGSFQGKFGWFPCNYVEKVLSSEKALSPKKALL PPTVSLSATSTSSQPPASVTDYHNVSFSNLTVNTTWQQKSAFTRTVSPGSVSPI HGQGQAVENLKAQALCSWTAKKENHLNFSKHDVITVLEQQENWWFGEVHG GRGWFPKSYVKLIPGNEVQRGEPEALYAAVTKKPTSTAYPVTSTAYPVGEDY IALYSYSSVEPGDLTFTEGEEILVTQKDGEWWTGSIGERTGIFPSNYVRPKDQE NFGNASKSGASNKKPEIAQVTSAYAASGTEQLSLAPGQLILILKKNTSGWWQ GELQARGKKRQKGWFPASHVKLLGPSSERTMPTFHAVCQVIAMYDYMANN EDELNFSKGQLINVMNKDDPDWWQGETNGLTGLFPSNYVKMTTDSDPSQQ WC ADLQ ALDTMQPTERKRQG YIHELIQTEERYMDDDLQL VIEVFQKRMAEE GFLTEADMALIFVNWKELIMSNTKLLRALRVRKKTGGEKMPVQMIGDILAAE LSHMQAYIRFCSCQLNGATLLQQKTDEDTDFKEFLKKLASDPRCKGMPLSSF LLKPMQRITRYPLLIRSILENTPQSHVDHSSLKLALERAEELCSQVNEGVREKE NSDRLEWIQAHVQCEGLAEQLIFNSLTNCLGPRKLLHSGKLYKTKSNKELHA FLFNDFLLLTYLVRQFAAASGHEKLFNSKSSAQFRM YKTPIFLNEVLVKLPTD PSGDEPVFHISHIDRVYTLRTDNINERTAWVQKIKGASEQYIDTEKKKREKAY QARSQKTSGIGRLMVHVIEATELKACKPNGKSNPYCEVSMGSQSYTTRTLQD TLNPKWNFNCQFFIKDLYQDVLCLTMFDRDQFSPDDFLGRTEVPVAKIRTEQE SKGPTTRRLLLHEVPTGEVWVRFDLQLFEQKTLL

References

1. H. Riezman. P. G. Woodman. G. van Meer. M. Marsh. Molecular 5 mechanisms of Endocytosis. Cell 91: 731-738. 1997.

2. S. L. Schmid. Clathrin-coated vesicle formation and protein sorting: an integrated process. Annu. Rev. Biochem. 66: 51 1-548. 1997.

10 3. M. S. Robinson. Coats and budding vesicles. Trends Cell. Biol. : 99-102.

1997.

4. D. E. Warnock. S. L. Schmid. Dynamin GTPase, a force-generating molecular switch. BioEssays 18: 885-893. 1996.

15

5. R. Urrutia, J. R. Henley, T. Cook. M. A. McNiven. The dynamins: redundant or distinct functions for an expanding family of related GTPases? Proc. Natl. Acad. Sci. USA 94: 377-384, 1997.

20 6. P. Wigge. K. Kohler. Y. Vallis. C. A. Doyle. D. Owen. S. P. Hunt. H. T.

McMahon. Amphiphysin Heterodimers: Potential Role in Clathrin-mediated Endocytosis. Molecular Biology of the Cell 8: 2003-2015. 1997.

7. A. L. Munn. B. J. Stevenson, M. I. Geli. H. Riezman. end5. end6 and

25 end7: mutations that cause actin delocalization and block the intemalization step of endocytosis in Saccharomyces cerevisiae. Molecular Biology of the Cell 6: 1721- 1742. 1995.

8. O. Shupliakov. P. Low, D. Grabs, H. Gad. H. Chen. C. David. K. Takei. P. De 30 Camilli. L. Brodin. Synaptic vesicle endocytosis impaired by disruption of dynamin-

SH3 domain interactions. Science 276: 259-263, 1997.

9. P. Wigge, Y. Vallis. H. T. McMahon. Inhibition of receptor-mediated endocytosis by the amphiphysin SH3 domain. Current Biology ^~: 554-560. 1997.

J 5 10. H. McLauchlan. J. Newell. N. Morrice. A. Osbome, M. West. E. Smythe. A novel role for Rab5-GDI in ligand sequestration into clathrin-coated pits. Current Biology 8: 34-45. 1997.

1 1. P. J. Robinson. J.-M. Sontag, J.-P. Liu. E. M. Fykse. C. Slaughter. H. McMahon. T. C. Sudhof. Dynamin GTPase regulated by protein kinase C phosphorylation in nerve terminals. Nature 365: 163-166. 1993.

12. J.-P. Liu. A. T. R. Sim, P. J. Robinson. Calcineurin inhibition of Dynamin GTPase activity coupled to nerve terminal depolarization. Science 265: 970-973.

1994.

13. A. Wilde. F. M. Brodsky. In vivo phosphorylation of Adaptors regulates their interaction with Clathrin. The Journal of Cell Biology 135: 635-645. 1996.

14. R. Bauerfeind. K. Takei, P. De Camilli. Amphiphysin I is associated with coated endocytic intermediates and undergoes stimulation-dependent dephosphorylation in nerve terminals. J. Biol. Chem. 272: 30984-30992. 1997.

15. S. van Delft. R. Govers. G. J. Strous. A. J. Verkleij, P. M. P. van Bergen en Henegouwen. Epidermal growth factor induces ubiquitination of Eps 15. Journal of Biological Chemistry 272: 14013-14016. 1997.

16. J.-M. Galan. R. Haguenauer-Tsapis. Ubiquitin Lys63 is involved in ubiquitination of a membrane plasma membrane protein. EMBO J 16: 5847-5854. 1997.

17. J. Terrel. S. Shih. R. Dunn. L. Hicke. A function for monoubiquitination in the intemalization of a G protein-coupled receptor. Molecular Cell 1: 193-202. 1998.

18. R. Govers. P. van Kerkhof. A. L. Schwartz, G. J. Strous. Linkage of the ubiquitin-conjugating system and the endocytic pathway in ligand-induced intemalization of the growth hormone receptor. EMBO J. 16: 4851 -4858. 1997.

19. P. De Camilli. S. D. Emr. P. S. McPherson. P. Novick. Phosphoinositides as regulators in membrane traffic. Science 2~1: 1533-1539. 1996. 20. E. Kubler. H. Riezman. Actin and fimbrin are required for the intemalization step of endocytosis in yeast. EMBO J. 12: 2855-2862. 1993.

21. H. Benedetti. S. Raths. F. Crausaz, H. Riezman. The END3 gene encodes a protein that is required for the intemalization step of endocytosis and for actin cytoskeleton organization in yeast. Mol. Biol. Cell. 5: 1023-1037, 1994.

22. M. I. Geli. H. Riezman. Role of Type I Myosin in receptor-mediated endocytosis in yeast. Science 272: 533-535, 1996.

23. H.-Y. Tang, M. Cai. The EH-domain-containing protein Panl is required for normal organization of the actin cytoskeleton in Saccaromyces cerevisiae. Mol. Cell. Biol. 16: 4897-4914. 1996.

24. V. Moreau, J.-M. Galan, G. Devilliers, R. Haguenauer-Tsapis. B. Winsor. The yeast Actin-related protein Arp2p is required for the intemalization step of endocytosis. Molecular Biology of the Cell 8: 1361-1375. 1997.

25. B. Wendland. S. D. E r. Panlp. Yeast eps 15. functions as a multivalent adaptor that coordinates protein-protein interactions essential for endocytosis. Journal of Cell Biology 141: 71-84. 1998.

26. F. Fazioli. L. Minichiello. B. Matoskova. W. T. Wong. P. P. Di Fiore. eps 15. A novel tvrosine kinase substrate, exhibits transforming activity. Mol. Cell. Biol. 13:

5814-5828, 1993.

27. A. Benmerah. J. Gagnon. B. Begue. B. Megarbane. A. Dautry-Varsat. N. Cerf- Bensussan. The Tvrosine kinase substrate EPS 15 is constitutively associated with the plasma membrane adaptor AP2. J. Cell Biol. 131: 1831-1838. 1995.

28. F. Tebar. T. Sorkina. A. Sorkin. M. Ericsson. T. Kirchausen. Eps 15 Is a component of Clathrin-coated Pits and Vesicles and is located at the Rim of Coated Pits. Journal of Biological Chemistry ⁷/: 28727-28730. 1996. 29. F. Tebar. S. Confalonieri. R. E. Carter. P. P. Di Fiore. A. Sorkin. Eps 15 is Constitutivelv Oligomerized due to Homolphihc interaction of its Coiled-coil domain. Journal of Biological Chemistry 2^~2: 15413-15418, 1997.

30. R. Carbone. S. Fre. G. Iannolo. F. Belleudi. M. P.. P. G. Pelicci. M. R. Torrisi, P. P. Di Fiore. eps 15 and epsl SR are essential components of the endocytic pathway. Cancer Research 57: 5498-5504. 1997.

31. A. Benmerah. C. Lamaze, B. Begue, S. L. Schmid. A. Dautry-Varsat. N. Cerf- Bensussan. AP-2/Epsl5 interaction is required for receptor-mediated endocytosis.

Journal of Cell Biology 140: 1055-1062, 1998.

32. W. T. Wong. C. Schumacher. A. E. Salcini. A. Romano. P. Castagnino. P. G. Pelicci. P. P. Di Fiore. A protein-binding domain. EH. identified in the receptor tvrosine kinase substrate EPS 15 and conserved in evolution. Proc. Natl. Acad. Sci. USA 92: 9530-9534. 1995.

33. P. P. Di Fiore. P. G. Pelicci, A. Sorkin. EH: a novel protein-protein interaction domain potentially involved in intracellular sorting. Trends. Biochem. Sci. 22: 41 1 -413, 1997.

34. C. Schumacher. B. S. Knudsen, T. Ohuchi. P. P. Di Fiore. R. H. Glassman. H. Hanafusa. The SH3 domain of Crk binds specifically to a conserved proline-rich motif in Eps 15 and Epsl 5R. Journal of Biological Chemistry 270: 15341-15347. 1995.

35. A. Benmerah. B. Begue. A. Dautry-Vasat. N. Cerf-Bensussan. The Ear of alpha- Adaptin interacts with the COOH-terminal domain of the EPS 15 protein. Journal of Biological Chemistry 271: 121 1 1-121 16. 1996.

36. G. Iannolo. A. E. Salcini. I. Gaidarov. O. B. J. Goodman. J. Baulida. G. Carpenter. P. G. Pelicci. P. P. Di Fiore. J. H. Keen. Mapping of the molecular determinants involved in the interaction between Epsl 5 and AP2. Cancer Research

57: 240-245. 1997.

37. L. Coda. A. E. Salcini. S. Confalonieri. G. Pelicci, T. Sorkina. A. Sorkin. P. G. Pelicci. P. P. Di Fiore. Epsl5R is a tvrosine kinase substrate with characteristics of a docking protein possibly involved in coated pits-mediated intemalization. Journal of Biological Chemistry 2^~3: 3003-3012. 1998.

38. B. Wendland. J. M. McCaffery. Q. Xiao. S. D. Emr. A Novel Fluorescence- activated Cell Sorter-based screen for yeast Endocytosis mutants identifies a yeast homologue of mammalian eps 15. J. Cell Biol. 755: 1485-1500. 1996.

39. S. Raths. J. Rohrer. F. Crausaz. H. Riezman. end3 and end4: Two mutants defective in receptor-mediated and fluid-phase endocytosis in Saccaromyces cerevisiae. The Journal of Cell Biology 120: 55-65, 1993.

40. H. Y. Tang. A. Munn. M. Cai. EH domain proteins Panlp and End3p are components of a complex that plays a dual role in organization of the cortical actin cytoskeleton and endocytosis in Saccharomyces cerevisiae. Mol. Cell. Biol. H: 4294-4304. 1997.

41. T. Zoladek. A. Tobiasz, G. Vaduva, M. Boguta. N. C. Martin. A. K. Hopper. MDP1. a Saccharomyces cerevisiae gene involved in mitochondrial/cytoplasmic protein distribution, is identical to the ubiquitin-protein ligase gene RSP5. Genetics 145: 595-603. 1997.

42. P. S. McPherson. E. P. Garcia. V. I. Slepnev. C. David. X. Zhang. D. Grabs. W. S. Sossin. R. Bauerfeind. Y. Nemoto. P. De Camilli. A presynaptic inositol-5- phosphatase. Nature 379: 353-357. 1996.

43. A. E. Salcini. S. Confalonieri. M. Doria. E. Santolini. E. Tassi. O. Minencova. G. Cesareni, P. G. Pelicci. P. P. Di Fiore. Binding specificty and in vivo targets of the EH domain, a novel protein-protein interaction module. Genes & Development //: 2239-2249, 1997.

44. I. Gout. R. Dhand. I. D. Hiles. M. J. Fry. G. Panayotou. P. Das. O. Truong. N. F. Totty. J. Hsuan. G. W. Booker. I. D. Campbell. M. D. Waterfield. The GTPase dynamin binds to and is activated by a subset of SH3 domains. Cell 75: 25-36. 1993. 45. C. David. P. S. McPherson. O. Mundigl. P. De Camilli. A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. Proc. Natl. Acad. Sci. USA 93: 331-335. 1996.

46. M. H. Butler. C. David. G.-C. Ochoa. Z. Freyberg. L. Daniell, D. Grabs. O. Cremona. P. De Camilli. Amphiphysin II (SH3P9:BIN1), a member of the Amphiphysin/Rvs family, is concentrated in the cortical cytomatrix of axon initial segments and Nodes of Ranvier in brain and around T Tubules in skeletal muscle. Journal of Cell Biology 137: 1355-1367, 1997.

47. C. Leprince. F. Romero, D. Cussac, B. Vayssiere. R. Berger. A. Tavitian. J. H. Camonis. A new member of the Amphiphysin family connecting endocytosis and signal transduction pathways. J. Biol. Chem. 272: 15101-15105. 1997.

48. A. R. Ramjaun. K. D. Micheva, I. Bouchelet. P. S. McPherson. Identification and characterization of a nerve terminal-enriched amphiphysin isoform. J. Biol. Chem. 272: 16700-16706, 1997.

49. A. Wesp. L. Hicke. J. Palecek, R. Lombardi, T. Aust. A. L. Munn, H. Riezman. End4p/Sla2p Interacts with Actin-associated proteins for endocytosis in Saccharomyces cerevisiae. Molecular Biology of the Cell 8: 2291-2306, 1997.

50. E. de Heuvel. A. W. Bell. A. R. Ramjaun. K. Wong. W. S. Sossin. P. S. McPherson. Identification of the major Synaptojanin-binding proteins in the brain. J. Biol. Chem. 2^~2: 8710-8716. 1997.

51. N. Ringstad. Y. Nemoto, P. De Camilli. The SH3p4/SH3p8/SH3pl3 protein family: binding partners for synaptojanin and dynamin via a Grb2-like Src homology 3 domain. Proc. Natl. Acad. Sci. USA 94: 8569-8574, 1997.

52. Z. Wang. M. F. Moran. Requirement for the Adapter protein Grb2 in EGF receptor endocytosis. Science 272: 1935-1939. 1996.

53. A. B. Sparks. N. G. Hoffman. S. J. McConnel, D. M. Fowlkes. B. K. Kay. Cloning of Hgand targets: Sytematic isolation of SH3 domain-containing proteins. Nature Biotechnology 14: 741-744. 1996. 54. P. Cupers. E. ter Haar. W. Boll. T. Kirchhausen. Parallel dimers and anti- parallel tetramers formed by Epidermal Growth Factor Receptor Pathway Substrate Clone 15 (Epsl 5). Journal of Biological Chemistry 272: 33430-33434. 1997.

55. H. Stenmark. C. Bucci. M. Zerial. Expression of Rab GTPases using recombinant vaccinia virus. Meth. Enzymol. 257: 155-164. 1995.

56. S. van Delft. C. Schumacher. W. Hage, A. J. Verkleij. P. M. P. van Bergen en Henegouwen. Association and Colocalization of Eps 15 with Adaptor Protein-2 and Clathrin. The Journal of Cell Biology 136: 81 1-821. 1997.

57. M. Toth. J. Grimsby. G. Buzsaki, G. P. Donovan. Epileptic seizures caused by inactivation of a novel gene, jerky, related to centromere binding protein-B in transgenic mice. Nature Genetics //: 71-75, 1995.

58. J. Sambrook, E. F. Fritsch. T. Maniatis, Molecular Cloning, a laboratory manual. Second Edition. (Cold Spring Harbor Press, Cold Spring Harbor. 1989).

59. Roos, J. and Kelly. R. B. Dap 160, a Nerual-specific Epsl 15 homology and multiple SH3 domain-containing protein that interacts with Drosophila Dynamin. J.

Biol. Chem. 273. 19108-191 19. 1998.

60. Ren. R.. Mayer. B.J. Cicchetti. P. and Baltimore. D. Identification of a Ten- Amino Acid Proline-Rich SH3 Binding Site. Science. 259. 1 157-1 161. 1993.

61. Hall. A. Rho GTPases and the actin cytoskeleton. Science. 279. 509-514. 1998.

62. Nalefski. E.A. and Falke. J.J. The C2 domain calcium-binding motif: Structural and functional diversity. Protein Science. 5. 2375-2390. 1996.

63. Chen. H.. et al.. Epsin is an EH-domain binding protein implicated in clathrin- mediated endocytosis. Nature. 394, 793-797.

64. Stukenberg. P.T. et al.. Systematic identification of mitotic phosphoproteins. Current Biology. 7. 338-348. 1997. 65. Tang. H. Y. and Cai. M. The EH-domain containing protein Panl is required for normal organization of the actin cytoskeleton in Saccaromvces cerevisiae. Mol. Cell. Biol. 16. 4897-4914. 1996.

TABLE 1

Ese Proteins

Esel MAOFPTPFGGSLDV AITVEERAKHDOOFLSLKPIAGFITGDOARNFFFO Ese2 MAOFPTAM GGPNM AITSEERTKHDKOFDNLKPSGGYITGDOARTFFLO EH1 5GLPOPVLACIWALADMNNDGRMDOVEFSIAMKLIKLKLOGYOLPSTLPP 100

SGLPAPVLAEIWALSDLNKDGKMDOOEFSIAMKLIKLKLOGOOLPWLPP 100

VMKQQPVAISSAPA-FGIGGIASMP PLTAVAPV--PMGSIPWGMSP

IMKQPPMFSPLISARFGMGSMPNLSIHQPLPPVAPIATPLSSATSGTSIP PLVSS VPPAAVPP ANGAPPVIQPLPAFAHPAAT PKSSSFSRSGPG 191

• • _* • • _*• ••»• • • •• • •

PLMMPAP VPSVSTSSLPNGTASLIQPLS- I PYSSSTLPHASSYSL MGG 199

SQLNTKLQKAQSF-DVASAPPAA EWAVPOSSRLKY

FG-GASIOKAOSLIDLGSSSSTSSTASLSGNSPKTGTSE AVPOPSRLKY EH2 ROLFNSHDKT SGHLTGPOARTILMOSSLPOAOLASIWNLSDIDODGKLT 275

ROKFNSLDKGMSGYLSGFOAR ALLOSNLSOTOLATI TLADIDGDGOLK 298

AEEFILAMHLIDVAMSGOPLPPVLPPEYIPPSFRRVRSGSGMSVISSSSV

AEEFILAMHLTDMAKAGOPLPLTLPPELVPPSFR GGKQV DSV

DQR PEEPSSEDEQQPEKKLPVTFEDKKRENFERGSVELEKRRQALLEQQ 375

NGTLPSYQKTQEEE- PQKKLPVTFEDKRKANYERGNMELEKRRQVLMEQQ 389 RKEQERLAQLERAEQERKERERQEQEAKRQLELEKQLEKQRELERQREEE QREAERKAQKEKEEWERKQRELQEQE KKQLELEKRLEKQRELERQREEE

RRKEIERREAAKRELERQRQLEWER RRQELLNQRNKEQEGTWLKARRK 475

RRKEIERREAAKQELERQRRLEWERLRRQELLSQKTREQEDIVRLSSRKK 489 C-C TLEFELEALNDKKHQ EGKLQDIRCRLATQRQEIESTNKSRELRIAEITH

SLHLELEAVNGKHQQISGRLQDVQIRKQTQKTELEVLDKQCDLEIMEIKQ LQQQLQESQQMLGRLI PEKQILSDQLKQVQQN-- SLHRDSLLT KRA EA 573

LQQELKEYQNKLIYLVPEKQLLNERIKNMQLSNTPDSGISLLHKKSS-E- 587

KELARQQLREQLDEVERETRSKLQEIDVFNNQLKELREIHSKQQLQKQRS

KEELCQRLKEQLDA EKETASKLSEMDSF QLKELRESYNTQQLA EQL TABLE 1 - Cont'd

LEAARLKQKEQERKSLE-LEKQKED--AQRRV-QERDKQWLEHVQQEEQP 669

HKIKRDKLKEIERKRLEQIQKKKLEDEAARKAKQGKENL RESIRKEEEE 687 RPRKPHEEDRLKREDSVRKKEAEERAKPEMQDKQSRLFHPHQEPAKLATQ

_*• • _* • ••• • • _*••

KQK RLQEEKSQDKTQEEER-KAEA--KQSET

SH^'-A APWfiTTEKGPLTISAOESVKWYYRALYPFESRSHDEITi: P riV VPΞ 769

• ••••_*••• • ••• ••_{* *} • • ASALV YRALYPFEARNHDEMSF5SGDII.^"VLE 748

SCT EPG'Λ'IGGELKGKTG''FPANYAEKIPENEVPTPAKPVTDLTSAPAPK

KTv iE?GV:LVisF; 3KFT.-FPCNYVEKVLSSE KALSPK

LALRETPAPLPVTSSEPSTTPNNWADFSSTWPSSSNEKPETDNWDTWAAQ 869

KALLPPTVSLSATST-SSQPPASVTDYHNV SFSNLTVNTTWQ 627

PSLTVPSAGOLRQRSAFTPATATGSSPSPVLGOGEKVEGLOAOALYP PA QKSAFTRTVSPGSV-SPIHGQGQAVENLKAOAL-SV.' A

SH35 FLXHLNFXKSEVXTYLF; : DMW FGEV: G KGWFPK5YVKLISGPVRKS 969

KKEXKLNFSFHEVITVLE; ;ENW FGEVHGGF ;WFPKSYVKLIPGNEVOR 914

TSIDTGPTESPASLKRVASPAA PAIP-GEEFIAMYTYEESΞ GDLTF; :

GEPEALYAAV KKPTSTAYPVTSTAYPVGEDYIALYFY.-.-^'VEPGELTFTE

SH ? Z VI TKKE3EL^JT3TYIEK53VFP3NYVRLKDSEGSGTAGKTGSLGKK 1068

H-i: PEIAOVIA5VAAT ;?E.^~ LT1AP ; LILEPKKXP ; JW/E ΞL: PGF ? I I PEIAOVTSAVAAS TE : L. LAP iZ L ZLILKKXTS./JV-¹: 3ELCAP KKP; F jWFPANYVKLLSPGTSKITPTELPKTAVOPAVCOVI JMYEYTACXEEELA 1168

3WFPA5HVKLLGPSSERTMPT FHAVCOVIAMYEYMANNEEELX 1107

5H"Ξ FSK3;IINVLNKΞRPD'^ΠΛ'K3ΞVSJ:V LFPSXYVKLTTDMDPSOO 1213

FSK- ; L:NVMNKLDPΓV, .'I 3ETN JLTGLF??XYVKMTTDSDPSOO CADL 1157

QALDTMQPTERKRQGYIHELIQTEERYMDDLQLFEQKTLL 1197 TABLE 2

Ese Proteins

Claims

We Claim:

1. An isolated nucleic acid comprising a nucleotide sequence encoding a mammalian Esel protein or a splice variant thereof.

2. The nucleic acid of claim 1. wherein said nucleotide sequence encodes a murine Ese 1 protein or a splice variant thereof.

3. The nucleic acid of claim 1. wherein said nucleotide sequence encodes a human Esel protein or a splice variant thereof.

4. The nucleic acid sequence of claim 1. wherein said nucleic acid comprises a nucleotide sequence selected from the group consisting of a genomic sequence, a cDNA sequence, a polydeoxyribonucleic acid nucleotide sequence, a polyribonucleic acid nucleotide sequence, an allelic variant or homologue thereof.

5. The nucleic acid of claim 1 encoding a protein comprising the amino acid sequence of Sequence ID No. 3 or Sequence ID No. 24.

6. The nucleic acid of claim 1 comprising the sequence of Sequence ID No. 1. Sequence ID No. 2. Sequence ID No. 22 or Sequence ID No. 23.

7. An isolated nucleic acid comprising a nucleotide sequence of at least 10 consecutive nucleotides selected from the group consisting of Sequence ID

No. 1. Sequence ID No. 2, Sequence ID No. 22. Sequence ID No. 23 and a sequence complementary to any of these sequences.

8. The nucleic acid of claim 7, wherein said sequence is used as a probe or a primer.

9. A recombinant vector comprising the isolated nucleic acid of any of the preceding claims.

10. A host cell comprising the recombinant vector of claim 9.

1 1. A substantially pure mammalian Esel or Esel L protein.

12. A substantially pure murine Esel or Esel L protein.

13. A substantially pure human Esel or EselL protein.

14. The protein of claim 1 1 wherein the protein comprises an Esel protein comprising the amino acid sequence of Sequence ID No. 3 or the EselL protein comprising the amino acid sequence of Sequence ID No. 24.

15. A substantially pure polypeptide comprising an amino acid sequence of at least 5 consecutive amino acid residues of Sequence ID No. 3 or Sequence ID

No. 24.

16. A substantially pure polypeptide comprising at least one functional domain of a mammalian Esel protein or a mammalian Esel L protein.

17. A substantially pure polypeptide comprising an antigenic determinant of a mammalian Esel protein or a mammalian EselL protein.

18. An antibody which binds specifically to a polypeptide of claim 16.

19. A process for recombinantly producing murine Esel protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 2. 3 or 4 under conditions whereby the Esel protein is expressed and isolating the Esel protein therefrom.

20. An isolated nucleic acid comprising a nucleotide sequence encoding a mammalian Ese2 protein or a splice variant thereof.

21. The nucleic acid of claim 20. wherein said nucleotide sequence encodes a murine Ese2 protein or a splice variant thereof.

22. The nucleic acid of claim 20. wherein said nucleotide sequence encodes a human Ese2 protein or a splice variant thereof.

23. The nucleic acid sequence of claim 20. wherein said nucleic acid comprises a nucleotide sequence selected from the group consisting of a genomic sequence. a cDNA sequence, a polydeoxyribonucleic acid nucleotide sequence, a polyribonucleic acid nucleotide sequence, an allelic variant or homologue thereof.

24. The nucleic acid of claim 20 encoding a protein comprising the amino acid sequence of Sequence ID No. 6 or Sequence ID No. 27.

25. The nucleic acid of claim 20 comprising the sequence of Sequence ID No. 4, Sequence ID No. 5, Sequence ID No. 25 or Sequence ID No. 26.

26. An isolated nucleic acid comprising a nucleotide sequence of at least 10 consecutive nucleotides selected from the group consisting of Sequence ID No. 4. Sequence ID No. 5. Sequence ID No. 25. Sequence ID No. 26 and a sequence complementary to any of these sequences.

27. The nucleic acid of claim 26. wherein said sequence is used as a probe or a primer.

28. A recombinant vector comprising the isolated nucleic acid of any of claims 20 to 26.

29. A host cell comprising the recombinant vector of claim 28.

30. A substantially pure mammalian Ese2 or Ese2L protein.

31. A substantially pure murine Ese2 or Ese2L protein.

32. A substantially pure human Ese2 or Ese2L protein.

33. The protein of claim 32 wherein the protein comprises an Ese2 protein comprising the amino acid sequence of Sequence ID No. 6 or the Ese2L protein comprising the amino acid sequence of Sequence ID No. 27.

34. A substantially pure polypeptide comprising an amino acid sequence of at least 5 consecutive amino acid residues of Sequence ID No. 6 or Sequence ID

No. 27.

35. A substantially pure polypeptide comprising at least one functional domain of a mammalian Ese2 protein or a mammalian Ese2L protein.

36. A substantially pure polypeptide comprising an antigenic determinant of a mammalian Ese2 protein or a mammalian Ese2L protein.

37. An antibody which binds specifically to a polypeptide of claim 36.

38. A process for recombinantly producing murine Ese2 protein comprising culturing a host cell comprising a recombinant vector comprising the nucleic acid of claim 20. 21 or 22 under conditions whereby the Ese2 protein is expressed and isolating the Ese2 protein therefrom.

39. A pharmaceutical composition for the treatment of mammalian disorders which involve abnormal endocytosis leading to altered cellular functioning. said composition comprising an active ingredient selected from the group consisting of: a) an Ese protein selected from the group consisting of Esel. EselL. Ese2,

Ese2L. b) a fragment or mimetic thereof or a non- functional mutant protein, fragment or mimetic thereof of the proteins of a); and c) a pharmaceutically acceptable carrier.

40. A method of screening a candidate compound for efficacy in treating a disorder characterized by an abnormality in the endocytotic pathway, wherein said pathway involves an interaction between an Esel . Esel L. Ese2 or Ese2L protein and a binding partner of any one of these proteins, comprising screening said candidate compound for its ability to disrupt or promote said interaction as an indication of its efficacy.

41. A method for preventing or treating a disorder in a mammal characterized by an abnormality in the endocytotic pathway, wherein said pathway involves an interaction between an Esel. Esel L. Ese2 or Ese2L protein and a binding partner of any one of these proteins, comprising the step of disrupting or promoting said interaction in vivo.

42. The method of claim 40 or 41. wherein said disorder is selected from the group consisting of cancer, abnormal cell division, abnormal cell migration, viral infection, abnormal receptor signalling, abnormal tissue development and abnormal synaptic transmission disorders.

43. A method for screening a candidate compound for effectiveness as an antagonist of an Ese protein selected from the group consisting of Esel. EselL. Ese2 and Ese2L. said method comprising:

(a) providing an assay method for determining the endocytotic regulatory capacity of a selected Ese protein; and

(b) determining the endocytotic regulatory capacity of the selected Ese protein in the presence or absence of the candidate compound, wherein a reduced level of endocytotic regulatory capacity in the presence of the candidate compound indicates effectiveness of the compound as an antagonist.

44. A method for treating in a mammal a disorder associated with an undesired level of endocytotic activity of an Ese protein selected from the group consisting of Esel. EselL. Ese2 and Ese2L. said method comprising administering to the mammal an effective amount of a substance selected from the group consisting of:

(a) an Ese protein antagonist;

(b) an antibody which binds specifically to an Ese protein;

(c) an antisense strand comprising a nucleic acid sequence complementary to a sequence or fragment of the sequence represented by Sequence ID Nos. 1, 2. 4, 5. 22. 23. 25 and 26 and capable of hybridizing to the nucleic acid sequence encoding an Ese protein;

(d) an agent which down regulates the expression of an Ese gene encoding for an Ese protein;

(e) an antagonist of an Ese protein binding partner: and (f) an Ese agonist.

45. A method for suppressing in a mammal, abnormal proliferation of a cell capable of being stimulated to proliferate by a growth factor receptor, the method comprising administering to the mammal an effective amount of a Ese protein antagonist, an Ese agonist or an antibody which binds specifically to an Ese protein, wherein the Ese protein is selected from the group consisting of Esel. Esel L. Ese2 and Ese2L.

46. A method for preventing viral infection in a mammal, said method comprising administering to the mammal an effective amount of an Ese protein antagonist, an Ese agonist or an antibody which binds specifically to an Ese protein or an Ese mutant protein not capable of regulating endocytosis. wherein the Ese protein is selected from the group consisting of Esel. EselL, Ese2 and Ese2L.

47. A method for promoting endocytosis in selected cells in a mammal in need of such treatment, said method comprising administering to the mammal an effective amount of an Ese protein or an active analogue, mimic or fragment thereof, wherein the Ese protein is selected from the group consisting of Esel. EselL. Ese2 and Ese2L.

48. A method for blocking clathrin-mediated endocytosis in cultured cells or in selected cells in a mammal in need of such treatment, said method comprising overexpressing Ese 1 protein or an active analogue, mimic or fragment thereof in said cells.

49. A method for regulating endocytosis in cultured cells or in selected cells in a mammal in need of such treatment, said method comprising providing an Esel-Esps 15 complex and further binding dynamin to said complex to regulate components of the endocytic pathway.